lansoprazole has been researched along with omeprazole in 1383 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.29) | 18.7374 |
| 1990's | 521 (37.67) | 18.2507 |
| 2000's | 737 (53.29) | 29.6817 |
| 2010's | 96 (6.94) | 24.3611 |
| 2020's | 25 (1.81) | 2.80 |
| Authors | Studies |
|---|---|
| Figala, V; Klemm, K; Kohl, B; Krüger, U; Rainer, G; Schaefer, H; Senn-Bilfinger, J; Simon, WA; Sturm, E | 1 |
| Bergman, NA; Fryklund, J; Kühler, TC; Larsson, H; Lee, A; Weilitz, J | 1 |
| Nakamura, K; Nishikawa, Y; Seto, Y; Tada, K; Tanitame, A; Terauchi, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Fromm, MF; Klotz, U; Pauli-Magnus, C; Rekersbrink, S | 1 |
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bariwal, J; Bhosale, AV; Jagtap, JR; Jain, KS; Kale, AP; Shah, AK; Shelke, SM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fako, VE; Liu, JY; Pflug, B; Wu, X; Zhang, JT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Bala, V; Chhonker, YS | 1 |
| Beghyn, T; Bosc, D; Charton, J; Deprez, B; Deprez-Poulain, R; Guillaume, V; Herledan, A; Hermant, P; Landry, V; Leroux, F; Liang, W; Pottiez, V; Sheng, L; Tang, WJ; Urata, S; Warenghem, S | 1 |
| Chen, WL; Chen, X; Guo, XK; Jiang, ZY; Li, DD; Wang, YZ; Xu, JJ; You, QD | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Igata, H; Okabe, S | 1 |
| Horikoshi, T; Kusano, M; Nishioka, T; Sekiguchi, T | 1 |
| Okita, K; Tada, M; Yanai, H | 1 |
| Harada, Y; Ikeda, H; Kawai, T; Saitou, T | 1 |
| Nagaya, H; Satoh, H | 1 |
| Asaka, M; Kato, M; Miyazaki, T; Sato, Y | 1 |
| Arakawa, T | 1 |
| Yukawa, E; Yukawa, K | 1 |
| Kamada, T; Kawano, S; Tsuji, S | 1 |
| Ogawa, N | 1 |
| Håkanson, R; Karlsson, A; Lee, H; Mattsson, H; Sundler, F | 1 |
| Barradell, LB; Faulds, D; McTavish, D | 1 |
| Flouvat, B; Landes, BD; Miscoria, G | 1 |
| Bergmann, JF; Caulin, C; Chassany, O; Lemaire, M; Segrestaa, JM; Simoneau, G | 1 |
| Flouvat, B; Karolac-Tamisier, S; Lefebvre, RA; Moerman, E; Van Ganse, E | 1 |
| Berlin, I; Cournot, A; Dellatolas, F; Duchier, A; Duchier, J; Durrel, J; Molinier, P | 1 |
| Abe, S; Asaki, S; Hirasawa, Y; Hongo, M; Ohara, S; Toyota, T | 1 |
| Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA | 1 |
| Greski, PA; Hoyos, PA; Jennings, DE; Page, JG; Sanders, SW; Tolman, KG | 1 |
| Hirose, M; Kasano, T; Kihira, K; Kimura, K; Koyama, H; Sato, K; Taniguchi, Y; Yoshida, Y | 1 |
| Büdingen, C; Fahr, S; Kinder, B; Koske, M; Simon, WA | 1 |
| Holt, S | 1 |
| Inatomi, N; Nagaya, H; Nohara, A; Satoh, H | 1 |
| Boyanova, L; Lamouliatte, H; Megraud, F | 1 |
| Arakawa, T; Fukuda, T; Higuchi, K; Kobayashi, K; Nakamura, H | 1 |
| Aoki, I; Okumura, M; Yashiki, T | 1 |
| Benoit, M; Cournot, A; Delhotal-Landes, B; Dellatolas, F; Flouvat, B; Vermerie, N | 1 |
| Fukutomi, H; Kashimura, H; Nakahara, A | 1 |
| Eastwood, GL; Kuwayama, H; Matsuo, Y | 1 |
| Inatomi, N; Nagaya, H; Satoh, H | 1 |
| Inatomi, N; Nagaya, H; Satoh, H; Shino, A; Takami, K | 1 |
| Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B | 1 |
| Imada, A; Iwahi, T; Iwasaki, T; Kubo, K; Nakao, M; Satoh, H; Tamura, T; Yamazaki, T | 1 |
| Kaneko, T; Kubo, K; Nohara, A; Oda, K; Satoh, H | 1 |
| Maki, Y; Nagaya, H; Satoh, H | 1 |
| Dammann, HG; Leucht, U; Müller, P; Simon, B | 1 |
| Kubo, K; Maki, Y; Nagaya, H; Satoh, H | 1 |
| Inada, I; Inatomi, N; Maki, Y; Nagaya, H; Nakamura, N; Nohara, A; Satoh, H | 1 |
| Kihira, K | 1 |
| Dítĕ, P; Prásek, J | 1 |
| Aoki, T | 1 |
| Fraker, DL; Jensen, RT | 1 |
| Faulds, D; Spencer, CM | 1 |
| Alexander, K; Granneman, GR; Karol, MD | 1 |
| Nakao, M; Tada, M; Tsuchimori, K; Uekata, M | 1 |
| Arcari, ML; Bertaccini, G; Grandi, D; Morini, G | 2 |
| Adami, M; Bertaccini, G; Coruzzi, G | 1 |
| Ahmed, W; Ali, A; Qureshi, H; Shamsi, ZU; Zuberi, SJ | 1 |
| Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W | 1 |
| Iga, T; Katashima, M; Sawada, Y; Sugiura, M; Yamamoto, K | 1 |
| Ando, T; Fort, FL; Hamashima, T; Hodgen, GD; Kitazaki, T; Mahony, MC; Miyajima, H; Sato, S; Suzuki, T; Yamamoto, M | 1 |
| Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S | 1 |
| Ogura, K; Ota, S; Shimada, T; Terano, A | 1 |
| Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A | 1 |
| Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E | 1 |
| Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H | 1 |
| Kajiwara, M; Kokubun, N; Murai, S; Nakagawa, T; Ohara, H; Saito, N; Suzuki, T; Tsujino, D; Yamamoto, M; Yoneshima, M | 1 |
| Itoh, H; Nakata, H; Nishioka, S | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 2 |
| Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y | 1 |
| Harasawa, S; Kobayashi, H; Kurumada, T; Miwa, T; Ohta, U; Shirai, T; Takagi, A | 1 |
| Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I | 1 |
| Aoki, T; Matsuo, Y; Sugiyama, M | 1 |
| Inoue, M; Nakamura, M | 1 |
| Aoki, T; Kitajima, M; Otani, Y; Sugiyama, M; Watanabe, Y | 1 |
| Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E | 1 |
| Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H | 1 |
| Ajima, H; Ejiri, Y; Ishihata, R; Kasukawa, R; Kondo, Y; Kuwana, T; Mukai, S; Obara, K; Okubo, Y; Yokogi, K | 1 |
| Arisawa, T; Goto, H; Hase, S; Hayakawa, T; Niwa, Y; Tsukamoto, Y; Yoshikane, H | 1 |
| Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y | 1 |
| Ishii, K; Komuro, Y; Miyake, Y; Oida, M; Saigenji, K; Tanabe, S | 1 |
| Arakawa, T; Fukuda, T; Higuchi, K; Kobayashi, K; Ohtani, K; Shimizu, Y | 1 |
| Fujio, Y; Hirohata, S; Honsako, Y; Kashio, Y; Konishi, M; Kumada, H; Miura, J; Miyamoto, M; Tamada, F; Yamamoto, T | 1 |
| Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T | 1 |
| Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T | 2 |
| Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F | 1 |
| Ashida, K; Egashira, Y; Katsu, K; Sakaguchi, M; Takiuchi, H; Tanaka, M | 1 |
| Hoshino, E; Kimura, M; Miki, K; Miyashita, H; Oka, M; Sano, J; Umeda, N; Yahagi, N | 1 |
| Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H | 1 |
| Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y | 1 |
| Akiba, Y; Inoue, J; Ishii, H; Ito, T; Nakamura, M; Oda, M; Tsuchiya, M | 2 |
| Eto, T; Haraguchi, Y; Ohashi, T; Sakata, J | 1 |
| Aoyama, N; Chiba, T; Himeno, S; Kasuga, M; Kinoshita, Y; Misaki, F | 1 |
| Arakawa, Y; Iwasaki, A; Kuwayama, H; Nakajima, N | 1 |
| Ishii, H; Miura, S; Mori, M; Nakamura, M; Suzuki, M; Tsuchiya, M | 1 |
| Kato, T; Ogoshi, K; Sakagawa, T | 1 |
| Bardhan, KD; Brocklebank, D; Hawkey, CJ; Long, RG; Morgan, AG; Moules, IK; Wormsley, KG | 1 |
| Ashworth, HM; Baron, JH; Gummett, PA; Harris, AW; Logan, RP; Misiewicz, JJ | 1 |
| Hirano, M; Oka, H; Sakurabayashi, S; Sezai, S; Yamamoto, Y | 1 |
| Nos, P; Ponce, J | 1 |
| Asano, M; Maekawa, N; Mikawa, K; Nishina, K; Obara, H | 1 |
| Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ | 1 |
| Beattie, S; Cahill, RJ; Hamilton, H; Kilgallen, C; O'Morain, C; Xia, H | 1 |
| Flouvat, B; Landes, BD; Petite, JP | 1 |
| Johnson, CD; Ozmen, MM | 1 |
| Bigard, MA; Choné, L; Fléjou, JF; Grignon, Y | 1 |
| Hoshino, E; Miki, K; Umeda, N | 1 |
| Mégraud, F | 1 |
| Lamouliatte, H | 2 |
| Nakao, M | 1 |
| Fukuda, Y; Okui, M; Shimoyama, T; Tamura, K; Yamamoto, I | 1 |
| Axon, AT | 1 |
| Azuma, T; Hirai, M; Ito, S; Kato, T; Kohli, Y | 1 |
| Asaka, M; Hokari, K; Takeda, H | 1 |
| Scheen, AJ | 1 |
| Nagata, K; Nakao, M; Nakazawa, T; Okamura, H; Satoh, H; Takagi, E; Tamura, T; Tsuda, M | 1 |
| Celle, G; Mela, GS; Savarino, V; Vigneri, S; Zentilin, P | 1 |
| Buratti, P; Capelli, M; Corinaldesi, R; De Giorgio, R; Gaetani, M; Pasquali, R; Stanghellini, V | 1 |
| Brunner, G; Fuchs, W; Hell, M; Hengels, KJ; Hennig, U | 1 |
| Bazin, B; Bigard, MA; Colin, R; Duhamel, C; Legoux, JL; Michel, P; Person, B; Raoul, JL; Sallerin, V | 1 |
| Harada, T | 1 |
| Avner, D; Greski-Rose, PA; Jennings, DE; Jhala, N; Robinson, M; Sahba, B | 1 |
| Anker-Hansen, O; Carling, L; Ekström, P; Sellström, H; Sjöstedt, S; Unge, P | 1 |
| Hett, DA; Risdall, JE; Scott, RC | 1 |
| Akiba, Y; Fujiwara, T; Inoue, J; Ishii, H; Ito, T; Nakamura, M; Oda, M; Tsuchiya, M | 1 |
| Ejlersen, E; Tage-Jensen, U | 1 |
| Morii, M; Takeguchi, N; Tomiyama, Y | 1 |
| Fuchs, W; Klotz, U; Sennewald, R | 1 |
| Bonfils, C; Cosme, J; Curi-Pedrosa, R; Domergue, J; Guengerich, FP; Jacqz-Aigrain, E; Joyeux, H; Maurel, P; Pichard, L | 1 |
| Cadiot, G; Forestier, S; Joubert-Collin, M; Mignon, M; Paul, G; Ramdani, A; Ruszniewski, P; Vallot, T | 1 |
| Creutzfeldt, W | 2 |
| Armstrong, D; Blum, AL; Fraser, R; Verdú, EF | 1 |
| Chijiiwa, Y; Maruoka, A; Nawata, H; Tanaka, M | 1 |
| Campbell, DR; Robinson, M; Sabesin, SM; Sontag, S | 1 |
| Colin-Jones, D | 1 |
| Schönhöfer, PS | 1 |
| Florent, C | 1 |
| Di Fede, F; Dobrilla, G | 1 |
| Bruley des Varannes, S; Dellatolas, F; Galmiche, JP; Lartigue, S; Lemaire, M; Levy, P | 1 |
| Sampliner, RE | 1 |
| Bigard, MA | 2 |
| Ahlberg, J; Bardhan, KD; Hislop, WS; Lindholmer, C; Long, RG; Morgan, AG; Sjostedt, S; Smith, PM; Stig, R; Wormsley, KG | 1 |
| Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C | 1 |
| Feldman, M; Fisher, RS; Greski-Rose, PA; Harford, WV; Jennings, DE; Murray, SB; Sampliner, RE | 1 |
| Arnold, R | 2 |
| Delchier, JC; Dutreuil, C; Scoule, JC; Vidon, N | 1 |
| Clair, P; Curi-Pedrosa, R; Daujat, M; Domergue, J; Fourtanier, G; Gervot, L; Joyeux, H; Lesca, P; Ourlin, JC; Pichard, L | 1 |
| Tucker, GT | 1 |
| Bigard, MA; Bommelaer, G; Colin, R; Dupas, JL; Lemaire, M; Michel, P; Rambaud, JC; Verwaerd, JC | 1 |
| Forestier, S; Hochlaf, S; Joubert-Collin, M; Mignon, M; Ruszniewski, P; Vatier, J | 1 |
| Seifert, E | 1 |
| Forestier, S; Mignon, M; Pospai, D; Vallot, T; Vatier, J | 1 |
| Annibale, B; Biancone, L; Capurso, L; Delle Fave, G; Luzza, F; Marcheggiano, A; Pallone, F; Torsoli, A | 1 |
| Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG | 1 |
| Kawano, S; Murai, M; Tamura, K; Tanaka, M | 1 |
| Delhotal-Landes, B; Dellatolas, F; Duchier, J; Flouvat, B; Lemaire, M; Molinie, P | 1 |
| Arakawa, T; Fukuda, T; Higuchi, K; Kimura, S; Kobayashi, K; Uchida, T | 1 |
| Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL | 1 |
| Feigenbaum, K; Gardner, JD; Jensen, RT; Koviack, PD; Maton, PN; Metz, DC; Pisegna, JR; Ringham, GL | 1 |
| Berstad, A; Carling, L; Ekström, P; Halvorsen, L; Hatlebakk, JG; Hovdenak, N; Stallemo, A; Svedberg, LE; Trondstad, R; Unge, P | 1 |
| Balks, HJ; Damaschke, A; Dammann, HG; Fuchs, W; Hennig, U; Schwarz, JA; Steinhoff, J; von zur Mühlen, A | 1 |
| Berstad, A; Hatlebakk, JG | 4 |
| Mignon, M; Vallot, T | 1 |
| Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC | 1 |
| Arnold, R; Brunner, G; Fuchs, W; Hennig, U | 1 |
| Colin-Jones, DG | 1 |
| Iwahi, T; Nagata, K; Satoh, H; Shimoyama, T; Tamura, T | 1 |
| Cavanaugh, JM; Karol, MD; Machinist, JM | 2 |
| Kromer, W | 2 |
| Kaplan, B; Mears, JM | 1 |
| Cadiot, G; Mignon, M; Pospai, D; Potet, F; Ruszniewski, P; Vissuzaine, C | 1 |
| Ehrlich, A; Fuder, H; Kleist, P; Lücker, PW; Ripke, H; Timmer, W; Wieckhorst, G | 1 |
| Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB | 1 |
| Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE | 1 |
| Cavanaugh, JH; Granneman, GR; Karol, MD; Locke, CS | 1 |
| Agostini, H; Lemaire, M; Poynard, T | 1 |
| Hentschel, E; Schütze, K | 1 |
| Avner, D; Haber, M; Lanza, F; Robinson, M | 1 |
| Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Shiga, M; Takao, Y | 2 |
| Nagata, K; Okamura, H; Satoh, H; Takagi, E; Tamura, T | 1 |
| Goldstein, JA; Parkinson, A; Pearce, RE; Rodrigues, AD | 1 |
| Ihara, N; Kokufu, T; Koyama, H; Mori, S; Nakajima, K; Ohta, T; Sugioka, N | 1 |
| Charrasse, S; Daujat, M; Fabre, I; Jounaïdi, Y; Larroque, C; Lesca, P; Maurel, P; Poellinger, L | 1 |
| Inada, I; Satoh, H | 1 |
| Fukuda, S; Fukuda, Y; Munakata, A; Shimoyama, T; Yoshida, Y | 2 |
| Chen, S; Pei, Y; Wang, B | 1 |
| Girre, C; Padoin, C; Palombo, S; Rizzo, N; Scherrmann, JM | 1 |
| Arimori, K; Fujioka, Y; Fujiyama, S; Katafuchi, S; Katsuki, H; Nakamura, C; Nakano, M; Yagi, H | 1 |
| Bell, JM; Lambert, JR; Midolo, PD; Turnidge, JD | 1 |
| Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F | 1 |
| Hussar, DA | 1 |
| Levy, N; Stermer, E | 1 |
| Cammarota, G; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A | 1 |
| Baniukiewicz, A; Bielański, W; Gabryelewicz, A; Hahn, EG; Jedynak, M; Konturek, PC; Konturek, SJ; Kwiecień, N; Sito, E | 1 |
| Blum, RA | 1 |
| Jaup, BH; Norrby, A | 1 |
| Dickey, W; Kenny, BD; McConnell, JB | 1 |
| Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ | 1 |
| Castell, DO; Haber, MM; Richter, JE; Robinson, M; Sontag, SJ | 1 |
| Campbell, DR; Fleischmann, R; Haber, M; Kogut, DG; Richter, J; Sontag, SJ | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ | 1 |
| Huber, R; Kolassa, N; Radtke, HW; Steinijans, VW; Zech, K | 1 |
| Barth, H; Gerloff, J; Heintze, K; Mignot, A | 1 |
| Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET | 1 |
| Andersson, T | 1 |
| Isoda, K; Itakura, Y; Itoyama, S; Matsumura, O; Mitarai, T; Murakawa, M; Tamura, H; Tokushima, H | 1 |
| Hirschowitz, BI; Mohnen, J; Shaw, S | 2 |
| Fraser, AG; Hudson, M; Pounder, RE; Sawyerr, AM; Smith, MS | 1 |
| Cooper, BT; Fosters, CS; Garrett, AD; Gough, AL; Langworthy, CH; Long, RG | 1 |
| Dhar, A; Gupta, VK; Sharma, MP; Srinivasan, S | 1 |
| Logan, RP | 1 |
| Herman, R; Konturek, JW; Konturek, SJ; Lorens, K; Tabor, S; Thor, P | 1 |
| Mee, AS; Rowley, JL | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
| Hossain, A; Ikawa, S; Kato, H; Kikuchi, H; Miyazaki, J; Mizuno, M; Watanabe, M | 1 |
| Asano, S; Maeda, R; Murakami, I; Satoh, H | 1 |
| Meyer, UA | 1 |
| Maruyama, M | 1 |
| Maeda, K; Nagashima, R; Ohno, S; Takahashi, T; Takeda, H | 1 |
| Castell, DO; Elkin, EP; Mathias, SD; Matosian, ML | 1 |
| Dekker, W; Gerretsen, M; Mulder, CJ | 1 |
| Hopefl, A | 1 |
| Kawano, S; Murakami, M; Saita, H; Tsuji, S | 1 |
| Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Fukuda, Y; Shimoyama, T; Tamura, K; Tonokatsu, Y; Tsujiai, T | 1 |
| Fujioka, T; Kodama, R; Kubota, T; Murakami, K; Nagai, J; Nasu, M; Nishizono, A; Tokieda, M | 1 |
| Leonhardt, U; Ramadori, G; Ritzel, U | 1 |
| Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C | 1 |
| Garnett, WR | 1 |
| Bell, NJ; Hunt, RH | 1 |
| Cammarota, G; Cuoco, L; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A; Veneto, G | 1 |
| Cole, RA; el-Zimaity, HM; Genta, RM; Graham, DY; Malaty, H | 1 |
| Baron, JH; Gabe, SM; Harris, AW; Karim, QN; Langworthy, H; Misiewicz, JJ; Pryce, DI; Walker, MM | 1 |
| Cavanaugh, JH; Karol, MD | 1 |
| Arai, H; Baba, S; Furuta, T; Futami, H; Kaneko, E | 1 |
| Hayashi, T; Hirano, M; Ishikawa, F; Kakiuchi, T; Miyazawa, I; Nomura, T; Nonaka, Y; Suzuki, T | 1 |
| Hirose, H; Isoda, K; Itoyama, S; Matsumura, O; Mitarai, T; Murakawa, M; Sekine, S; Tamura, H; Tokushima, H | 1 |
| Bock, H; Mares, A | 1 |
| Koike, M; Nio, Y; Sumi, S; Tamura, K; Tanigawa, K; Xu, G | 1 |
| Asano, S; Inatomi, N; Murakami, I; Nagaya, H; Satoh, H; Yukishige, K | 1 |
| Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H | 1 |
| Mansmann, U; Roots, I; Rost, KL | 1 |
| Amano, K; Goto, A; Kondo, H; Moriwaki, H; Muto, Y; Seko, A; Shimizu, H; Sugie, S; Takagi, S; Yoshimi, N | 1 |
| Kajiwara, M; Kawada, H; Kidaira, K; Kimura, K; Nishifuku, K; Sato, K; Sohara, H; Taniguchi, Y; Wang, XM | 1 |
| Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A | 1 |
| Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E | 1 |
| Hildebrandt, AG; Kleeberg, U; Krusekopf, S; Ruckpaul, K | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ | 1 |
| Chejfec, G; Karpf, J; Kurucar, C; Levine, G; Schnell, TG; Sontag, SJ | 1 |
| Eberle, D; Hummel, RP; Kuhn, R | 1 |
| Florent, C; Forestier, S | 1 |
| Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ | 1 |
| Chey, WD; DelValle, J; Nostrant, TT; Scheiman, JM; Woods, M | 1 |
| Buchi, KN; Jennings, DE; Karol, MD; Ringham, GL; Sanders, SW; Tolman, KG | 1 |
| Adachi, H; Ahmed, T; Hori, T; Matsubara, T; Nakahara, A; Sumazaki, R; Takita, H; Yamada, M | 1 |
| Daskalopoulous, G; Hazell, SL; Massey, D; Mitchell, HM | 1 |
| Akahane, T; Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Shimizu, T | 1 |
| Lambert, JR; Midolo, PD; Turnidge, JD | 1 |
| Andersson, T; Unge, P | 1 |
| Müller, P; Simon, B | 1 |
| Richter, JE | 1 |
| Bozymski, EM; Shaheen, NJ | 1 |
| Camargo, E; Sampliner, RE; Sharma, P | 1 |
| Bargiggia, S; Bianchi Porro, G; Lazzaroni, M | 1 |
| Arnestad, JS; Kleveland, PM; Waldum, HL | 1 |
| Burkhardt, F; Dammann, HG; Fuchs, W; Richter, G; Walter, TA; Wolf, N | 1 |
| Kimura, M; Seki, H; Urakami, Y | 1 |
| Hakusui, H; Masubuchi, N; Okazaki, O | 2 |
| Ishizaki, T; Kim, HK; Kwon, JT; Sohn, DR | 1 |
| Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N | 1 |
| Crabtree, JE; Dattilo, M; Figura, N | 1 |
| Bateman, DN | 1 |
| de Muret, A; Dewerdt, S; Lorette, G; Machet, L; Vaillant, L | 1 |
| Arroyo Villarino, MT; Esteva Díaz, F; Lanas Arbeloa, A; Ortego Fernández de Retana, J; Sainz Samitier, R | 1 |
| Chakravarthy, BK; Gandhi, TP; Modi, IA; Modi, RI; Mody, VD; Pandya, KK; Satia, MC | 1 |
| Harris, RA; Kuppermann, M; Richter, JE | 2 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Chambers, S; Gould, SR; Lim, AG; Walker, C | 1 |
| Baxter, G; Jones, RH | 1 |
| Dhar, A; Gupta, VK; Rattan, A; Sharma, MP; Srinivasan, S | 1 |
| Flury, R; Fried, M; Kayser, S; Wirth, HP; Zbinden, R | 1 |
| Chen, P; Flockhart, DA; Ko, JW; Sukhova, N; Thacker, D | 1 |
| Hoffman, JS | 1 |
| Horvat, D; Ivandić, A; Ivanis, N; Karner, I; Rubinić, M; Stimac, D; Vcev, A; Vceva, A; Volarić, M | 1 |
| Daskalopoulos, G; Hanna, G; Hazell, SL; Mitchell, HM | 1 |
| Arimori, K; Fujiyama, S; Katsuki, H; Nakamura, C; Nakano, M | 1 |
| Besancon, M; Sachs, G; Shin, JM; Simon, A | 1 |
| Langtry, HD; Wilde, MI | 1 |
| Alvarez García, M; Carvajal García-Pando, A; Sánchez Sánchez, A; Viana de Miguel, C | 1 |
| Fuchs, W; Müller, P; Simon, B | 1 |
| Isolauri, J; Nevalainen, J; Viljakka, M | 1 |
| Hirakawa, T | 1 |
| Matsukura, N | 1 |
| Ammon, S; Klotz, U; Treiber, G | 1 |
| Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM | 1 |
| Levy, N; Neeman, I; Stermer, E; Tabak, M | 1 |
| Chiba, N | 1 |
| Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J | 1 |
| el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M | 1 |
| Harris, A | 1 |
| Lal, S; Sheikh, RM; Zuberi, BF | 1 |
| Brummer, RJ; Geerling, BJ; Stockbrügger, RW | 1 |
| Festen, HP; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG | 1 |
| Haber, M; Kidd, S; Riff, DS; Rose, P; Siepman, N; Weissfeld, A | 1 |
| Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A | 1 |
| Haber, M; Kidd, S; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A | 1 |
| Jaup, BK | 1 |
| Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS | 1 |
| Malfertheiner, P; Mégraud, F | 1 |
| de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ | 1 |
| Castell, DO; Katz, PO | 1 |
| Masubuchi, N; Okazaki, O | 1 |
| Andersson, K; Bayati, A; Lee, H; Lorentzon, P | 1 |
| Chiocca, JC; Salis, GB | 1 |
| Caputi, AP; Greco, S; Mazzaglia, G; Pagliaro, L | 1 |
| Dixon, JS; Pipkin, GA; Williamson, R; Wood, JR | 1 |
| Isomoto, H; Kohno, S; Matsunaga, K; Mizuta, Y; Oofukuji, M; Osabe, M; Syukuwa, S; Takeno, Y | 1 |
| Ahmed, SM; Bano, S; Khan, RM; Panja, C | 1 |
| Aoki, T; Fukuchi, Y; Kashiwagi, H; Omura, K; Omura, N | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Seki, M; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Fujiki, K; Horiuchi, T; Ohkusa, T; Shimoi, K; Suzuki, S; Takashimizu, I | 1 |
| Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J | 1 |
| Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y | 1 |
| Battiston, L; Moretti, M; Pozzato, G; Tulissi, P | 1 |
| Fennerty, MB | 1 |
| Bardhan, KD; Cooper, BT; Dixon, MF; Harris, AW; Kerr, GD; Langworthy, H; Levi, S; Misiewicz, JJ; O'Morain, C; Piper, D | 2 |
| Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H | 1 |
| Franko, TG; Richter, JE | 1 |
| Dorsch, E; Earnest, DL; Greski-Rose, PA; Jennings, DE; Jones, J | 1 |
| Boku, N; Ohtsu, T | 1 |
| Dattilo, M; Russo, A | 1 |
| Hibi, T; Ishii, H; Iwai, N; Miyayama, A; Mori, M; Oonuki, M; Suzuki, H; Suzuki, M; Tsunematsu, N | 1 |
| Chang, KL; Gums, JG; Smith, JD | 1 |
| Cho, SW; Hahm, KB; Joo, HJ; Kim, JH; Kim, YS; Lee, KJ; Yim, H | 1 |
| Haga, Y; Nakamura, Y; Nakatsura, T; Ogawa, M; Sameshima, H; Shibata, Y; Tanimura, M | 1 |
| Abbasciano, V; Caselli, M; Ruina, M; Sartori, S; Trevisani, L; Verdianelli, G | 1 |
| King, VJ | 1 |
| Arakawa, Y; Horie, T; Kaneko, M; Kawamura, F; Kurosaka, H; Kuwayama, H; Matsukawa, Y; Murakami, M; Nishinarita, S; Takei, M | 1 |
| El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL | 1 |
| Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD | 1 |
| Malfertheiner, P; Nakao, M | 1 |
| Johnsen, R; Lindsetmo, RO; Revhaug, A | 1 |
| Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P | 2 |
| Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M | 1 |
| Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ | 1 |
| Scott, BB | 1 |
| de Boer, WA; Schneeberger, PM; van Etten, RJ | 1 |
| Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A | 1 |
| Andersson, T; Holmberg, J; Röhss, K; Walan, A | 1 |
| Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M | 1 |
| Ajmi, S; Mehdi, A | 1 |
| Yu, Z | 1 |
| Liu, W; Lü, B; Xiao, S | 1 |
| Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M | 1 |
| Goya, T; Matsuo, K; Nakamoto, M; Nishihara, G; Takeda, K; Ueno, K; Urabe, M; Yasunaga, C | 1 |
| Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H | 1 |
| Akiba, Y; Ishii, H; Nakamura, M; Oda, M | 1 |
| Barbet, JP; Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J | 1 |
| Ouatu-Lascar, R; Triadafilopoulos, G | 1 |
| Bracy, NA; Castell, DO; Katz, PO; Peghini, PL | 1 |
| Ikezawa, K; Kashimura, H; Mahmudul, H; Matsuzaki, Y; Mutoh, H; Nakahara, A; Tanaka, N; Yanaka, A | 1 |
| Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M | 1 |
| Ishii, H; Miura, S; Mori, M; Sakaguchi, AA; Suzuki, H; Suzuki, M | 1 |
| Forget, P; Forget, PP; Hendriks, JJ; Tran, TM; Van den Neucker, A | 1 |
| Hetzel, D | 1 |
| Bierti, L; Bortoli, A; Colombo, E; Fertitta, AM; Lanzi, GL; Minoli, G; Spinzi, GC; Venturelli, R | 1 |
| de Boer, SY; Siem, TH | 1 |
| Lambert, JR; Treiber, G | 1 |
| Ahuja, V; Bal, C; Dhar, A; Sharma, MP | 1 |
| Al, MJ; Michel, BC; Rutten, FF; van Hout, BA | 1 |
| Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J; Senouci, L | 1 |
| Hahn, H; Vogt, K | 1 |
| Blum, RA; Greski-Rose, PA; Hunt, RH; Jennings, DE; Kidd, SL; Shi, H | 1 |
| Geus, WP; Lamers, CB; Mulder, PG; Nicolai, JJ; Van den Boomgaard, DM | 1 |
| Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H | 1 |
| Coremans, A; de Boer, WA; Schneeberger, PM; van Etten, RJ | 1 |
| Hashimoto, Y | 1 |
| Bashford, JN; Chapman, SR; Norwood, J | 1 |
| Alarcón, T; Domingo, D; López-Brea, M; Martínez, MJ; Sánchez, I; Sanz, JC | 1 |
| Kaitani, K; Kita, T; Murakami, M; Nishio, K; Saita, H; Sou, Y; Takahashi, Y | 1 |
| Higashi, Y; Kashima, K; Kodama, T; Sasaki, Y; Sawai, N; Tanahashi, T; Tatsumi, Y; Yamaoka, Y | 1 |
| Kiel, G; Meining, A; Stolte, M | 1 |
| Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M | 1 |
| Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB | 1 |
| Cayla, R; de Mascarel, A; Forestier, S; Joubert-Collin, M; Lamouliatte, H; Mégraud, F; Zerbib, F | 1 |
| Li, AP; Masubuchi, N; Okazaki, O | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
| Gleiter, CH | 1 |
| Estrada, R; Fennerty, MB; Knigge, K; Laine, L; Trujillo, M | 1 |
| Kotze, D; Louw, JA; Marks, IN; Moola, S; Van Rensburg, CJ | 1 |
| Baczek, J; Laskowiec, G | 1 |
| Aoki, T; Gang, C; Kashiwagi, H; Omura, K; Omura, N | 1 |
| Zaigler, M | 1 |
| Axelsson, CK; Bonnevie, O; Carling, L; Ekström, P; Forssell, H; Kraglund, K; Stubberöd, A | 1 |
| De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A | 1 |
| Goff, JS | 1 |
| Howden, CW; Hunt, RH | 1 |
| Burnham, WR; Kamm, MA; Newton, M | 1 |
| Chiba, T; Fukui, H; Hassan, S; Kinoshita, Y; Maekawa, T; Okada, A; Okamoto, H; Waki, S | 1 |
| Ariake, K; Fujiki, K; Horiuchi, T; Ishii, K; Kumagai, J; Ohkusa, T; Sakurazawa, T; Shimoi, K; Suzuki, S; Takashimizu, I; Tanizawa, T | 1 |
| Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T | 1 |
| Fuchs, W; Müller, P; Peifer-Weiss, A; Simon, B | 1 |
| Howden, CW; Sharma, VK; Ugheoke, EA; Vasudeva, R | 1 |
| Andou, T; Fujinami, T; Hara, M; Hirako, M; Kamiya, T; Kobayashi, Y; Misu, N; Nagao, T | 1 |
| Cadiot, G; Coste, T; Escourrou, J; Forestier, S; Mignon, M; Pospaï, D; Ruszniewski, P | 1 |
| Fukuda, S; Haga, Y; Mikami, T; Munakata, A; Murata, Y; Shimoyama, T; Tanaka, M; Yamagata, R; Yoshimura, T | 1 |
| Ahuja, V; Bal, CS; Sharma, MP | 1 |
| Fujita, T; Kobayasi, I; Mine, T; Suzuki, J | 1 |
| Dattilo, M; Figura, N | 1 |
| Akiba, Y; Ishii, H; Kishikawa, H; Nakamura, M; Oda, M | 1 |
| Hibi, T; Ishii, H; Kitahora, T; Mori, M; Nagahashi, S; Suzuki, H; Suzuki, M | 1 |
| Arimori, K; Katsuki, H; Nakano, M; Yasuda, K | 1 |
| Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T | 1 |
| Anderson, C; Castell, DO; Katz, PO; Khoury, R | 1 |
| Abbasciano, V; Caselli, M; Galvani, F; Ruina, M; Sartori, S; Trevisani, L; Verdianelli, G | 1 |
| Bock, H; Domschke, W; Heep, M; Kirchner, T; Lehn, N; Pohle, T; Stoll, R | 1 |
| Boixeda, D; Gisbert, JP; Martín de Argila, C | 1 |
| Blandino, G; Carbone, M; Ciliberti, FA; Cusumano, V; De Sarro, A; De Sarro, GB; Fera, MT; Riggio, G | 1 |
| Fujishima, K; Ito, H; Kawabe, N; Kazumiya, H; Kobayashi, S; Kurokawa, S; Miyata, F; Murase, K | 1 |
| Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S | 1 |
| Freedman, MD | 1 |
| Collier, DS; Olsen, KM; Peddicord, TE | 1 |
| Bertaccini, G; Coppelli, G; Coruzzi, G; Frati, P | 1 |
| Iwasaki, A | 1 |
| Harasawa, S; Kouda, K; Kurumada, T; Miwa, T; Shirai, T; Tada, U; Takagi, A; Wada, T; Watanabe, S | 1 |
| Kawamura, N; Nakagawa, M; Nakagawa, S; Ooishi, M; Ooizumi, H; Saitou, M; Yoda, Y | 1 |
| Kihira, K; Kimura, K; Kumakura, Y; Sato, K; Sugano, K; Yoshida, Y | 1 |
| Kanayama, S | 1 |
| Eastham, JH; McAndrews, KL | 1 |
| Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA | 1 |
| Liu, WZ; Shi, Y; Tytgat, GN; Wu, SM; Xiao, SD; Xu, WW; Zhang, DZ | 1 |
| Crouch, SL; Jones, R | 1 |
| Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T | 1 |
| Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S | 1 |
| Cuddihy, PJ; Griffith, H; Maheshwar, A | 1 |
| Hassan, M; Ikezawa, K; Kashimura, H; Mutoh, H; Nakahara, A; Sawahata, T; Suzuki, K; Tanaka, N; Watanabe, T | 1 |
| Axon, AT; Everett, S; Langworthy, H; Mapstone, NP; Moayyedi, P; Neville, PM; Tompkins, D | 1 |
| Gisbert, JP | 1 |
| Capodicasa, E; De Bellis, F; Pelli, MA | 1 |
| Addolorato, G; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, GB; Papa, A | 1 |
| Helbling, A; Pichler, WJ; Schnyder, B | 1 |
| Saika, M; Senba, E; Ueyama, T | 1 |
| Bozzola, L; Di Mario, F; Fortunato, A; Franceschi, M; Leandro, G; Meli, S; Pilotto, A; Rassu, M; Scagnelli, M; Soffiati, G; Valerio, G | 1 |
| Peckman, HJ | 1 |
| Eriksson, LS; Hedenström, H; Thoring, M | 1 |
| Arimori, K; Fujii, J; Masa, K; Miyamoto, S; Nakano, M; Nakayama, T | 1 |
| Della Monica, P; Lombardo, L; Masoero, G; Pera, A | 1 |
| Bohr, U; Glasbrenner, B; Möricke, A; Riediger, C; Trautmann, M; Vogt, K | 1 |
| Mulder, PG; Samsom, M; Smout, AJ; van Herwaarden, MA; van Nispen, CH | 1 |
| Hirai, S; Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Watanabe, S | 1 |
| Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S | 1 |
| Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE | 1 |
| Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D | 1 |
| Fuchs, W; Hörner, M; Schlauch, D; Sellinger, M; Sieg, A | 1 |
| Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
| Araki, T; Kakinoki, B; Morinaka, Y; Takeuchi, Y; Uchiyama, K; Wakatsuki, D | 1 |
| Grade, AJ; Medlin, SM; Ramirez, FC; Shah, IA | 1 |
| Flockhart, DA; Jang, IJ; Ko, JW; Nam, SK; Shin, JG; Shin, SG | 1 |
| Faure, C; Languepin, J; Pelatan, C | 1 |
| Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
| Enatsu, I; Hanada, Y; Kuyama, Y; Makino, H; Mineshita, S; Qi, J; Sanaka, M; Tanaka, H; Yamanaka, M | 1 |
| Howden, CW; Sharma, VK; Vasudeva, R | 1 |
| de los Ríos, IL; Pérez Roldán, F; Rodríguez Quinzaños, E | 1 |
| Cockayne, SE; Gawkrodger, DJ; Glet, RJ; McDonagh, AJ | 1 |
| Fitzgerald, RC; Ouatu-Lascar, R; Triadafilopoulos, G | 1 |
| Fuchs, W; Harder, H; Kiel, G; Pfützer, R; Singer, MV; Stephan, F; Teyssen, S | 1 |
| Horbach, S; Kromer, W; Lühmann, R | 1 |
| Itoh, M; Joh, T; Kurokawa, T; Sasakii, M; Seno, K; Tsuchida, K; Yokoyama, Y | 1 |
| Barclay, ML; Begg, EJ; Ketelbey, JW; Peters, WA; Robson, RA | 1 |
| Bravo, LE; Campo, C; Correa, P; Mera, R; Realpe, JL | 1 |
| Dobrilla, G; Fiocca, R; Piazzi, L | 1 |
| Colwell, HH; Henning, JM; Hunt, RH; Mathias, SD; Pasta, DJ | 1 |
| Arakawa, T; Ohara, T | 1 |
| Holm, A; Magnusson, KE; Oberg, A; Sundqvist, T | 1 |
| Dave, B; Rubin, W | 1 |
| Dilger, K; Klotz, U; Zheng, Z | 1 |
| Ekpe, A; Jacobsen, T | 1 |
| Jakobs, R; Maass, S; Martin, WR; Riemann, JF; Spiethoff, A | 1 |
| de Boer, WA; de Grauw, WJ; Lai, JY | 1 |
| Bildfell, R; Dewey, CE; Friendship, RM; Melnichouk, S | 1 |
| Condra, LJ; Marcus, D; Morreale, AP; Stolley, SN | 1 |
| Blandizzi, C; Carignani, D; Colucci, R; Del Tacca, M; Gherardi, G; Lazzeri, G; Marveggio, C; Natale, G | 1 |
| Norinder, A; Ohlin, B; Tennvall, GR | 1 |
| Aoki, T; Chen, G; Kashiwagi, H; Omura, N; Suzuki, Y; Yano, F | 1 |
| Fask, A; Saltiel, E | 1 |
| Furukawa, M; Nagashima, R; Nishise, S; Shinzawa, H; Takahashi, T; Takeda, H | 1 |
| Chow, MS; Dunn, A; Quercia, RA; Reddy, P; White, CM | 1 |
| Cavanaugh, JH; Karol, MD; Locke, CS | 2 |
| Hirasaki, S; Koide, N; Ogawa, H; Tsuji, T | 1 |
| Jansen, JB; Van Oene, JC | 1 |
| Howden, CW | 3 |
| Reilly, JP | 1 |
| Sharma, VK | 1 |
| Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA | 1 |
| Cryer, B; Feldman, M; Lee, E; Sammer, D; Spechler, SJ | 1 |
| Castell, DO; Katzka, DA | 1 |
| Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J | 1 |
| Kohigashi, K; Matsukawa, Y; Nakazawa, T; Saita, H; Sekikawa, A; Shio, S; Sou, Y; Takahashi, Y; Yoshinaga, T | 1 |
| Fujishiro, M; Gotoda, T; Kondo, H; Oda, I; Ono, H; Saito, D; Yamaguchi, H | 1 |
| Hoshiya, S; Ishida, H; Itoh, T; Ninomiya, H; Saito, S; Shingaki, M; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| De Boer, WA; Jansen, JB; Schneeberger, PM; Van De Wouw, BA; Van Etten, RJ; Van Oijen, AH | 1 |
| Chang, CS; Chen, GH; Ko, CW; Poon, SK; Tsai, WL; Yeh, HZ; Yu, HK | 1 |
| Bustamante, M; Stollman, N | 1 |
| Bong, JL; Douglas, WS; Lucke, TW | 1 |
| Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD | 1 |
| Claessens, AA; Heerdink, ER; Lamers, CB; Leufkens, HG; van Eijk, JT | 4 |
| Akamatsu, T; Furihata, K; Miyabayashi, H; Shimizu, T; Ueno, I | 1 |
| de Boer, WA; Nouhan, N; Plaisier, AP; Quint, WG; Schneeberger, PM; van Doorn, LJ | 1 |
| Alexandridis, T; Meining, A; Seifert, E; Stolte, M | 1 |
| Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S | 1 |
| Castell, DO; Hatlebakk, JG; Katz, PO | 2 |
| Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T | 1 |
| Ozaltín, N | 1 |
| Bueno, ML; Castro, LP; Coelho, LG; Gomes, BS; Lopes, LG; Martins, GM; Passos, MC | 1 |
| Dinkhauser, P; Fürst, J; Gschwentner, M; Laich, A; Lang, F; Paulmichl, M; Ritter, M; Rossmann, H; Scandella, E; Schmarda, A; Seidler, U; Wöll, E | 1 |
| Brousal, A; Kearney, DJ | 1 |
| Ducóns, JA; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S; Vera, J | 1 |
| Moustafa, AA | 1 |
| Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L | 1 |
| Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y | 1 |
| Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y | 1 |
| Achari, R; Cavanaugh, JH; Chun, AH; Erdman, K; Zhang, Y | 1 |
| McCaffrey, E | 1 |
| Lin, CH; Peters, J; Rabah, R; Shashidhar, H; Thomas, R; Tolia, V | 1 |
| Fass, R; Gerson, LB; Hatton, BN; Jones, W; Pulliam, G; Ryono, R; Sampliner, RE; Triadafilopoulos, G | 1 |
| Grobecker, H; Holstege, A; Ittner, KP; Kees, F; Lock, G; Schölmerich, J; Zimmermann, M | 1 |
| Comas, A; Hidalgo, A; Salgueiro, E | 1 |
| Capurso, L; Dobrilla, G | 1 |
| Fujita, N; Kassai, K; Kondo, M; Naito, Y; Tanaka, Y; Yoshida, N; Yoshikawa, T | 1 |
| Azuma, T; Ito, S; Ito, Y; Kato, T; Kuriyama, M; Miyaji, H; Suto, H; Yamazaki, Y | 1 |
| Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V | 1 |
| Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA | 1 |
| Kaushik, SP; Vu, C | 1 |
| Hori, K; Hoshino, U; Kohno, M; Okumura, T; Yamada, M; Yoshimura, T | 1 |
| Ammon, S; Kees, F; Klotz, U; Treiber, G | 1 |
| Bhasin, DK; Pathak, CM; Ray, P; Sharma, BC; Singh, K | 1 |
| Bergman, KL; DiGiacinto, JL; Hoie, EB; Olsen, KM | 1 |
| Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE | 1 |
| Kristl, A; Vrecer, F | 1 |
| Kamiya, S; Osaki, T; Taguchi, H; Takahashi, M; Yamaguchi, H | 1 |
| Howden, CW; Peyton, B; Raufman, JP; Sharma, VK; Spears, T | 1 |
| Adachi, K; Hashimoto, T; Hirakawa, K; Ishihara, S; Kaji, T; Kawamura, A; Kinoshita, Y; Niigaki, M; Okuyama, T; Sato, H; Takashima, T; Watanabe, M | 1 |
| Samsom, M; Smout, AJ; van Herwaarden, MA | 1 |
| Joubert-Collin, M; Lamouliatte, H; Perie, F | 1 |
| Imai, T; Konno, M; Muraoka, S; Takahashi, M | 1 |
| Kurosawa, A; Minowa, T; Miwi, H; Murai, T; Nagahara, A; Ohkura, R; Ohtaka, K; Sato, K; Sato, N; Yamada, T | 1 |
| Galmiche, JP | 1 |
| Shimizu, T; Tamura, Y; Taneike, I; Toyoda, S; Yamamoto, T; Yamashiro, Y | 1 |
| Fuchs, W; Göksu, MA; Müller, P; Schlüter, F; Simon, B | 1 |
| Bart, A; Beumer, HJ; Cattoli, G; Klaver, PS; Kuipers, EJ; Kusters, JG; Pot, RG; Robijn, RJ; van der Gaag, I; van Vugt, R; Vandenbroucke-Grauls, CM | 1 |
| Malki, SA; Yeomans, ND | 1 |
| Andrea Grassi, S; Battaglia, F; Benedetti, E; Bottona, E; Caroli, A; Costan-Biedo, F; Dal Bò, N; De Bastiani, R; Di Mario, F; Germanà, B; Leandro, G; Madia, D; Marcon, V; Marin, R; Monica, F; Olivieri, P; Orzes, N; Pilotto, A; Ronzani, G; Saggioro, A; Tafner, G | 1 |
| Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
| Amidon, PB; Jankovich, R; Kaul, AF; Stoukides, CA | 1 |
| Ehlert, DA; Geurkink, EA; Nelson, WW; Reichelderfer, M; Vermeulen, LC | 1 |
| Weinstein, WM | 1 |
| Huang, AH; Huang, CC; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Endo, M; Sugihara, K | 1 |
| Habu, Y; Inokuchi, H; Kawai, K; Kiyota, K; Oyasu, K; Sumitomo, Y; Wakamatsu, T | 1 |
| Adachi, K; Amano, K; Fukuda, R; Ishihara, S; Katsube, T; Kawamura, A; Kinoshita, Y; Takashima, T; Watanabe, M; Yuki, M | 1 |
| Camacho-Lobato, L; Castell, DO; Hatlebakk, JG; Katz, PO | 1 |
| Dunn, NR; Freemantle, S; Martin, RM; Shakir, S | 1 |
| Bock, H; Heep, M; Koop, H; Lehn, N | 1 |
| Botta, F; Chiarbonello, B; Fasoli, A; Giannini, E; Lantieri, PB; Malfatti, F; Risso, D; Romagnoli, P; Savarino, V; Testa, R | 1 |
| Abo, T; Fukuda, M; Kawamura, T; Miyaji, C; Toyabe, S; Watanabe, H | 1 |
| Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H | 1 |
| Färkkilä, M; Jousimies-Somer, H; Nuutinen, H; Salaspuro, M; Tillonen, J; Väkeväinen, S | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Kato, M; Komatsu, Y; Mizushima, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
| Thomson, AB | 1 |
| De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M | 1 |
| Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T | 1 |
| Aviv, JE; Close, LG; Kaplan, ST; Liu, H; Parides, M | 1 |
| Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y | 1 |
| Sloet van Oldruitenborgh-Oosterbaan, MM; van den Wollenberg, L | 1 |
| Akura, Y; Fujiwara, T; Hamazaki, K; Ikeda, Y; Matsumoto, T; Murashima, N; Nishisita, C; Umekawa, Y | 1 |
| Fass, R; Hayden, CW; Kovacs, TO; Malagon, IB; Murthy, U; Pulliam, G; Wendel, C | 1 |
| Haber, MM; Hirschowitz, BI | 1 |
| Bell, N; Greski-Rose, P; Hunt, RH; Jennings, DE; Karol, MD; Sachs, G | 1 |
| Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G | 1 |
| Garnett, WR; Prescott, J | 1 |
| Brasil, DD; Brito, AR; de Almeida, AB; de Paula, AC; Gracioso, JD; Hiruma-Lima, CA; Muller, AH; Toma, W | 1 |
| Alexandridis, T; Schmitz, JM; Seifert, E; Stolte, M; Vieth, M | 1 |
| Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH | 1 |
| Howden, CW; Leontiadis, GI; Sharma, VK | 1 |
| Mukherjee, S | 2 |
| Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA | 1 |
| Romaguera, C; Vilaplana, J | 1 |
| Chiba, T; Fukuda, R; Ishihara, S; Kawashima, K; Kazumori, H; Kinoshita, Y | 1 |
| Lanas, AI | 1 |
| Aegerter, PH; de Mascarel, A; Lavergne, A; Megraud, F; Molina, T; Palazzo, L; Rambaud, JL; Ruskoné-Fourmestraux, A | 1 |
| Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF | 1 |
| Hirche, H; Jöckel, KH; Küppers, B; Ose, C; Rammler, B; Warth, L | 1 |
| Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Kato, M; Sugiyama, T; Takeda, H | 1 |
| Kohgo, Y; Satoh, T; Shibata, N; Tanabe, H; Watari, J; Yokota, K | 1 |
| Ohkusa, T; Watanabe, M | 1 |
| Castell, DO | 1 |
| Alam, SM; Carlson, JD; Dham, R; Dugger, HA; Erdmann, GR; Henderson, W | 1 |
| Harada, H; Kobayashi, S; Miki, H; Ohmori, M; Sotozono, M; Uraoka, T; Yamanoi, Y | 1 |
| Arakawa, Y; Ishii, Y; Kato, K; Kawamura, F; Kawamura, Y; Komuro, S; Nagata, T; Nemoto, N; Nishinarita, S; Sugitani, M; Takahashi, Y; Yanai, M | 1 |
| Bianchi Porro, G; Imbesi, V; Maconi, G; Parente, F; Russo, A; Vago, L | 1 |
| Furuta, T; Hanai, H; Ishizaki, T; Kaneko, E; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F | 1 |
| Eishi, Y; Fujiki, K; Kumagai, J; Ohkusa, T; Takashimizu, I; Tanizawa, T; Watanabe, M; Yokoyama, T | 1 |
| Alam, E; Mehdi, I; Qureshi, H | 1 |
| Arimori, K; Fujii, J; Hamada, A; Masa, K; Nakano, M | 1 |
| Abe, S; Hoshino, E; Motegi, H; Suzuki, D; Tansho, S; Yamaguchi, H | 1 |
| Endo, H; Higuchi, S; Ohmi, N; Yoshida, H | 2 |
| Blum, RA; Jusko, WJ; Krzyzanski, W; Puchalski, TA | 1 |
| Ozaltin, N; Yardimci, C | 1 |
| Castell, DO; Katz, PO; Katzka, DA; Ramakrishnan, A; Srinivasan, R; Vela, MF | 1 |
| Anic, T; Aralica, G; Bilic, I; Buljat, G; Ivankovic, D; Mikus, D; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rotkvic, I; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Stancic-Rokotov, D; Zoricic, I | 1 |
| Nagata, K; Sone, N; Tamura, T | 1 |
| Avidan, B; Bar-Meir, S; Keller, N; Melzer, E | 1 |
| Almeida, AB; Brasil, DS; Gracioso, JS; Hiruma-Lima, CA; Muller, AH; Paula, AC; Souza Brito, AR; Toma, W | 1 |
| Ahmed, F; Chathadi, KV; Chey, WD; Montague, J; Murthy, U | 1 |
| Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM | 1 |
| Castell, DO; Katz, PO; Xue, S | 1 |
| Carvajal García-Pando, A; Cuervo Martín, JR; García Ortega, P; Sánchez Sánchez, A | 1 |
| Akamatsu, H; Mikawa, K; Nishina, K; Niwa, Y | 1 |
| Athmann, C; Boldt, JH; Brunner, G | 1 |
| Bradley, CP; Greenfield, SM; Jones, MI; Jowett, S; Seal, R | 1 |
| Boknik, P; Domschke, W; Fischer, H; Huber, V; Konturek, JW; Luess, H; Neumann, J; Schmitz, W | 1 |
| Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF | 1 |
| Miehsler, W; Oberhuber, T; Püspök, A; Vogelsang, H | 1 |
| Bardou, M | 1 |
| Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V | 1 |
| Dupas, JL; Houcke, P; Samoyeau, R | 1 |
| Gerson, LB; Triadafilopoulos, G | 1 |
| Cathomas, G; Dent, J; Fried, M; Guldenschuh, I; Menne, D; Schwizer, W; Thumshirn, M | 1 |
| Belafsky, PC; Koufman, JA; Postma, GN | 1 |
| Arimori, K; Hamada, A; Katsuki, H; Nakamura, C; Nakano, M | 2 |
| McGuigan, JE | 1 |
| Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N | 1 |
| Scully, C | 1 |
| Dixon, CA; Hopkins, RJ; Meyer, JM; Siepman, NY; Silliman, NP; Sugg, JE | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Bateson, MC | 1 |
| Kawabe, T; Maeda, S; Ogura, K; Okamoto, M; Omata, M; Shiratori, Y; Yamaji, Y; Yoshida, H | 1 |
| Kawamura, K; Kimura, M; Mukai, K; Nakamura, S; Nakamura, T; Sawa, H; Shiku, H; Suzuki, H; Toyoda, H; Yamaguchi, M | 1 |
| Gürakan, F; Koçak, N; Ozen, H; Saltik, IN; Yüce, A | 1 |
| Tytgat, GN | 2 |
| Carrière, F; Grandval, P; Joubert-Collin, M; Laugier, R; Renou, C; Ville, E | 1 |
| Biswas, SK; Kamei, K; Miyaji, M; Nishimura, K; Yokoyama, K | 1 |
| Chiu, YL; Freston, J; Lukasik, N; Pan, WJ; Täubel, J | 1 |
| Bhattacharjya, AS; Dean, BB; Ofman, JJ; Siddique, RM; Yamashita, BD | 1 |
| Adachi, K; Fujishiro, H; Hashimoto, T; Hattori, S; Hirakawa, K; Ishihara, S; Ishimura, N; Kaji, T; Kawamura, A; Kinoshita, Y; Niigaki, M; Sato, H; Watanabe, M | 1 |
| Aoyama, N; Hohda, T; Kasuga, M; Kita, T; Nishiguchi, K; Nishitora, Y; Okumura, K; Sakaeda, T; Sakai, T; Sirasaka, D; Tamura, T; Tanigawara, Y | 1 |
| Fass, R; Hayden, C; Klaurens, LM; Malagon, I; Pulliam, G; Raisch, DW | 1 |
| Fung, TT; Hui, PK; Lam, KM; Lau, CF; Loo, CK; Tung, SY; Wong, AM | 1 |
| Hansen, T; Jacobsen, CD; Juul-Hansen, P; Rydning, A | 1 |
| Farup, PG; Juul-Hansen, PH; Rydning, A | 1 |
| Cole, AT; Hawkey, CJ; Hawkey, GM; Long, RG; McIntyre, AS | 1 |
| Beglinger, C; Burnand, B; Froehlich, F; Gonvers, JJ; Hildebrand, P; Saraga, E; Schneider, C; Vader, JP; Wietlisbach, V | 1 |
| Doan, TT; Griffin, JS; Lukasik, NL; O'Dea, RF; Pan, WJ; Wang, Q | 1 |
| Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A | 1 |
| Caro, JJ; Salas, M; Ward, A | 1 |
| Grigor'ev, PIa; Iakovenko, EP; Talanova, EV | 1 |
| Inaba, M; Ishizeki, K; Makino, I; Tamori, K; Tani, M; Yokohama, S | 1 |
| Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
| Aragona, F; Di Vita, G; Leo, P; Montalto, G; Patti, R | 1 |
| Carrière, F; Grandval, P; Laugier, R; Renou, C; Ville, E | 1 |
| Faure, C; Hankard, R; Jacoz-Aigrain, E; Laurence, M; Michaud, L; Mougenot, JF; Navarro, J; Popon, M; Shaghaghi, EK | 1 |
| McColl, KE | 2 |
| Galmiche, JP; Jones, RH; Malfertheiner, P; Stanghellini, V | 1 |
| Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC | 1 |
| Morreale, A | 1 |
| Chey, WD; Fendrick, AM | 1 |
| Cohen, JS | 1 |
| Forget, PP; Hendriks, HJ; van Kreel, B | 1 |
| Bakker, JA; Forget, PP; Heijmans, H; Hendriks, HJ; Menheere, PP; Spaapen, LJ; ter Heide, H | 1 |
| Amin, MR; Digges, N; Johnson, P; Koufman, JA; Postma, GN | 1 |
| Araj, GF; Chahine, C; Chedid, M; Moukhachen, O; Sharara, AI | 1 |
| Ho, B; Ling, KL; Luman, W; Ng, HS | 1 |
| Cimmino, A; Melton, ST | 1 |
| Herszényi, L; Tulassay, Z | 1 |
| Her, HH; Jang, JY; Kim, KH; Kim, SW; Park, SJ; Park, YH | 1 |
| Jovanović, D; Kilibarda, V; Maksimović, M | 1 |
| Asaka, M; Hamashima, C; Ikeda, S; Tamamuro, T | 1 |
| Hirschowitz, BI; Mohnen, J; Simmons, J | 3 |
| Chiu, YL; Lukasik, NL; Pan, WJ; Pilmer, BL; Sharma, VK; Täubel, JJ | 1 |
| Dekker, W; Geboes, K; Mulder, CJ; Nusteling, K | 1 |
| Asaka, M; Fujioka, T; Fukuda, Y; Kato, M; Kimura, K; Kobayashi, S; Kuwayama, H; Satoh, K; Shimizu, K; Shimoyama, T; Sugiyama, T; Takemoto, T | 2 |
| Kearney, DJ; Mégraud, F | 1 |
| Malfertheiner, P | 1 |
| Durai, D; Murphy, JK; Salam, I; Sundaram, B | 1 |
| Jarvis, B; Matheson, AJ | 1 |
| Achazi, R; Bogaert, T; Menzel, R | 1 |
| Fukushima, Y; Hasegawa, J; Ieiri, I; Ishizaki, T; Kishimoto, Y; Kitano, M; Momiyama, K; Morisawa, T; Morita, T; Nakagawa, K; Okochi, H; Otsubo, K | 1 |
| Azerad, MA; Fassotte, C; Penson, J; Puttemans, M | 1 |
| Niimi, S; Saigusa, H; Saigusa, U; Yagi, T | 1 |
| Colwell, HH; Henning, JM; Mathias, SD; Miller, DP; Ofman, JJ; Pasta, DJ | 1 |
| Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Xiao, F | 1 |
| Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ | 1 |
| Endo, H; Higuchi, S; Ohmi, N; Ohta, K; Yoshida, H | 1 |
| Naesdal, J; Wilson, I | 1 |
| Mai, AL; Mai, KT | 1 |
| Inoue, R; Maekawa, T; Misaki, F; Ohji, G; Shimada, T; Shimoyama, M | 1 |
| Mattia, A; Wilcox, GM | 1 |
| Eiro, M; Katoh, T; Watanabe, T | 1 |
| Maceri, DR; Zim, S | 1 |
| Ammon, S; Klotz, U; Treiber, G; van Doorn, LJ; Walker, S; Wittig, J | 1 |
| Agrawal, NM; Campbell, DR; Collis, C; Graham, DY; Haber, MM; Huang, B; Lukasik, NL | 1 |
| Aoyama, N; Okumura, K; Shirasaka, D | 1 |
| Bavbek, N; Koçkar, C; Oztürk, M | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K | 2 |
| Gremse, DA | 1 |
| Goto, H; Hino, R; Kikuta, T; Ota, A; Tsuji, H | 1 |
| Furukawa, F; Sakurane, M; Shiotani, A | 1 |
| Boivin, JF; Chayette, C; Cheaib, S; Deplus, R; Macaigne, G; Simon, P | 1 |
| Barth, J; Hahne, W | 1 |
| De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V | 3 |
| Alampi, G; Bazzoli, F; Berretti, D; De Luca, L; Di Pietro, C; Fossi, S; Morelli, P; Nicolini, G; Pozzato, P; Ricciardiello, L; Roda, E; Zagari, RM | 1 |
| Ishii, H; Kitahora, T; Miyazawa, M; Nagahashi, S; Suzuki, H; Suzuki, K; Suzuki, M | 1 |
| Chang, CS; Chen, GH; Lai, CH; Poon, SK; Su, J; Wang, WC; Yang, CC | 1 |
| Beck, IT | 1 |
| Appelman, SA; Chiu, YL; Goldwater, DR; Huang, JQ; Hunt, RH; James, CF; Keith, RG; Pilmer, BL; Sridhar, S; Thomson, AB | 1 |
| Haapiainen, R; Härkönen, M; Kokkola, A; Kosunen, TU; Puolakkainen, P; Rautelin, H; Sipponen, P | 1 |
| Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA | 1 |
| Anderloni, A; Bianchi Porro, G; Imbesi, V; Maconi, G; Parente, F; Sainaghi, M; Sangaletti, O | 1 |
| Adachi, K; Fujishiro, H; Ishihara, S; Kawamura, A; Kazumori, H; Kinoshita, Y; Moriyama, N; Okuyama, T; Sato, H; Suetsugu, H; Watanabe, M | 1 |
| Bastaki, SM; Chandranath, SI; Singh, J | 1 |
| Barbier, C; Benhamou, PH; Bergeret, M; Dupont, C; Gottrand, F; Husson, MO; Kalach, N; Raymond, J | 1 |
| Koyama, H; Nomura, F; Odaka, T; Saisho, H; Yamaguchi, T | 1 |
| Heim-Hall, J; Kazantsev, GB; Schwesinger, WH | 1 |
| Bruni, AT; Ferreira, MM; Leite, VB | 1 |
| Hinder, RA | 1 |
| De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G | 1 |
| Bown, RL | 1 |
| Furuta, T; Hanai, H; Ishizaki, T; Kajimura, M; Ohashi, K; Shirai, N; Xiao, F | 1 |
| Andriulli, A; Clemente, R; Festa, V; Merla, A; Perri, F; Quitadamo, M | 1 |
| Kampitakis, E; Kouroumalis, E; Melissas, J; Mouzas, J; Schoretsanitis, G; Tsiftsis, DD | 1 |
| Bell, RH; Longnecker, DS; McDonald, JM | 1 |
| Anderson, CG; Zlabek, JA | 1 |
| Kim, JD | 1 |
| Nakamura, T | 1 |
| Asaka, M; Kato, M; Komatsu, Y; Shimizu, Y; Sugiyama, T; Takeda, H | 1 |
| Satoh, K | 2 |
| Ohkusa, T; Sato, N | 1 |
| Miwa, H; Miyazaki, A; Nagahara, A; Sato, N | 1 |
| Furuta, T; Shirai, N | 1 |
| Mitsuno, Y; Yoshida, H | 1 |
| Asaka, M; Kagaya, H; Kato, M | 1 |
| Inoue, K; Sugano, K | 1 |
| Kurosawa, A; Miwa, H; Sato, N | 1 |
| Haruma, K; Kamada, T; Kusunoki, H | 1 |
| Matsuoka, T; Miyazawa, K; Mizokami, Y; Nakamura, H; Narushima, K; Otsubo, T; Shiraishi, T | 1 |
| Hirakawa, R; Miyatani, H; Tokuyama, T; Yoshida, Y | 1 |
| Sawada, A | 1 |
| Chiba, T; Watanabe, T | 1 |
| Kawata, H; Satoh, K | 1 |
| Azuma, T; Ito, S; Yamazaki, Y | 1 |
| Takahashi, S; Tanaka, A | 1 |
| Kiriyama, Y; Koizumi, K; Kuwayama, H; Ohara, T; Suga, M; Suzuki, K; Takahashi, M; Takata, H | 1 |
| Adachi, K; Kinoshita, Y | 1 |
| Isomoto, H; Kohno, S | 1 |
| Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G | 1 |
| Sugano, K | 1 |
| Astudillo, L; Rodriguez, JA; Schmeda-Hirschmann, G | 1 |
| Ballard, ED; Freston, JW; Huang, B; Jackson, RL | 1 |
| D'Athis, P; Dupont, C; Pariente-Khayat, A; Pons, G; Rey, E; Sallerin, V; Tran, A | 1 |
| Dhir, V; Laine, L | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 2 |
| Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A | 1 |
| Byrne, M; Kay, E; Patchett, S; Sheehan, K | 1 |
| Mignon, M; Ramdani, A; Samoyeau, R | 1 |
| de Groot, GH; Mulder, CJ; Otten, MH; Oudkerk Pool, M; Smit, JM; Tan, TG; van Milligen de Wit, AW; Westerveld, BD | 1 |
| de Silva, KK; Young, P | 1 |
| Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, CL; Lai, KC; Lam, SK; Lau, GK; Wong, BC; Wong, J; Wong, WM; Yuen, MF | 1 |
| Baldi, F; Cappiello, R; Ghersi, S; Morselli-Labate, AM | 1 |
| De Silva, M; Prasad, R | 1 |
| Inaba, T; Kawai, K; Miyoshi, M; Mizuno, M; Oguma, K; Okada, H; Take, S; Tsuji, T; Yokota, K | 1 |
| Adamek, HE; Riemann, JF; Schilling, D | 1 |
| Shcherbynina, MB | 1 |
| Grove, O; Johnsson, F; Moum, B; Simren, M; Thoring, M; Vilien, M | 1 |
| Asaka, M; Shimodan, M; Sugiyama, T; Tsuchida, M; Yokota, K | 1 |
| Hirayama, Y; Kanisawa, Y; Kogawa, K; Kohda, K; Koike, K; Kuga, T; Kuroiwa, G; Niitsu, Y; Sato, Y | 1 |
| Murray, JA; Nzeako, UC | 1 |
| Echizen, H; Nachi, S; Ohnishi, A; Ushiama, H | 1 |
| Cha, IJ; Hyun, MH; Kim, KA; Kim, MJ; Kim, MK; Park, JY; Shin, JG; Shon, JH; Yoon, YR; Yun, DH | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Subbiah, V; Tayek, JA | 1 |
| Endo, H; Higuchi, S; Ohmi, N; Ohta, K; Suga, T; Yoshida, H | 1 |
| Fujimoto, K; Fujise, T; Ishibashi, S; Iwakiri, R; Kawasaki, S; Kikkawa, A; Oda, K; Ootani, A; Ootani, H; Sakata, H; Shimoda, R; Tadano, J; Tsunada, S; Yoshida, T | 1 |
| Hiraishi, H; Ota, S; Terano, A | 1 |
| Dodd, S; Durkin, M; Hall, J; Sloan, S | 1 |
| Hayashi, N; Hoshino, Y; Matsumoto, R; Mitsunaga, A; Murata, Y; Nakamura, S; Oi, I | 1 |
| Nakamura, T; Terano, A | 1 |
| Adachi, K; Amano, Y; Fujishiro, H; Kinoshita, Y | 1 |
| Chen, JH; Lin, MD; Lin, YS; Lo, CY; Sheu, BS; Wu, HW; Wu, JJ | 1 |
| Endo, H; Kohno, Y; Suga, T; Yoshida, H | 1 |
| Nyrén, O | 1 |
| Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF | 1 |
| Achari, R; Cavanaugh, JH; Chiu, YL; Chun, AH; Erdman, K; Pilmer, BL | 1 |
| Asano, T; Fukushima, Y; Hirakawa, J; Ishikawa, T; Katsube, T; Mori, H; Ogawa, K; Ohkawa, S; Otsuka, H; Saitoh, T | 1 |
| Furukawa, K; Hisabe, T; Imamura, K; Kanda, M; Kikuchi, M; Matsui, T; Ohshima, K; Tsuda, S; Yao, T | 1 |
| Morozov, IA | 1 |
| Campbell, DR; Collis, C; Goldstein, JL; Haber, MM; Huang, B; Lukasik, N; Sheldon, E | 1 |
| O'Morain, CA; Qasim, A | 1 |
| Levin, M; Mercola, M; Nogi, T; Robinson, KR; Thorlin, T | 1 |
| Coyle, W; Dunteman, T; Nemec, R; Sullivan, B | 1 |
| Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M | 1 |
| Gitlin, N; Weaver, AL | 1 |
| Abe, H; Arita, T; Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S | 1 |
| Chuang, CH; Huang, AH; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Michael, RC | 1 |
| Sachs, G; Shin, JM | 1 |
| Borner, K; Koeppe, P; Kotwas, J; Lode, H; Mainz, D | 1 |
| Abdel-Razak, O; Gazy, AA; Mahgoub, H; Moneeb, MS; Wahbi, AA | 1 |
| Babkova, IV; Cherniakevich, SA; Mikhalev, AI | 1 |
| Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A | 1 |
| Harris, AW; Maiden, LP | 1 |
| Hori, M; Kakiuchi, Y; Kawai, N; Kawano, S; Kimura, A; Komori, M; Murata, H; Sasaki, Y; Sun, WH; Tsuji, S; Tsujii, M; Yasumaru, S | 1 |
| Frissora, C; Katz, PO | 1 |
| Kawano, S | 1 |
| Abib, E; Barrientos-Astigarraga, RE; da Silva, DR; de Nucci, G; Mendes, GD; Oliveira, CH | 1 |
| Chung, IS; Chung, KW; Kim, JI; Kim, JK; Park, SH; Sun, HS | 1 |
| Rai, R; Rai, S | 1 |
| Abraham, D; Saltoun, CA | 1 |
| Guda, N; Vakil, N | 1 |
| Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS | 1 |
| Scott, LJ | 1 |
| Ali, E; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Chattopadhyay, I; Varadaraj, A | 1 |
| Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H | 1 |
| Ayan, S; Bagcivan, I; Gökçe, G; Kiliçarslan, H; Saraç, B; Sarioglu, Y; Yildirim, S | 1 |
| Adachi, K; Fujishiro, H; Kinoshita, Y; Komazawa, Y; Mihara, T | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM | 1 |
| Nelson, DB; Sawhney, MS | 1 |
| Haag, S; Holtmann, G | 1 |
| Ballard, ED; Chiu, YL; Freston, JW; Mulford, DJ | 1 |
| Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH | 1 |
| Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V | 1 |
| Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V | 1 |
| Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H | 1 |
| Chiu, YL; Fitzgerald, J; Gremse, D; Gunasekaran, T; Gupta, S; Karol, M; Keith, R; Pan, WJ | 1 |
| Aoyama, N; Baba, T; Kakumoto, M; Kasuga, M; Kawahara, Y; Kirita, S; Kita, T; Kurimoto, Y; Okamura, N; Okumura, K; Sakaeda, T | 1 |
| Arima, N; Tsudo, M | 1 |
| Kallay, MC; Poe, RH | 1 |
| Sano, T; Urakami, Y | 1 |
| Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP | 1 |
| Humphries, M; McCarthy, J; O'Leary, C; Quigley, E; Shanahan, F | 1 |
| Hamada, S; Iijima, K; Kawamura, M; Kayaba, S; Koike, T; Noguchi, K; Noguchi, M; Ohara, S; Shimosegawa, T; Suzuki, J | 1 |
| Beckerling, A; Gatz, G; Ulmer, HJ | 1 |
| Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Nishiyama, H; Omagari, K; Shikuwa, S | 1 |
| Matsuda, M; Noda, Y; Takemori, Y | 1 |
| Kleeberg, U; Krusekopf, S; Roots, I | 1 |
| Radi, A | 1 |
| Koelz, HR; Labenz, J; Petersen, KU; Rösch, W | 2 |
| Asaka, M | 2 |
| Hamajima, N; Ikehara, Y; Matsuo, K; Matsuura, A; Nakamura, T; Suzuki, T; Tajima, K; Tominaga, S | 1 |
| Anai, M; Asano, T; Fujishiro, M; Fukushima, H; Fukushima, Y; Haraikawa-Onishi, Y; Honda, M; Ichinose, M; Inukai, K; Ishikawa, T; Katagiri, H; Kurihara, H; Kurihara, Y; Nagai, R; Ogihara, T; Ohashi, Y; Omata, M; Ono, H; Saitoh, T; Sakoda, H; Shimizu, Y; Shindo, T; Shojima, N; Wang, Y | 1 |
| Baldi, F; Malfertheiner, P | 1 |
| Chayama, K; Haruma, K; Ito, M; Kamada, T; Masuda, H; Miyamoto, M; Nishisaka, T; Sumioka, M; Tanaka, S; Yoshihara, M | 1 |
| Fedele, E | 1 |
| Good, CB; Lasky, SS; Pohland, CJ; Scavnicky, SA | 1 |
| El-Serag, HB; El-Zimaity, HM; Graham, DY; Hammoud, F; Kim, JG; Osato, MS | 1 |
| Huang, AH; Huang, JJ; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Kamolz, T; Pointner, R; Velanovich, V | 1 |
| Bilgen, C; Bor, S; Kesimli-Dinç, H; Kirazli, T; Ogüt, F | 1 |
| Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M | 1 |
| Ford, A; Moayyedi, P | 1 |
| Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU | 1 |
| Chen, TK; Huang, SH; Lai, YC; Lee, CL; Wang, TH; Wu, CH; Yang, SS | 1 |
| Fujita, I; Kato, S; Masuda, G; Matsukura, N; Tajiri, T; Togashi, A; Tokunaga, A; Yamada, N | 1 |
| Hellström, PM; Vitols, S | 1 |
| Adachi, H; Ando, T; Hirako, M; Kamiya, T; Kimura, G; Kobayashi, Y; Matsuhisa, E; Misu, N; Nagao, T; Shikano, M | 1 |
| Delattre, M; Felicio, L; Le, GH; Morreale, AP; Okino, L; Plowman, BK; Schaefer, MG | 1 |
| Hamaguchi, N; Igari, Y; Morimoto, S; Nakano, Y; Shimizu, T; Tabata, T | 1 |
| Asaumi, N; Kiguchi, T; Masuda, K; Niiya, K; Niiya, M; Tanimoto, M; Yoshida, C | 1 |
| Uthaisaengsook, W | 1 |
| Hamaguchi, N; Igari, Y; Iki, H; Kameoka, N; Shimizu, T; Tabata, T | 1 |
| Granneman, GR; Hogan, DL; Hussein, Z; Isenberg, JI; Koss, MA; Mukherjee, D; Samara, E | 1 |
| Cournot, A; Delhotal-Landes, B; Dellatolas, F; Flouvat, B | 1 |
| Demleitner, K; Fischbach, W; Fuchs, W; Layer, P; Leodolter, A; Malfertheiner, P; MOssner, J; Stolte, M | 1 |
| Chun, JH; Hyun, MH; Kim, KA; Kim, MJ; Lee, SS; Liu, KH; Park, JY; Shin, JG; Shon, JH; Yoon, YR | 1 |
| Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L | 1 |
| Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S | 1 |
| Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
| Aydin, C; Koyuncu, A; Sarac, B; Sarioglu, Y; Sen, M; Yildirim, S | 1 |
| Hamaguchi, N; Igari, Y; Izutsu, D; Mizukami, Y; Nakano, Y; Okochi, K; Shimizu, T; Sugaya, M; Tabata, T | 1 |
| Crawley, JA; Shaw, MJ | 1 |
| Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M | 1 |
| Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM | 1 |
| Coulson, M; Gibson, GG; Graham, M; Hammond, T; Plant, N | 1 |
| Fujiwara, K; Karasuyama, M; Murata, I; Shin, M; Tanabe, T; Ueoka, R | 1 |
| Ciancaglini, P; Larson, RE; Magalhães, PP; Paulino, TP; Thedei, G | 1 |
| Balashova, NN; Busarova, GA; Maev, IV | 1 |
| Asaumi, N; Niiya, K; Niiya, M; Shibakura, M; Tanimoto, M; Yoshida, C | 2 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Aoyama, N; Fukuda, M; Kachi, M; Kasuga, M; Kuroda, K; Maekawa, S; Miki, I; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
| Gerarduzzi, T; Marchetti, F; Ventura, A | 1 |
| Andrade, RJ; Fernández, MC; García-Cortés, M; Lucena, MI; Romero-Gómez, M | 1 |
| Inaba, T; Ishiki, K; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Shiratori, Y; Take, S; Yamamoto, K; Yokota, K; Yoshida, T | 1 |
| Takahashi, S | 1 |
| Borjesson, M; Mannheimer, C; Pilhall, M; Rolny, P | 1 |
| Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Abu Farsakh, N | 1 |
| Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Juul-Hansen, P; Rydning, A | 2 |
| Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I | 1 |
| Aiba, M; Hamaguchi, K; Katsube, T; Konno, S; Ogawa, K | 1 |
| Castell, DO; Katz, PO; Tutuian, R; Xue, S | 1 |
| Chan, AO; Hu, WH; Huang, JQ; Hui, WM; Lai, KC; Lam, CL; Lam, KF; Lam, SK; Wong, BC; Wong, NY; Wong, WM; Xia, HH | 1 |
| Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Lazzeri, G; Lubrano, V; Natale, G; Vassalle, C | 1 |
| Cury, EK; Faintuch, S; Schraibman, V | 1 |
| Batista, LM; Calvo, TR; de Almeida, AB; de Pietro Magri, L; Souza Brito, AR; Toma, W; Vilegas, W | 1 |
| Cezard, JP | 1 |
| Barker, T; Ross, C; Torpey, N | 1 |
| Inui, K; Ito, N; Motohashi, H; Ogawa, O; Okuda, M; Takahashi, K; Yamamoto, S; Yonezawa, A | 1 |
| El-Omar, EM; Furuta, T; Ishizaki, T; Ohashi, K; Rabkin, CS; Shirai, N; Sugimura, H; Xiao, F | 1 |
| Johnston, G; Lee, C; Stolle, J; Tolia, V | 1 |
| Allain, H; Bentué-Ferrer, D; Boulliat, J; Colin, F; Polard, E | 1 |
| Asaka, M; Sugiyama, T | 1 |
| Ishii, H; Masaoka, T; Suzuki, H | 1 |
| Maartmann-Moe, H; Viste, A; Waldum, H; Øvrebø, K | 1 |
| Ahuja, V; Bal, CS; Chaudhary, A; Das, B; Pandey, RM; Sharma, MP | 1 |
| Miura, M; Suzuki, T; Tada, H | 1 |
| Fukui, K; Hayashi, T; Ishii, H; Mizuki, A; Nagata, H; Nishiya, H; Tatemichi, M; Tsukada, N | 1 |
| Amarapurkar, A; Amarapurkar, D; Das, HS; Makesar, M | 1 |
| Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS | 1 |
| Ayub, K; Cole, RA; Graham, DY; Helaly, AZ; Ibrahim, A; Jamecci, A; Qureshi, WA | 1 |
| Chiu, YL; Freston, JW; Griffin, JS; Lee, CQ; Pilmer, BL; Stolle, JC; Wang, Q | 1 |
| Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H | 1 |
| Kovacs, TO; Metz, DC; Peura, DA; Pilmer, BL; Siepman, N; Talley, NJ | 1 |
| Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP | 1 |
| Donnelly, JR; Gremse, DA; Kukulka, MJ; Lee, C; Lloyd, E | 1 |
| Altintas, E; Aydin, O; Camdeviren, H; Sezgin, O; Ulu, O | 1 |
| Granström, M; Hoang, TT; Nilsson, LE; Phuncarg, DC; Sörberg, M; Wheeldon, TU | 1 |
| Fujiyama, Y; Inoue, T; Kakinoki, R; Sakabe, H; Yagi, Y; Yoshikawa, K | 1 |
| Kmietowicz, Z | 1 |
| Becker, TL; de Mendonça, S; Gambero, A; Maróstica, M; Pedrazzoli, J; Ribeiro, ML | 1 |
| Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H | 1 |
| Hinner, H; Kraus, J; Schuppert, F; Tiesmeier, J | 1 |
| Karaoglu, AO; Yasa, MH; Yukselen, V | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Cucchiara, S; de'Angelis, GL; Ferzetti, A; Franco, MT; Kuvidi, M; Lerro, P; Marinello, D; Oderda, G; Pensabene, L; Romano, C; Strisciuglio, P | 1 |
| Bengtsson, C; Blennow, M; Casswall, TH; Granström, M; Sörberg, M; Tindberg, Y | 1 |
| Barrientos-Astigarraga, RE; de Nucci, G; Mendes, GD; Oliveira, CH; Peres, O; Rezende, VM | 1 |
| Homma, M; Itagaki, F; Kohda, Y; Naito, S; Nishimura, M; Ohkohchi, N; Ueda, N; Yuzawa, K | 1 |
| Ishii, H; Kamiya, AG; Masaoka, T; SuzukiKurabayashi, HK | 1 |
| Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kondo, Y; Nomura, T; Ohara, H; Oshima, T; Sasaki, M; Tanida, S | 1 |
| Freston, JW; Kukulka, MJ; Lee, C; Lloyd, E | 1 |
| Hu, YR; Kan, QC; Qiao, HL | 1 |
| Curran, MP; Wellington, K | 1 |
| Ichikawa, H; Isozaki, Y; Katada, K; Naito, Y; Okanoue, T; Takagi, T; Tomatsuri, N; Uchiyama, K; Yoshida, N; Yoshikawa, T | 1 |
| Dando, TM; Plosker, GL | 1 |
| Takeda, H | 2 |
| Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T | 1 |
| Hoshino, E; Ishiyama, A; Tsuchida, T | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Dogrukol-Ak, D; Tuncel, M; Yeniceli, D | 1 |
| Alonso, C; Bernal, JL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Güliter, S; Kandilci, U | 1 |
| Kagayama, A; Naritomi, Y; Terashita, S | 1 |
| Aoyama, N; Ebara, S; Kasuga, M; Kuroda, K; Maekawa, S; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
| Klotz, U; Schaeffeler, E; Schwab, M; Treiber, G | 1 |
| Bago, J; Bago, P; Belosić Halle, Z; Bevanda, M; Bilić, A; Galović, A | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 3 |
| Fujioka, T; Kodama, M; Miyajima, H; Murakami, K; Nasu, M; Ogata, M; Ohtsuka, E; Okimoto, T; Saburi, Y; Sato, R; Watanabe, K | 1 |
| de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ | 1 |
| Jacob, S; Rajabally, YA | 1 |
| Hill, RK; Larson, N; Simpson, CB; Velazquez, R | 1 |
| Freston, JW | 1 |
| Chiu, YL; Kovacs, TO; Lee, CQ; Metz, DC; Pilmer, BL | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Miura, T; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Izquierdo Prieto, OM; Moreno Alía, E; Rosillo González, A | 1 |
| Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Mequid, S; Ramzan, I | 1 |
| Irie, S; Iwasaki, K; Nakamura, K; Sakurai, Y; Shibata, N; Takada, K; Takagi, N; Yoshikawa, Y | 1 |
| D'Ambrosio, LP; Franceschi, M; Leandro, G; Longoa, MG; Orsitto, G; Perri, FC; Pilotto, A; Scarcelli, C | 1 |
| Hellström, PM | 1 |
| Cha, IJ; Jung, WM; Kang, W; Kim, MJ; Liu, KH; Shin, JG | 1 |
| Asfeldt, AM; Florholmen, J; Goll, R; Løchen, ML; Nestegard, O; Paulssen, EJ; Steigen, SE; Straume, B | 1 |
| Cao, X; Kaminishi, M; Kumagai, T; Mizoshita, T; Nozaki, K; Shimizu, N; Tatematsu, M; Tsukamoto, T | 1 |
| Ardau, R; Chillotti, C; De Lisa, R; Del Zompo, M; Severino, G | 1 |
| Irie, S; Ito, Y; Iwasaki, K; Nakamura, K; Sakurai, Y; Shibata, N; Takada, K; Takagi, N | 1 |
| Fukuda, S; Fukushi, M; Mikami, T; Munakata, A; Shimoyama, T | 1 |
| Bowling, JC; Bunker, CB; Edmonds, EV; Francis, ND; Heaton, NR; Morar, N | 1 |
| Hoffman, JM; Shah, ND; Vermeulen, LC | 1 |
| Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y | 1 |
| Katz, PO | 2 |
| Asaoka, D; Hojo, M; Iijima, K; Kawabe, M; Kurosawa, A; Miwa, H; Miyazaki, A; Nagahara, A; Ohkusa, T; Sato, N; Terai, T | 1 |
| Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B | 1 |
| Inoue, M; Koma, M; Maeda, H; Matsuda, H; Sawabata, N; Takeda, S; Tokunaga, T | 1 |
| Arkkila, PE; Färkkilä, M; Kosunen, TU; Mäkinen, J; Rautelin, H; Seppälä, K; Sipponen, P | 1 |
| Arai, H; Ito, Y; Iwasaki, K; Shibata, N; Takada, K; Uchino, K | 1 |
| Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 2 |
| Bellotti, M; Botta, F; Chiarbonello, B; Cotelessa, T; Emanuela, T; Fumagalli, A; Giannini, E; Malfatti, F; Milazzo, S; Podestà, E; Polegato, S; Testa, R | 1 |
| Fossmark, R; Johanessen, E; Johnsen, G; Waldum, HL | 1 |
| Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR | 1 |
| Imase, K; Ishida, H; Itoh, T; Kai, A; Sugano, H; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T | 1 |
| Bossuyt, A; Mana, F; Urbain, D; Van Laer, W; Van Laere, W | 1 |
| Fukuda, Y; Hori, K; Matsumoto, T; Miwa, H; Ohkusa, T; Shintani, S; Tanaka, J; Tomita, T | 1 |
| Baldeck, JD; Marquis, RE; Nguyen, PT; Olsson, J | 1 |
| Razmilic, I; Rodríguez, JA; Sánchez, M; Schmeda-Hirschmann, G; Theoduloz, C; Yáñez, T | 2 |
| Inoue, D; Kubo, H; Nishimura, H; Sasaki, H; Sasaki, T; Yamada, M; Yamaya, M; Yasuda, H | 1 |
| Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V | 1 |
| Pashankar, DS; Rahhal, RM; Ramkumar, DP | 1 |
| de Mascarel, A; Dubus, P; Lavergne-Slove, A; Megraud, F; Merlio, JP; Ruskone-Fourmestraux, A | 1 |
| Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lee, YJ; Lien, GS; Lou, HY; Pan, S | 1 |
| Feng, LY; Jiang, SL; Yao, XX | 1 |
| Munakata, A; Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Färkkilä, MA; Heikkinen, MT; Koivisto, TT; Koskenpato, JP; Rautelin, HI; Voutilainen, ME | 1 |
| Arakawa, M; Fukuhara, S; Hibi, T; Hosoda, H; Ishii, H; Kangawa, K; Kitajima, M; Masaoka, T; Minegishi, Y; Suzuki, H | 1 |
| Cha, IJ; Kang, W; Kim, MJ; Liu, KH; Moon, YS; Seol, SY; Shin, JG; Shon, JH | 1 |
| Dohmen, W; Fuchs, W | 2 |
| Collier, AC; Kosel, BW; Storey, SS | 1 |
| Attila, T; Blom, D; Koch, TR; Komorowski, R; Santharam, R | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Babic, Z; Lucijanic-Mlinac, M; Marusic, M; Nesanovic, M; Stajcar, V | 1 |
| Amer, F; Chiu, YL; Griffin, JS; Karol, MD; Locke, CS; Lukasik, NL; Pan, WJ | 1 |
| Caner, B; Gedik, GK; Karaduman, A; Sivri, B | 1 |
| Barry, M; Bennett, K; McGowan, B; Tilson, L | 1 |
| Cartell, A; Edelweiss, MI; Francesconi, CF; Mazzoleni, LE; Ott, EA; Prolla, JC; Rivero, LF; Sander, GB; Somm, G; Theil, AL; Uchôa, DM; Wortmann, AC | 1 |
| Scarpignato, C | 1 |
| Niv, Y | 1 |
| Hiki, N; Imamura, K; Kaminishi, M; Kubota, K; MaFune, K; Nozaki, K; Shimizu, N; Shimoyama, S; Takeshita, Y; Ueda, T; Yamaguchi, H | 1 |
| Kulas, J; Menzel, R; Rödel, M; Steinberg, CE | 1 |
| Oh, DS; Ohning, GV; Pisegna, JR | 1 |
| Gerson, LB; Shetler, K; Triadafilopoulos, G | 1 |
| Futagami, S; Hiratsuka, T; Kusunoki, M; Miyake, K; Nakajima, A; Nishigaki, H; Sakamoto, C; Shinji, Y; Suzuki, K; Tatsuguchi, A; Tsukui, T; Ueki, N; Wada, K; Yoshino, S | 1 |
| Cao, Q; Si, JM; Wu, JG | 1 |
| Egashira, T; Furuta, T; Hishida, A; Ishizaki, T; Kenmotsu, K; Kodaira, M; Nagano, M; Nakamura, A; Ohashi, K; Sagehashi, Y; Shirai, N; Sugimoto, M; Ueda, K; Yoneyama, M | 1 |
| Furuta, T; Hishida, A; Kajimura, M; Nakamura, A; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
| Alvarado, M; Hernández, J; Jiménez, S; Porcel, S; Rodríguez, A | 1 |
| Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T | 1 |
| Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K | 1 |
| Astudillo, L; Rodríguez, J; Schmeda-Hirschmann, G; Theoduloz, C; Yáñez, T | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bagel-Boithias, S; Chopineau, J; Messaouik, D; Sautou-Miranda, V | 1 |
| Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Lazzeri, G; Lubrano, V; Natale, G; Vassalle, C | 1 |
| Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M | 1 |
| Hou, XH; Xie, XP; Xu, JY | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Adem, A; Adeyemi, EO; Bastaki, SA; Chandranath, IS; Fahim, M; Hasan, MY | 1 |
| Isaev, VA | 1 |
| Beinborn, M; Ishida, H; Nagamatsu, S; Takahashi, S; Watanabe, K | 1 |
| Horikawa, Y; Inoue, M; Kuroiwa, T; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Mori, A; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Umehara, S; Yamato, H | 1 |
| Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H | 1 |
| Goto, H; Kitabatake, S; Niwa, Y | 1 |
| Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y | 1 |
| Klotz, U; Schwab, M; Treiber, G | 1 |
| Abasiyanik, MF; Huten, O; Salih, BA; Sander, E; Saribasak, H | 1 |
| Cho, YS; Kim, SS; Konkin, TA; Meitner, P; Moss, SF; Resnick, MB | 1 |
| Onur, R; Yenisehirli, A | 2 |
| Fujita, K; Hoshino, A; Ito, K; Kawada, E; Kogure, T; Mantani, N; Sakamoto, H; Tamura, J | 1 |
| Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK | 1 |
| Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M | 1 |
| Bigard, MA; Genestin, E | 1 |
| Carvalhaes, A; Magalhães, AF; Natan-Eisig, J; Paraíso-Ferraz, JG; Trevisan, M; Zaterkaad, S | 1 |
| Arai, D; Chen, G; Fukuchi, K; Gomi, K; Kikuchi, R; Takeuchi, Y | 1 |
| Brodsky, L; Ulualp, S | 1 |
| Bracke, A; Lambert, J; Meuleman, L; Nijsten, T; Vandermaesen, J | 1 |
| Devlin, JW; Olsen, KM; Welage, LS | 1 |
| Baggett, HC; Bruce, MG; Dunaway, E; Gessner, BD; Gold, BD; Muth, PT; Parkinson, AJ | 1 |
| Croom, KF; Scott, LJ | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Hibi, T; Ishii, H; Masaoka, T; Sakai, G; Suzuki, H | 1 |
| Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z | 1 |
| Cengiz, DU; Güliter, S; Keleş, H; Kolukisa, E; Ozkurt, ZN | 1 |
| Arakawa, T; Asada, M; Atsuda, K; Hibi, N; Higuchi, K; Matsui, H; Nakamura, M; Tsuchimoto, K; Watanabe, T | 1 |
| Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM | 1 |
| Brigante, M; DellaGreca, M; Iesce, MR; Previtera, L; Rubino, M; Temussi, F | 1 |
| Hansen, RA; Schommer, JC; Shaheen, NJ | 1 |
| Horn, JR; Howden, CW | 1 |
| Revuz, J | 1 |
| Habu, Y; Hayakumo, T; Hayashi, K; Kawai, K; Kusuda, T; Maeda, K; Shio, S; Watanabe, Y; Yamazaki, M; Yoshino, T | 1 |
| Ichikawa, H; Kuroda, M; Naito, Y; Okanoue, T; Okuda, T; Takagi, T; Yoshida, N; Yoshikawa, T | 1 |
| Hull, R; Marshall, RW; Marshall, VJ | 1 |
| Calvet, X; Gomollón, F | 1 |
| Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB | 1 |
| Krishna, M; Lalmuanpuii, J | 1 |
| Demirturk, L; Gurbuz, AK; Ozel, AM; Ozturk, R; Yazgan, Y; Yildirim, S | 1 |
| Hibi, T; Kurabayashi, K; Suzuki, H | 1 |
| Aoyagi, K; Maeda, K; Nishiyama, M; Sakisaka, S | 1 |
| Aoyama, N; Fukuda, Y; Koizuka, H; Tomita, T | 1 |
| Kawai, T; Kawakami, K; Moriyasu, F; Takagi, Y | 1 |
| Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
| Yanaka, A; Zhang, S | 1 |
| Nagahara, A; Sato, N | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
| Fujishiro, M; Kobayashi, K; Oka, M; Omata, M | 1 |
| Fujishiro, M; Ichinose, M; Oka, M; Omata, M | 1 |
| Asaka, M; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y | 1 |
| Konno, M | 1 |
| Katoh, H; Kuwano, H; Miyazaki, T; Tsukada, K | 1 |
| Bertin, P; Broutet, N; Combe, B; Joubert-Collin, M; Lamouliatte, H; Mégraud, F; Perié, F; Schaeverbeke, T; Zerbib, F | 1 |
| Gao, N; Guo, YZ; Hu, YR; Jia, LJ; Qiao, HL; Tian, X; Zhang, LR | 1 |
| Inoue, M; Kuroiwa, T; Mieno, H; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC | 1 |
| Asano, M; Sato, Y; Shimizu, T; Taniwaki, H; Tsuji, D | 1 |
| Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
| Naseri, E; Yenisehirli, A | 2 |
| Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F | 1 |
| Levine, JS; Naar, E; Poole, JA; Silvers, WS; Weber, RW | 1 |
| Shiwani, MH | 1 |
| Furuta, T; Hishida, A; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Eckstein, RP; Heap, TR; Hilmer, SN; Lauer, CS; Shenfield, GM | 1 |
| Hartmann, HJ; Simon, WA; Sturm, E; Weser, U | 1 |
| Bednarczyk, E; Berenson, CS; Difrancesco, R; Eberhardt, E; Morse, GD; Ogundele, AB; Smith, PF; Tomilo, DL | 1 |
| Kagaya, H; Miura, M; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Agustí-Escasany, A; Vallano-Ferraz, A | 1 |
| Ariyama, I; Furusyo, N; Hayashi, J; Kochi, S; Kubo, N; Murata, M | 1 |
| Cubero, AG; González Sánchez, LA; Mosquera, MR; Pérez Pimiento, AJ; Prieto Lastra, L; Rodríguez Cabreros, MI | 1 |
| Hibino, T; Ishii, Y; Levin, M; Nishino, A | 1 |
| Asada, M; Hibi, N; Inoue, J; Matsui, H; Nakamura, M; Oda, M; Tsuchimoto, K | 1 |
| Chapman, W; Cooper, BT; Gearty, JC; Neumann, CS | 1 |
| Amer, F; Howden, CW; Hunt, B; Kukulka, M; Metz, DC; Samra, N; Vakily, M | 1 |
| Amer, F; Hunt, B; Kukulka, MJ; Metz, DC; Samra, N; Vakily, M | 1 |
| Avorn, J; Canning, C; Dormuth, CR; Glynn, RJ; Maclure, M; Schneeweiss, S | 1 |
| Chen, JY; Ji, F; Li, YM; Ning, JW; Wang, QY; Wang, ZW | 1 |
| Li, W; Liu, ZD; Pan, WS; Peng, B; Yang, XG; Zhang, GH | 1 |
| Chua, CJ; Goh, KL; Liam, CK; Wong, CH | 1 |
| Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP | 1 |
| Asaka, M; Kato, M; Katsuyama, T; Kikuchi, S; Tominaga, S | 1 |
| Dhar, V; Laine, L; Nathwani, RA; Nowain, A; Pais, SA | 1 |
| Becker, JC; Domschke, W; Erdmann, K; Grosser, N; Pohle, T; Schröder, H; Schulz, S; Waltke, C | 1 |
| Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB | 1 |
| Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC | 1 |
| El-Bardicy, MG; El-Sherif, ZA; El-Tarras, MF; Mohamed, AO | 1 |
| Miura, M | 1 |
| Clark, DW; Strandell, J | 1 |
| Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M | 1 |
| Kaneko, S; Niioka, T; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G | 1 |
| Akyol, H; Barisik, NO; Bingul, S; Colak, E; Kaptanoglu, L; Kucuk, HF; Kurt, N; Torlak, OA | 1 |
| Classen, M; Li, J; Lin, SR; Liu, WD; Ma, JL; Pan, KF; Shen, L; Xiao, SD; You, WC; Zhang, L | 1 |
| El-Eswed, B; Qaisi, AM; Tutunji, LF; Tutunji, MF | 1 |
| Hunt, RH; Padol, IT; Padol, S; Thabane, M; Yuan, Y | 1 |
| Chen, L; Geng, B; Ke, Y; Lou, LX; Pan, CS; Qi, YF; Tang, CS; Wang, X; Yu, F; Zhang, J | 1 |
| Inoue, H; Kobayashi, H; Sato, A; Tanifuji, Y | 1 |
| Akyol Erikci, A; Ozturk, A; Sayan, O | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Klotz, U | 1 |
| Calvo, A; Gorostiaga, C; Laredo, L; Moreno, A; Portolés, A; Resplandy, G; Terleira, A | 1 |
| Brørs, O | 1 |
| Haataja, R; Huuhka, K; Leinonen, E; Riutta, A; Ylitalo, P | 1 |
| Goh, KL; Wong, CH | 1 |
| Apikoglu-Rabus, S; Besisik, F; Dulger, G; Izzettin, FV; Sancar, M; Tozun, N | 1 |
| Bennett, J; Mahon, D; Mehta, S; Rhodes, M | 1 |
| Fujita, N; Handa, O; Kokura, S; Naito, Y; Okanoue, T; Takagi, T; Tanaka, Y; Ueda, M; Yoshida, N; Yoshikawa, T | 1 |
| Camargos, PA; Guimarães, EV; Marguet, C | 1 |
| Cline, RR; Hadsall, RS; Hansen, RA; Nyman, JA; Schommer, JC; Schondelmeyer, SW | 1 |
| Bertini, S; Cavestro, GM; Coruzzi, G; Grandi, D; Menozzi, A; Ossiprandi, MC; Pozzoli, C; Solenghi, E; Zullian, C | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Bakshi, A; Bungay, K; Devlin, JW; Olsen, KM | 1 |
| Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS | 1 |
| El-Serag, HB; Hassall, E; Kerr, W | 1 |
| Bomford, A; Geissler, CA; Hutchinson, C; Powell, JJ | 1 |
| Andersson, S; Nelander, H; Ohlén, K | 1 |
| Forrester, MB | 1 |
| Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H | 1 |
| Inoue, T; Inui, Y; Katata, T; Kizu, T; Kohro, T; Matsumoto, Y; Miyoshi, R; Nishikawa, M; Watanabe, C; Yasunaga, Y | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Aoki, T; Itoi, T; Kawai, T; Kawakami, K; Matsumoto, Y; Mikinori, K; Moriyasu, F; Noguchi, N; Rimbara, E; Sasatsu, M; Takagi, Y; Takei, K; Watanebe, K | 1 |
| Serebrova, SIu | 1 |
| Chung, SJ; Hwang, JH; Jung, HC; Jung, SH; Kim, JW; Kim, N; Lee, DH; Lee, KH; Park, YS; Song, IS | 1 |
| Boyer, K; Tolia, V | 1 |
| Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Furuta, T; Ishizaki, T; Shirai, N; Sugimoto, M | 1 |
| Bakst, AW; Barron, JJ; Singer, J; Spalding, J; Tan, H | 1 |
| García Rodríguez, LA; Panés, J; Ruigómez, A | 1 |
| Bygum, A; Dam, C | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Franck, PF; Geus, WP; Hunfeld, NG; Kuipers, EJ; Mathot, RA; Mulder, PG; Touw, DJ; van Schaik, RH | 1 |
| Pérez-Manauta, J | 1 |
| Hashiguchi, M; Mochizuki, M; Uchikura, T; Yamauchi, N | 1 |
| Belal, F; El-Enany, N; Rizk, M | 1 |
| Andersson, T; Weidolf, L | 1 |
| Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N | 1 |
| Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Koner, AL; Nau, WM; Saleh, N | 1 |
| Johnson, DA; Katz, PO | 1 |
| Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK | 1 |
| Leufkens, HG; Martini, N; Sagliocca, L; Tafuri, G; Traversa, G; Trotta, F | 1 |
| Farrell, CP; Gabello, M; Martin, AP; Morgan, M; Mullin, JM; Murray, LJ; Rudolph, DS; Underwood, JC; Valenzano, MC | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Egawa, H; Hosohata, K; Inui, K; Kaido, T; Katsura, T; Masuda, S; Ogura, Y; Oike, F; Takada, Y; Uemoto, S | 1 |
| Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F | 1 |
| Hashioka, S; Klegeris, A; McGeer, PL | 2 |
| Zheng, RN | 1 |
| Pellicano, R | 1 |
| Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K | 1 |
| Friesen, MH | 1 |
| DAS, R; Edwards, SJ; Lind, T; Lundell, L | 1 |
| González F, CG; Harris, PR; Molina U, R; Torres, J | 1 |
| Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H | 1 |
| Falconer, M; Hennessy, M; Molloy, A; Molloy, D; O'Loughlin, C | 1 |
| Kume, K; Nagato, M; Otsuki, M; Yamasaki, M; Yoshikawa, I | 1 |
| Bretagne, JF | 1 |
| Cronican, AA; Fitz, NF; Fogg, A; Kifer, B; Koldamova, R; Lefterov, I; Pham, T | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Boussery, K; De Cock, P; De Paepe, P; De Smet, J; Remon, JP; Van Bocxlaer, J; Van Winckel, M | 1 |
| Erasala, GN; Gibb, RD; McKean, LA; McRorie, JW; Miner, PB; Ramsey, DL | 1 |
| Dutta, U; Kochhar, R; Noor, MT; Sidhu, GS; Singh, K; Udawat, H; Vaiphei, K | 1 |
| Keyhanfar, F; Mahmoudian, M; Motevalian, M; Noubarani, M | 1 |
| Reinke, T | 1 |
| Chan, JK; Graham, A; Phoenix, G; Sharma, S; Sleat, G | 1 |
| Hunt, R; Sachs, G; Shin, JM | 1 |
| Niioka, T | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Namiki, N; Nishino, M; Sugimoto, M; Uchida, S; Watanabe, H; Yamade, M | 1 |
| Benninga, MA; Omari, TI; Smits, MJ; Tabbers, MM; van der Pol, RJ; van Wijk, MP | 1 |
| Howden, CW; Hughes, N; Kahrilas, PJ | 1 |
| Illueca, M; Johnson, DA; Monyak, JT; Sharma, P | 1 |
| Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL | 1 |
| Hofmann, U; Nies, AT; Resch, C; Rius, M; Schaeffeler, E; Schwab, M | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
| Htun, WW; Huang, Y; Ko, W; Kwan, J; Kwan, TW | 1 |
| Buyukafsar, K; Erenmemisoglu, A; Ozkur, M; Pektas, M; Un, I; Yurtsever, AS | 1 |
| Basu, PP; Flynn, M; Krishnaswamy, N; Pacana, T; Rayapudi, K; Shah, NJ | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Gorodischer, R; Koren, G; Levy, A; Matok, I; Uziel, E; Wiznitzer, A | 1 |
| Babaoglu, MO; Balamtekin, N; Baysoy, G; Bozkurt, A; Demir, H; Gumus, E; Karaca, O; Uslu, N; Yasar, U; Yuce, A | 1 |
| Bernasconi, GC; Cass, QB; Cassiano, NM; Oliveira, RV | 1 |
| Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
| Edelman, M; Lai, J; Levine, J; Schuval, SJ | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Girish, RK; Mishra, PK; Nagappa, AN; Pandi, PV; Shanmukh, I | 1 |
| Dial, EJ; Graham, DY; Lichtenberger, LM; Lim, YJ; Phan, TM | 1 |
| Satoh, H | 1 |
| Kawahara, K; Moroga, T; Okamura, Y; Takahashi, Y; Takeno, S; Yamashita, S | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Harmon, JW; Hayashi, H; Kitagawa, H; Makino, I; Marti, GP; Matsui, D; Miyashita, T; Murakami, M; Nakagawara, H; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Shah, FA; Tajima, H; Takamura, H | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Babai, N; Hanneken, AM; Thoreson, WB | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Baker, RD; Baker, SS; Burlingame, AL; Egilmez, NK; Forte, JG; Liu, W; Trinidad, J; Virtuoso, LP; Zhu, L | 1 |
| Funaki, Y; Iida, A; Izawa, S; Kasugai, K; Kondo, Y; Mizuno, M; Ogasawara, N; Sasaki, M; Tamura, Y; Tokudome, K | 1 |
| Bhushan, R; Dixit, S; Dubey, R | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Metz, DC; Shah, P; Singh, MH; Yang, YX | 1 |
| Hatlebakk, JG; Jonasson, C; Tvete, IF | 1 |
| Forte, JG; Guan, S; Machen, TE; Watson, C; Zhu, L | 1 |
| D'Ugo, E; De Caterina, R; Rossi, S | 1 |
| Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M | 1 |
| Afonso, C; Rajab, A; Rudler, H; Seuleiman, M; Touma, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Cao, Z; Kang, T; Tian, C; Yu, D; Zhu, L; Zhu, R | 1 |
| Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L | 1 |
| Bartonkova, I; Dvorak, Z; Korhonova, M; Novotna, A; Srovnalova, A; Svecarova, M | 1 |
| Furuta, T; Ichikawa, H; Kagami, T; Kodaira, C; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T | 1 |
| Dvorak, Z; Novotna, A | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Liu, F; Shokrollahi, H | 1 |
| Bennie, M; Godman, B; Shankar, S; Truter, I; Woerkom, Mv | 1 |
| Hayasaki, A; Hosokawa, Y; Miyamoto, M; Tsujino, H; Uno, T; Yamashita, T; Yasuhara, Y | 1 |
| Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Benjak, A; Busso, P; Cole, ST; Pojer, F; Rybniker, J; Sala, C; Vocat, A | 1 |
| Saniee, P; Shahreza, S; Siavoshi, F | 1 |
| Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Andabak, M; Babic, Z; Banic, M; Bilić, B; Bogdanovic, Z; Dorosulic, Z; Heinzl, R; Kujundzic, M; Marusic, M; Petrovic, Z | 1 |
| Canitano, A; Fais, S; Federici, C; Iessi, E; Spugnini, EP | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Basso, A; Corsonello, A; Costarelli, L; Giacconi, R; Lattanzio, F; Maggio, MG; Malavolta, M; Piacenza, F; Provinciali, M | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Barbaud, A | 1 |
| Bhaskaran, K; Douglas, IJ; Langan, S; Smeeth, L; Thomas, S; Tomlinson, LA; Yates, TA | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Goyal, SN; Mahajan, UB; Ojha, S; Patil, AS; Patil, CR; Singh, AD | 1 |
| Pinheiro, LC; Tanus-Santos, JE | 1 |
| Abagyan, R; Dai, W; Dong, M; Shi, D; Zhang, Y | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Akiba, Y; Satoh, H; Urushidani, T | 1 |
| Ding, H; Hu, L; Huang, Q; Jiang, Y; Liu, Q; Liu, S; Yin, T | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Huang, X; Liu, Y; Shen, Y; Su, YW; Sun, LN; Wang, YQ; Yang, YQ; Ying, YW; Zhang, XH; Zhang, Y | 1 |
| Arnaud, B; Arnoult, C; Escoffier, J; Hograindleur, JP; Kaba, M; Le Blévec, E; Martinez, G; Nef, S; Ray, PF; Stévant, I | 1 |
| Dorraji, PS; Fotouhi, L; Mostafiz, B | 1 |
| Abramenko, N; Antonyová, V; Brogyányi, T; Dytrych, P; Ikeda-Saito, M; Jakubek, M; Kaplánek, R; Kejík, Z; Martásek, P; Pajková, M; Sýkora, D; Tatar, A; Veselá, K | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Parton, JR; Ritchie, J | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA | 1 |
| Jayasekara, R; Smith, I | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Chen, Y; Hou, Y; Li, H; Li, S; Lin, J; Liu, T; Ma, Y; Wang, Y; Yang, H; Zhang, X; Zhang, Y; Zhou, L; Zhou, X | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Chen, X; Jiang, H; Lu, S; Ma, Z; Xu, S; Yang, X; Zhang, Y; Zhao, J; Zhou, H | 1 |
| Cicala, G; Cutroneo, P; Dipasquale, V; Laganà, F; Romano, C; Spina, E; Trimarchi, G | 1 |
| Chen, B; Gao, N; Yan, S | 1 |
| Pongwecharak, J; Sanguanhong, S; Soorapan, S; Yusof, F | 1 |
| Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL | 1 |
| Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A | 1 |
| Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Sugiyama, A; Takei, Y | 1 |
198 review(s) available for lansoprazole and omeprazole
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Ellison Syndrome | 1992 |
Proton-pump inhibition for acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Rats | 1991 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides; Zollinger-Ellison Syndrome | 1995 |
Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 1994 |
Lansoprazole--another proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1995 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Clinical pharmacokinetics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestinal Diseases; Humans; Lansoprazole; Liver Failure; Omeprazole; Renal Insufficiency | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cells, Cultured; Chemotherapy, Adjuvant; Duodenal Diseases; Enzyme Inhibitors; Epithelium; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Diseases | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adjuvant; Chronic Disease; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1995 |
The potential value of lansoprazole in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1995 |
[New therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alprostadil; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Recurrence | 1995 |
[Are proton pump inhibitors safe?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Carcinogenicity Tests; Gastric Acid; Humans; Lansoprazole; Mutagenicity Tests; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Peptic Ulcer; Prodrugs; Proton Pump Inhibitors; Structure-Activity Relationship; Sulfoxides | 1994 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1993 |
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Multicenter Studies as Topic; Omeprazole; Randomized Controlled Trials as Topic; Recurrence | 1993 |
The interaction of proton pump inhibitors with cytochromes P450.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Half-Life; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1994 |
Safety of proton pump inhibitors--an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Disease Models, Animal; Drug Interactions; Enterochromaffin Cells; Gastrins; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1994 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Stomach Ulcer; Zollinger-Ellison Syndrome | 1994 |
Treatment of patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; Female; Gastric Acid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Zollinger-Ellison Syndrome | 1993 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Tinidazole | 1993 |
[Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pumps; Stomach Ulcer | 1993 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Ranitidine | 1993 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal Ulcer; Humans; Lansoprazole; Omeprazole | 1993 |
Safety of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical Trials as Topic; Humans; Lansoprazole; Middle Aged; Omeprazole | 1993 |
Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Sulfoxides | 1995 |
Proton pump inhibitors: new drugs and indications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Sulfoxides | 1996 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors; Wound Healing | 1995 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interactions; Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1996 |
Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1996 |
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1996 |
Lansoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Prodrugs; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Zollinger-Ellison Syndrome | 1996 |
Drug interactions with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Sulfoxides | 1997 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
[Helicobacter pylori eradication: modified triple therapy with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1996 |
Long-term management of gastroesophageal reflux disease and its complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Life Style; Omeprazole; Proton Pump Inhibitors; Time Factors | 1997 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1997 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Polymerase Chain Reaction; Ranitidine | 1997 |
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Recurrence | 1997 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Humans; Lansoprazole; Laparoscopy; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Recurrence; Sulfoxides | 1997 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pumps; Zollinger-Ellison Syndrome | 1998 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Pantoprazole; Piperidines; Ranitidine; Sulfoxides | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Odds Ratio; Omeprazole; Pantoprazole; Peptic Ulcer; Ranitidine; Stomach Ulcer; Sulfoxides; Treatment Outcome; Wound Healing | 1998 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Selection; Penicillins; Peptic Ulcer; Randomized Controlled Trials as Topic | 1998 |
[Lansoprazol ++ : a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Lansoprazole; Omeprazole; Peptic Ulcer | 1998 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1999 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
Safety profile of Lansoprazole: the US clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophageal Diseases; Gastric Acid; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine; United States | 1999 |
[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Nitroimidazoles; Omeprazole; Penicillins | 1999 |
[Proton pump inhibitors in pediatrics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Child; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Proton-Translocating ATPases; Sulfoxides | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stomach Ulcer; Sulfoxides | 1999 |
Benign gastric ulcer associated with Canidida infection in a healthy adult.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alanine; Anti-Infective Agents; Anti-Ulcer Agents; Candidiasis; Carnosine; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds; Quinolones; Stomach Ulcer; Zinc; Zinc Compounds | 1999 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Critical Care; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Safety profile of the proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diarrhea; Drug Interactions; Gastric Mucosa; Gastritis, Atrophic; Headache; Humans; Intestinal Absorption; Lansoprazole; Nausea; Omeprazole; Proton Pump Inhibitors; Safety | 1999 |
Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Controlled Clinical Trials as Topic; Drug Monitoring; Gastric Acidity Determination; Gastric Juice; Gastrostomy; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Suspensions; Tablets, Enteric-Coated; Time Factors | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Stomach Ulcer; Sulfoxides; Treatment Outcome | 2000 |
Medical therapy. Management of the refractory patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Recurrence | 1999 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Recurrence; Zollinger-Ellison Syndrome | 2000 |
[Two cases of ocular damage associated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Vision Disorders | 2000 |
Is it time to adopt proton pump inhibitors in the prevention of non-steroidal anti-inflammatory drug gastropathy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stomach Diseases; Sulfoxides | 2000 |
Proton pump inhibitors and H. pylori infection: why the concern?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Stomach Neoplasms | 1999 |
[Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Cost-Benefit Analysis; Enzyme Inhibitors; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2000 |
[Gastric ulceration in horses: etiology, diagnosis, and therapy: a review].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antacids; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Endoscopy, Gastrointestinal; Horse Diseases; Horses; Lansoprazole; Omeprazole; Stomach; Stomach Ulcer | 2000 |
Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Humans; Lansoprazole; Omeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
[Recent guidelines for the management of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2001 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Patient Compliance; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2001 |
Aggressive acid control: minimizing progression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach Ulcer; Sulfoxides | 2001 |
Proton pump inhibitors and their drug interactions: an evidence-based approach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Odds Ratio; Omeprazole; Ranitidine; Research Design; Retrospective Studies; United States; United States Food and Drug Administration | 2001 |
Shortcomings of the first-generation proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Biological Availability; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides; Treatment Outcome | 2001 |
Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Recurrence | 2001 |
Review article: tackling the "dyspeptic problem".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dyspepsia; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2001 |
Review article: managing the dyspeptic patient--an interactive discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dyspepsia; Female; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Sulfoxides | 2001 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Dyspepsia; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 2001 |
Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Histamine H2 Antagonists; Humans; Isoenzymes; Lansoprazole; Membrane Proteins; Misoprostol; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Humans; Lansoprazole; Omeprazole; Stomach Ulcer; Zollinger-Ellison Syndrome | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Misoprostol; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
[Guidelines for the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Practice Guidelines as Topic | 2002 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure; Treatment Outcome | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Diterpenes; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2002 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus acidophilus; Lansoprazole; Mouth Diseases; Omeprazole; Skin Diseases | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Secondary Prevention | 2002 |
[Intractable ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Drug Resistance; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Prognosis; Proton Pump Inhibitors | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
[Proton pump inhibitors: Efficacy of lansoprazole in eradicating Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Depression, Chemical; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug Resistance, Bacterial; Drug Therapy, Combination; Fatty Alcohols; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neutrophil Activation; Omeprazole; Peptic Ulcer; Prognosis | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpenes; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Secondary Prevention; Urease | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Urease; Zinc Compounds | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Esophagitis, Peptic; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Ranitidine | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Tetracycline | 2002 |
[Practice guidelines for diagnosis and treatment of Helicobacter pylori infections and their application in clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2002 |
Lansoprazole for maintenance of remission of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pumps; Recurrence | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[Treatment of NSAID-associated gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Ranitidine; Stomach Ulcer | 2002 |
[Reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Esophagitis, Peptic; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Life Style; Morpholines; Omeprazole; Proton Pump Inhibitors | 2002 |
[Eradication therapy of Helicobacter pylori for elderly patients in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Practice Guidelines as Topic | 2002 |
[Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibitors; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Practice Guidelines as Topic; Proton Pump Inhibitors | 2002 |
Motion--Helicobacter pylori causes or worsens GERD: arguments against the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Practice Guidelines as Topic | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[Helicobacter pylori induced gastritis: recent topics on eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Tetracyclines | 2002 |
Lansoprazole: in the management of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Gastroesophageal Reflux; Half-Life; Humans; Infant; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2003 |
Reflux disease and Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Fundoplication; GABA Agonists; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2003 |
Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Stomach Neoplasms; Thyroid Neoplasms; Thyroiditis, Autoimmune | 2003 |
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Microbiology; Omeprazole; Peptic Ulcer; Polyps; Practice Guidelines as Topic; Proton Pump Inhibitors; Societies, Medical; Stomach Neoplasms | 2003 |
Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Biological Availability; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tablets | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Nizatidine; Omeprazole; Proton Pump Inhibitors | 2003 |
The impact of gastroesophageal reflux disease on quality of life.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Esophagitis; Fundoplication; Gastroesophageal Reflux; Humans; Lansoprazole; Laparoscopy; Omeprazole; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2003 |
How can the current strategies for Helicobacter pylori eradication therapy be improved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Time Factors | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Improving health-related quality of life in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Japan; Lansoprazole; Omeprazole; Peptic Ulcer; Urease | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Safety | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Omeprazole; Peptic Ulcer; Stomach Neoplasms | 2003 |
Managing gastro-oesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Omeprazole; Treatment Outcome | 2004 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 2004 |
[Effect of proton pump inhibitors (PPIs) on wound healing of gastric mucosal cell injury].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Gastric Mucosa; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rats; Wound Healing | 2004 |
Delayed-release lansoprazole plus naproxen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Lansoprazole; Naproxen; Omeprazole; Ulcer | 2004 |
Intravenous lansoprazole: in erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; Gastric Acid; Humans; Injections, Intravenous; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2004 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Laparoscopy; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Markov Chains; Meta-Analysis as Topic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Depression, Chemical; Drug Resistance; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prognosis; Proton Pump Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Management of acid-related disorders in patients with dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Comorbidity; Deglutition Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prognosis; Proton Pump Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Purpura, Thrombocytopenic, Idiopathic | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter heilmannii; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole | 2005 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Quality of Life | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
[The clinical strategy for the Barrett's esophagus].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Digestive System Surgical Procedures; Enzyme Inhibitors; Esophageal Neoplasms; Esophagitis, Peptic; Esophagoscopy; Esophagus; Humans; Lansoprazole; Membrane Proteins; Nitrobenzenes; Omeprazole; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Sulfonamides | 2005 |
Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Capsules; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tablets | 2005 |
Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2005 |
Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Enzyme Inhibitors; Gastrointestinal Diseases; Gastrostomy; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2005 |
[H. pylori motility analysis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bacteriological Techniques; Computer Systems; Fimbriae, Bacterial; Gastric Acid; Helicobacter pylori; Lansoprazole; Movement; Omeprazole; Proton Pump Inhibitors; Urea; Urease | 2005 |
[Cap polyposis and Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Intestinal Polyposis; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[Recent topics on important drugs for H. pylori eradication: Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic | 2005 |
[Triple therapy for eradication of Helicobacter pylori in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Humans; Insurance, Health; Japan; Lansoprazole; Omeprazole; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors | 2005 |
[Adverse effects of Helicobacter pylori eradication and its prevention].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysis; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Monitoring; Gastric Acidity Determination; Gastroesophageal Reflux; Heart Diseases; Humans; Lansoprazole; Lung Diseases; Omeprazole; Otorhinolaryngologic Diseases; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2005 |
[Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2005 |
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Ranitidine; Skin Tests | 2006 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors | 2006 |
[Dosaging of proton pumps inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Gastroesophageal Reflux; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Sulfoxides | 2006 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barrett Esophagus; Child; Child, Preschool; Esophageal Stenosis; Esophagitis; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Infant; Lansoprazole; Life Style; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Syndrome; Vomiting | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
[Therapeutic innovations in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Catheter Ablation; Cisapride; Endoscopy; Enzyme Inhibitors; Fundoplication; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Imidazoles; Lansoprazole; Laparotomy; Omeprazole; Proton Pump Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Time Factors | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Omeprazole; Postprandial Period; Proton Pump Inhibitors; Quality of Life; Sleep Wake Disorders; Treatment Outcome | 2008 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Duodenal Ulcer; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Stomach Ulcer | 2000 |
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Child; Child, Preschool; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Incidence; Infant; Lansoprazole; Male; Netherlands; Omeprazole; Pantoprazole; Prognosis; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2011 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Omeprazole; Pain Measurement; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Intestine, Small; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rats; Stomach Ulcer | 2013 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Gastroesophageal Reflux; Humans; Immunologic Factors; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2013 |
Proton pump inhibitors and clopidogrel: an association to avoid?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Lansoprazole; Monitoring, Physiologic; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
509 trial(s) available for lansoprazole and omeprazole
| Article | Year |
|---|---|
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Famotidine; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Ellison Syndrome | 1992 |
Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Female; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Male; Membrane Potentials; Omeprazole; Reference Values; Stomach Ulcer | 1992 |
Influence of lansoprazole treatment on diazepam plasma concentrations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Anti-Ulcer Agents; Diazepam; Double-Blind Method; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Reference Values | 1992 |
Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Humans; Lansoprazole; Male; Omeprazole | 1992 |
Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Drug Administration Schedule; Drug Evaluation; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence | 1992 |
The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Gastric Acidity Determination; Gastrins; Humans; Lansoprazole; Male; Omeprazole | 1992 |
[Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH: 24-hour intragastric pH monitoring].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Biological Transport, Active; Female; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Hydrogen; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Protons; Stomach | 1991 |
H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dinoprostone; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Peptic Ulcer; Wound Healing | 1991 |
The effect of food and antacids on lansoprazole absorption and disposition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Biological Availability; Drug Combinations; Female; Food; Half-Life; Humans; Lansoprazole; Magnesium Hydroxide; Male; Omeprazole; Tablets, Enteric-Coated | 1991 |
Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine | 1991 |
Intravenous administration of lansoprazole: a preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Evaluation; Female; Gastric Acid; Gastrointestinal Hemorrhage; Hemostasis; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Omeprazole; Pilot Projects; Postoperative Complications | 1995 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pyloric Antrum; Ranitidine | 1995 |
Lansoprazole--another proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1995 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Factor 2; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach; Stomach Ulcer | 1995 |
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Molecular Sequence Data; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Pepsinogens; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Isotopes; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Spectrophotometry, Infrared; Urea | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Monitoring, Physiologic; Omeprazole; Penicillins; Pepsinogens; Stomach Ulcer; Urea | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Recurrence; Stomach Ulcer | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Duodenal Ulcer; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Recurrence; Stomach Ulcer | 1995 |
Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acid; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 1995 |
Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Gastric Acidity Determination; Humans; Infusions, Intravenous; Injections, Intravenous; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Proton Pump Inhibitors | 1995 |
Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Acid; Humans; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Postoperative Complications; Proton Pump Inhibitors; Stomach Ulcer; Stress, Physiological | 1995 |
Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Famotidine; Female; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Ultrasonography | 1995 |
Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Regeneration; Stomach Ulcer; Treatment Outcome; Ultrasonography | 1995 |
Endosonographic evaluation of the quality of ulcer healing induced by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastric Mucosa; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer; Ultrasonography | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Piperidines; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Effects of lansoprazole on gastric ulcer healing and mucin content.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Female; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Mucins; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Quantitative analysis of the gastric ulcer healing process using video endoscopic pseudocolor imaging systems.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Epithelium; Female; Hemoglobins; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer; Video Recording | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Time Factors | 1995 |
Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regeneration; Stomach Ulcer | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Ulcer | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodies, Bacterial; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Ulcer | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Time Factors | 1995 |
Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Cimetidine; Female; Gastric Acid; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Follow-Up Studies; H(+)-K(+)-Exchanging ATPase; Headache; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1995 |
Lansoprazole reduces preoperative gastric fluid acidity and volume in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Gastric Acidity Determination; Gastric Juice; Humans; Lansoprazole; Omeprazole; Pneumonia, Aspiration; Preanesthetic Medication; Proton Pump Inhibitors | 1995 |
Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Time Factors; Wound Healing | 1995 |
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Clarithromycin; Drug Therapy, Combination; Epithelium; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1995 |
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Time Factors | 1995 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies; Endoscopy, Digestive System; Esophagitis, Peptic; Famotidine; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Retrospective Studies | 1995 |
Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Phenolsulfonphthalein; Stomach Ulcer; Treatment Outcome | 1995 |
Chronic oral administration of lansoprazole does not affect the hypothalamic pituitary gonadal axis in healthy young men.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Follicle Stimulating Hormone; Humans; Hypothalamo-Hypophyseal System; Lansoprazole; Luteinizing Hormone; Male; Omeprazole; Radioimmunoassay; Testis; Testosterone | 1995 |
Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Female; Gastric Acid; Gastric Juice; Gastrins; Gastrointestinal Hormones; Humans; Hydrogen-Ion Concentration; Intrinsic Factor; Lansoprazole; Male; Omeprazole; Pepsin A; Pepsinogens | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Recurrence; Stomach Ulcer; Time Factors | 1994 |
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Alcohol Drinking; Anti-Ulcer Agents; Caffeine; Double-Blind Method; Drug Evaluation; Esophagitis, Peptic; Female; Gastroscopy; Humans; Lansoprazole; Longitudinal Studies; Male; Omeprazole; Proton Pump Inhibitors; Ranitidine; Smoking | 1995 |
Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing | 1995 |
Lansoprazole in the prophylaxis of acid aspiration during elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anesthesia, General; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Middle Aged; Omeprazole; Pneumonia, Aspiration | 1995 |
Lansoprazole does not affect the bioavailability of oral contraceptives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Biological Availability; Chromatography, High Pressure Liquid; Contraceptives, Oral; Cross-Over Studies; Estradiol; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Luteinizing Hormone; Menstrual Cycle; Omeprazole; Progesterone; Proton Pump Inhibitors; Sex Hormone-Binding Globulin; Therapeutic Equivalency | 1994 |
[Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Zollinger-Ellison Syndrome | 1994 |
Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Serologic Tests; Stomach | 1994 |
Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophagitis, Peptic; Esophagoscopy; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pilot Projects; Proton Pump Inhibitors; Time Factors; Wound Healing | 1995 |
Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Double-Blind Method; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Stomach | 1994 |
Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Epithelium; Esophagus; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1994 |
Rapid healing of gastric ulcers with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Safety; Stomach Ulcer | 1994 |
Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Gastric Mucosa; Gastrins; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Ranitidine | 1994 |
Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors | 1993 |
Does lansoprazole influence postprandial digestive function?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Bile Acids and Salts; Chymotrypsin; Digestion; Double-Blind Method; Duodenum; Eating; Gastric Acid; Gastric Emptying; Humans; Lansoprazole; Lipase; Male; Omeprazole | 1993 |
Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer | 1994 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins; Lansoprazole; Middle Aged; Omeprazole | 1993 |
Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Time Factors | 1993 |
[Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain | 1993 |
Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Time Factors; Zollinger-Ellison Syndrome | 1993 |
Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1993 |
The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Endocrine Glands; Hormones; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Stomach | 1993 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Ranitidine | 1993 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal Ulcer; Humans; Lansoprazole; Omeprazole | 1993 |
Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine Transaminase; Anti-Ulcer Agents; Aspartate Aminotransferases; Drug Administration Schedule; Fasting; Female; Follow-Up Studies; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Zollinger-Ellison Syndrome | 1993 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Duodenal Ulcer; Enterochromaffin Cells; Esophagitis; Female; Follicle Stimulating Hormone; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Luteinizing Hormone; Male; Omeprazole; Peptic Ulcer; Pyloric Antrum; Ranitidine; Stomach Ulcer; Testosterone | 1993 |
Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer | 1995 |
Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1995 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsules; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Pharyngitis; Stomatitis; Suspensions | 1995 |
A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome; Wound Healing | 1995 |
Pharmacokinetic interaction between lansoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Theophylline | 1995 |
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Female; Follow-Up Studies; Gastric Acid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Placebos; Proton Pump Inhibitors; Recurrence; Secretory Rate | 1996 |
A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Gastric Juice; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Preoperative Care; Ranitidine; Secretory Rate | 1996 |
[A clinical trial of lansoprazole in the treatment of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1995 |
Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Hydroxylation; Lansoprazole; Male; Methylation; Middle Aged; Omeprazole; Oxidoreductases; Proton Pump Inhibitors | 1996 |
Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Blood Proteins; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Microsomes, Liver; Omeprazole; Protein Binding; Proton Pump Inhibitors; Stereoisomerism; Structure-Activity Relationship; Tablets | 1996 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Penicillins; Tinidazole | 1996 |
Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Autoradiography; Binding Sites; Biopsy; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factor 2; Gastroscopy; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 1995 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Tinidazole | 1996 |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Tetracycline | 1996 |
A trial of lansoprazole in refractory gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Drug Resistance; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence; Sex Factors; Stomach Ulcer; Treatment Failure | 1996 |
Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Time Factors | 1996 |
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Follow-Up Studies; Gastric Mucosa; Gastrins; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Recurrence; Time Factors | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Premedication; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors | 1996 |
Pharmacokinetics and absolute bioavailability of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Analysis of Variance; Anti-Ulcer Agents; Biological Availability; Cross-Over Studies; Humans; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Omeprazole; Phenotype; Tablets, Enteric-Coated | 1996 |
Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dilatation; Double-Blind Method; Drug Administration Schedule; Esophageal Stenosis; Humans; Lansoprazole; Omeprazole; Prospective Studies; Ranitidine; Recurrence; Treatment Outcome | 1996 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastric Juice; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis | 1996 |
Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Dropouts; Prospective Studies; Proton Pump Inhibitors; Zollinger-Ellison Syndrome | 1996 |
Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Gastric Acid; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Dropouts; Pentagastrin; Proton Pump Inhibitors; Zollinger-Ellison Syndrome | 1996 |
Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Double-Blind Method; Enzyme Inhibitors; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 1996 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1996 |
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regression Analysis | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Synergism; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Stomach Ulcer | 1996 |
[Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1996 |
Health-related quality of life of patients with acute erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Analysis of Variance; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Reproducibility of Results; Surveys and Questionnaires | 1996 |
Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Denmark; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Severity of Illness Index; Treatment Outcome | 1996 |
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Protease Inhibitors; Stomach Ulcer | 1996 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 1996 |
High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1996 |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance | 1996 |
Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Glucocorticoids; Humans; Lansoprazole; Male; Omeprazole; Placebos; Prednisone; Proton Pump Inhibitors | 1996 |
Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Estradiol Congeners; Ethinyl Estradiol; Female; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Omeprazole; Placebos; Progesterone Congeners | 1997 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Biopsy; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Stomach Ulcer; Treatment Outcome | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline | 1997 |
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Headache; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1997 |
Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1997 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; Esophagitis, Peptic; Esophagoscopy; Fasting; Female; Follow-Up Studies; Gastrins; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Safety; Sleep; Sleep Stages; Ulcer; Wound Healing | 1997 |
The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Double-Blind Method; Gastrins; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Stomach | 1997 |
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Treatment Outcome | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Single-Blind Method; Time Factors | 1997 |
In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Capsules; Cross-Over Studies; Depression, Chemical; Gastric Acid; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine; Tablets | 1997 |
Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Depression, Chemical; Dose-Response Relationship, Drug; Enzyme Inhibitors; Food; Gastric Acid; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 1997 |
Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence | 1997 |
Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; Korea; Lansoprazole; Male; Mephenytoin; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors | 1997 |
Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Female; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer | 1997 |
Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Humans; Lansoprazole; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome | 1997 |
Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Male; Middle Aged; Norfloxacin; Omeprazole; Stomach Ulcer; Treatment Outcome | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Smoking; Treatment Outcome | 1997 |
Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Single-Blind Method | 1997 |
Influence of a proton pump inhibitor-based therapy on Helicobacter pylori strain selection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyloric Antrum; Random Amplified Polymorphic DNA Technique | 1997 |
[Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenoscopy; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Platelet Aggregation Inhibitors; Ranitidine | 1997 |
Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Chronic Disease; Cost of Illness; Enzyme Inhibitors; Female; Finland; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Health Care Costs; Humans; Lansoprazole; Life Expectancy; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quality of Life; Ranitidine | 1997 |
Age-dependent eradication of Helicobacter pylori with dual therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Ulcer Agents; Area Under Curve; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Ranitidine | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Smoking; Tetracycline; Tetracyclines | 1997 |
Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Capsules; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Postprandial Period; Reference Values; Time Factors | 1997 |
Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 1996 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Eruptions; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prevalence; Proton Pump Inhibitors; Research Design; Treatment Outcome | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Safety; Taste Disorders; Treatment Outcome | 1996 |
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenitis; Esophagitis; Female; Helicobacter Infections; Helicobacter pylori; Hernia, Hiatal; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Smoking; Treatment Outcome | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Proteins; Breath Tests; Carbon Isotopes; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Urea; Urease | 1996 |
Lansoprazole potentiates vecuronium paralysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cholecystectomy; Drug Synergism; Female; Humans; Lansoprazole; Male; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Omeprazole; Preanesthetic Medication; Proton Pump Inhibitors; Vecuronium Bromide | 1997 |
The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole | 1997 |
Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Duodenal Ulcer; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method | 1997 |
A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1998 |
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Recurrence; Treatment Outcome | 1997 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antioxidants; Chemokines; Cytokines; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Humans; Lansoprazole; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Quinolones | 1998 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Tinidazole; Treatment Outcome | 1998 |
Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Lansoprazole; Middle Aged; Omeprazole; Pepsinogens; Peptic Ulcer | 1997 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Penicillins; Tetracycline; Western Australia | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Recurrence; Vagotomy | 1998 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Cell Count; Double-Blind Method; Enterochromaffin-like Cells; Female; Follow-Up Studies; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Time Factors | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Pyloric Antrum; Severity of Illness Index; Stomach; Time Factors | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Diarrhea; Drug Therapy, Combination; Endoscopes; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Nausea; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Taste Disorders; Time Factors; Treatment Outcome | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anus Diseases; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hallucinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Omeprazole; Peptic Ulcer; Pregnancy; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Taste Disorders; Time Factors; Tongue Diseases; Treatment Outcome; Urea; Vomiting | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Netherlands; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Recurrence | 1998 |
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Breath Tests; Caffeine; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
[Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Fasting; Female; Humans; Islam; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Time Factors | 1997 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds | 1996 |
Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gels; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Miconazole; Middle Aged; Omeprazole; Penicillins | 1998 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Treatment Outcome | 1998 |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Stomach Ulcer | 1998 |
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Prognosis; Proton Pump Inhibitors; Recurrence; Regression Analysis | 1997 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pefloxacin; Proton Pump Inhibitors | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Spiramycin | 1998 |
Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Omeprazole; Peptic Ulcer | 1998 |
Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Gastric Acid; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1998 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disorders; Double-Blind Method; Endoscopy; Esophageal Stenosis; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Secondary Prevention; Sulfoxides; Treatment Outcome | 1998 |
Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Tetracycline | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Tinidazole | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Time Factors | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pyloric Antrum; Ranitidine; Treatment Outcome | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Stomach Ulcer | 1998 |
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Quinolones; Stomach Ulcer; Treatment Outcome | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Secondary Prevention; Time Factors | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Ranitidine; Time Factors; Tinidazole | 1998 |
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Polyps; Proton Pump Inhibitors; Single-Blind Method; Statistics, Nonparametric; Stomach Neoplasms | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Treatment Outcome | 1998 |
Effects of trimebutine maleate on gastric motility in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Gastric Emptying; Gastric Mucosa; Gastrointestinal Agents; Gastrointestinal Motility; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Treatment Outcome; Trimebutine | 1998 |
[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Secretory Rate; Zollinger-Ellison Syndrome | 1998 |
Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Carbon Radioisotopes; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Predictive Value of Tests; Prospective Studies; ROC Curve; Time Factors; Urea | 1998 |
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; ErbB Receptors; Female; Fibroblast Growth Factor 2; Humans; Intestinal Mucosa; Lansoprazole; Male; Omeprazole; Receptors, Fibroblast Growth Factor; Receptors, Transforming Growth Factor beta; Recurrence; Sucralfate | 1998 |
Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Circadian Rhythm; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Time Factors | 1998 |
Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Azithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polypharmacy; Prospective Studies; Time Factors; Tinidazole | 1998 |
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Resistance, Microbial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Pilot Projects; Polypharmacy; Roxithromycin | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Odds Ratio; Omeprazole; Penicillins; Prognosis; Prospective Studies; Time Factors | 1998 |
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Double-Blind Method; Esophagitis; Female; Gastric Acid; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1998 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Treatment Outcome | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds | 1999 |
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Gastric Acid; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Time Factors | 1999 |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Carnosine; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Penicillins; Prospective Studies; Protective Agents; Zinc Compounds | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Single-Blind Method; Treatment Outcome | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Sulfoxides; Tinidazole | 1999 |
Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Urticaria | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Humans; Lansoprazole; Male; Omeprazole; Time Factors | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Failure; Treatment Outcome | 1999 |
The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine | 1999 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 1999 |
Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Enzyme Inhibitors; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1999 |
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Recurrence | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; Duodenal Ulcer; Female; Gastric Mucosa; Gastrins; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Recurrence; Treatment Outcome; United States | 1999 |
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Prospective Studies; Proton Pumps; Reference Values; Single-Blind Method; Theophylline; Time Factors; Volunteers; White People | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Pharmacokinetic interaction between acetaminophen and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetaminophen; Adult; Analgesics, Non-Narcotic; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Gastric Emptying; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Reference Values | 1999 |
Simplified lansoprazole suspension--a liquid formulation of lansoprazole--effectively suppresses intragastric acidity when administered through a gastrostomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Gastric Acid; Gastric Acidity Determination; Gastrostomy; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Suspensions | 1999 |
Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Enzyme Inhibitors; Gastric Acidity Determination; Gastrins; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Postprandial Period; Proton Pump Inhibitors; Time Factors | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Multivariate Analysis; Nizatidine; Omeprazole; Patient Dropouts; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer; Treatment Outcome | 1999 |
Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Secondary Prevention; Time Factors | 1999 |
Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cell Count; Enzyme Inhibitors; Female; Humans; Intercellular Adhesion Molecule-1; Lansoprazole; Lymphocyte Subsets; Male; Monocytes; Omeprazole; Proton Pump Inhibitors; Ranitidine; Receptors, Interleukin-2 | 1999 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Diseases, Functional; Diarrhea; Eating; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Theophylline | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Quality of Life; Surveys and Questionnaires; Tetracycline; Time Factors; Treatment Outcome | 1999 |
Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animal Feed; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Enzyme Inhibitors; Food Deprivation; Helicobacter Infections; Lansoprazole; Omeprazole; Stomach Ulcer; Swine; Swine Diseases | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 1999 |
Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Anticonvulsants; Cross-Over Studies; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Humans; Injections, Intravenous; Lansoprazole; Male; Metabolic Clearance Rate; Omeprazole; Phenytoin | 1999 |
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Eructation; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain; Ranitidine; Time Factors | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Esophagitis; Female; Food; Gastric Acid; Gastric Emptying; Gastric Mucosa; Gastrins; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Penicillins; Polyethylene Glycols; Postprandial Period; Solvents | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Time Factors; Treatment Outcome; Urea | 1999 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline | 2000 |
Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Critical Illness; Enzyme Inhibitors; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Intubation, Gastrointestinal; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Time Factors | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Asia; Breath Tests; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Risk Factors; Urea | 2000 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Dental Plaque; DNA, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Mouth Mucosa; Omeprazole; Polymerase Chain Reaction; Saliva; Sensitivity and Specificity; Treatment Outcome; Urease | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Regression Analysis; Tetracycline; Treatment Outcome | 2000 |
Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cell Count; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Hypertrophy; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric | 2000 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonography; Enzyme Inhibitors; Esophagitis, Peptic; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Mucous Membrane; Muscle, Smooth; Omeprazole; Proton Pump Inhibitors | 2000 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2000 |
A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Elective Surgical Procedures; Female; Gastric Juice; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pneumonia, Aspiration; Prospective Studies; Rabeprazole; Ranitidine | 2000 |
Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adrenergic beta-Antagonists; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Propranolol; Proton Pump Inhibitors | 2000 |
Once-daily Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Family; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Stomach Neoplasms | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resistance, Microbial; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ornidazole; Penicillins; Peptic Ulcer; Treatment Outcome | 2000 |
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Biological Availability; Bronchodilator Agents; Delayed-Action Preparations; Drug Interactions; Humans; Lansoprazole; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Theophylline | 2000 |
Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Capsules; Cross-Over Studies; Female; Food; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Therapeutic Equivalency | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Omeprazole; Prospective Studies | 2000 |
Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Biological Availability; Cross-Over Studies; Drug Interactions; Drug Stability; Enzyme Inhibitors; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Roxithromycin | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomonal Agents; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Thailand; Tinidazole; Treatment Outcome | 2000 |
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer; Wound Healing | 2000 |
Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; China; Clarithromycin; Drug Therapy, Combination; Ethnicity; Female; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Likelihood Functions; Logistic Models; Malaysia; Male; Middle Aged; Omeprazole; Prospective Studies; Singapore | 2000 |
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2000 |
Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 2000 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Diarrhea; Double-Blind Method; Drug Administration Schedule; Esophagoscopy; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Risk Factors; Treatment Outcome | 2000 |
Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Capsules; Female; Humans; Lansoprazole; Omeprazole; Sodium Bicarbonate; Suspensions | 2000 |
Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Sucralfate; Treatment Outcome | 2000 |
Helicobacter pylori eradication increases nocturnal acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 2000 |
Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Penicillins; Prospective Studies; Sensitivity and Specificity | 2000 |
Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Omeprazole; Pentagastrin; Proton Pump Inhibitors; Tablets | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Recurrence; Tinidazole | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Treatment Outcome | 2000 |
[Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; Enzyme Inhibitors; Esophagitis, Peptic; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Long-Term Care; Omeprazole; Proton Pump Inhibitors | 2000 |
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2000 |
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Enzyme Inhibitors; Female; Food-Drug Interactions; Gastric Acid; Gastric Acidity Determination; Humans; Lansoprazole; Male; Manometry; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Radioisotopes; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 2000 |
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Endosonography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Proton Pump Inhibitors; Stomach Ulcer; Time Factors; Wound Healing | 2000 |
Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetaldehyde; Achlorhydria; Adult; Anti-Ulcer Agents; Bacteria; Ethanol; Gastric Juice; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2000 |
High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Single-Blind Method; Treatment Outcome | 2000 |
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Time Factors | 2000 |
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-ce
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies | 2000 |
Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Enzyme Inhibitors; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Male; Omeprazole; Pentagastrin; Time Factors | 2001 |
Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Child; Child, Preschool; Enzyme Inhibitors; Esophagitis; Female; Gastric Acid; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2000 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Esophagus; Gastroesophageal Reflux; Humans; Hyperplasia; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Time Factors; Ulcer | 2000 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer | 2001 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Sensitivity and Specificity; Tinidazole | 2001 |
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; Body Mass Index; Body Weight; Bronchial Hyperreactivity; Child; Child, Preschool; Cystic Fibrosis; Enzyme Inhibitors; Exocrine Pancreatic Insufficiency; Feces; Female; Forced Expiratory Volume; Humans; Inspiratory Capacity; Lansoprazole; Lipid Metabolism; Lung; Male; Omeprazole; Peak Expiratory Flow Rate; Prospective Studies; Proton Pump Inhibitors; Residual Volume; Statistics, Nonparametric; Total Lung Capacity | 2001 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Quinolones; Stomach; Time Factors | 2000 |
[Usefulness of new triple therapy containing PPI].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors | 2001 |
Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Analysis of Variance; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Cross-Over Studies; Humans; Lansoprazole; Male; Middle Aged; Molecular Structure; Omeprazole; Therapeutic Equivalency | 2001 |
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Omeprazole; Prognosis; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Duodenal Ulcer; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Treatment Outcome | 2001 |
Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Penicillins; Roxithromycin | 2000 |
Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Eating; Enzyme Activation; Gastric Acid; Gastric Acidity Determination; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Models, Biological; Omeprazole; Proton Pump Inhibitors; Regression Analysis; Time Factors | 2001 |
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Endoscopy, Digestive System; Epithelium; Esophagus; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2001 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Organometallic Compounds; Patient Selection; Penicillins; Peptic Ulcer; Time Factors; Treatment Failure | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngitis; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2001 |
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Therapeutic Equivalency | 2001 |
Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Clarithromycin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Electrophoresis, Polyacrylamide Gel; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Isoenzymes; Lansoprazole; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Omeprazole; Prostaglandin-Endoperoxide Synthases | 2001 |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Treatment Outcome | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Headache; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pruritus; Ranitidine; Recurrence; Taste Disorders; Tinidazole; Treatment Outcome | 2001 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Female; France; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain; Pantoprazole; Prospective Studies; Sulfoxides | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence; Treatment Outcome | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Family Practice; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Tetracycline | 2001 |
Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Polymerase Chain Reaction; Time Factors | 2001 |
Effects of lansoprazole on human gastric lipase secretion and intragastric lipolysis in healthy human volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Enzyme Inhibitors; Female; Gastric Acid; Gastric Emptying; Humans; Hydrogen-Ion Concentration; Hydrolysis; Lansoprazole; Lipase; Lipolysis; Male; Omeprazole; Reference Values; Time Factors | 2001 |
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Intubation, Gastrointestinal; Kinetics; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Random Allocation; Rosales; Stomach; Sulfoxides | 2001 |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Prospective Studies; Treatment Outcome; Urea; Urease | 2001 |
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2001 |
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Gastric Acid; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Time Factors | 2001 |
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusion; Blood Volume; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Odds Ratio; Omeprazole; Predictive Value of Tests; Recurrence; Tranexamic Acid; Treatment Outcome | 2001 |
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absenteeism; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Health Status; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Satisfaction; Penicillins; Referral and Consultation | 2001 |
Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Capsules; Cross-Over Studies; Female; Gastric Mucosa; Half-Life; Humans; Hydrogen-Ion Concentration; Intubation, Gastrointestinal; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2000 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Gastroesophageal Reflux; Half-Life; Humans; Hydrogen-Ion Concentration; Infant; Lansoprazole; Male; Metabolic Clearance Rate; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies | 1999 |
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lebanon; Omeprazole; Penicillins; Research Design; Safety; Treatment Outcome | 2001 |
Efficacy of a nitroimidazole containing tripletherapy regime in Singapore.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nitroimidazoles; Omeprazole; Singapore; Tinidazole | 2001 |
A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Half-Life; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Therapeutic Equivalency | 2001 |
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross-Over Studies; Enzyme Inhibitors; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Intubation, Gastrointestinal; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Suspensions | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhibitors; Esophagitis; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Risk Factors; Stomach Neoplasms | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Omeprazole; Peptic Ulcer | 2001 |
Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gastrins; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2001 |
[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Child; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Treatment Outcome | 2001 |
Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Omeprazole; Patient Satisfaction; Quality of Life; Ranitidine; Socioeconomic Factors; Surveys and Questionnaires | 2001 |
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Homozygote; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors | 2001 |
Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Regression Analysis; Treatment Outcome | 2002 |
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer | 2002 |
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Ascorbic Acid; beta Carotene; Clarithromycin; Disulfides; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Sulfinic Acids | 2001 |
Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Child; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Skin Diseases; Treatment Outcome | 2002 |
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Costs; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2002 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Pyloric Antrum; Rabeprazole; Stomach Ulcer | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Taiwan | 2002 |
Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Pantoprazole; Single-Blind Method; Sulfoxides | 2002 |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Combinations; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Moxifloxacin; Omeprazole; Patient Compliance; Quinolines; Treatment Outcome | 2002 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Drug Interactions; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Sensitivity and Specificity; Sulfoxides; Time Factors; Urea | 2002 |
Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regional Blood Flow; Stomach Ulcer; Tranexamic Acid | 2001 |
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastroesophageal Reflux; Hernia, Hiatal; Humans; Hydrogen-Ion Concentration; Lansoprazole; Manometry; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2002 |
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactams; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Case-Control Studies; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Headache; Humans; Incidence; Infant; Lansoprazole; Matched-Pair Analysis; Middle Aged; Netherlands; Omeprazole; Risk Factors; Surveys and Questionnaires | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastroesophageal Reflux; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Quality of Life; Urea | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Pronase; Treatment Outcome | 2002 |
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Gastric Acidity Determination; Gastrins; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Time Factors; Zollinger-Ellison Syndrome | 2002 |
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre t
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Satisfaction; Proton Pump Inhibitors; Sulfoxides | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Proton Pump Inhibitors; Recurrence; Statistics, Nonparametric | 2002 |
Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Female; Gastric Acid; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Secondary Prevention; Stomach; Treatment Outcome | 2002 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; DNA; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Probability; Sweden; Treatment Outcome | 2002 |
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrocortisone; Lansoprazole; Liver Function Tests; Male; Middle Aged; Omeprazole; Oxidoreductases, N-Demethylating; Penicillins; Protein Synthesis Inhibitors | 2002 |
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Half-Life; Humans; Korea; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Stereoisomerism | 2002 |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Bifidobacterium; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Probiotics; Yogurt | 2002 |
Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Double-Blind Method; Drug Administration Schedule; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Quality of Life | 2002 |
Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Beverages; Biological Availability; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Food; Half-Life; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Ranitidine; Time Factors; Wound Healing | 2002 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Lansoprazole; Male; Metronidazole; Omeprazole; Severity of Illness Index; Stomach Diseases; Treatment Outcome; Vitamin E | 2002 |
Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Area Under Curve; Clarithromycin; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Male; Omeprazole | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Circadian Rhythm; Clarithromycin; Drug Therapy, Combination; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Treatment Outcome | 2002 |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Clarithromycin; Delayed-Action Preparations; Drug Therapy, Combination; Family Health; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Neoplasms; Tablets; Treatment Outcome | 2003 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Manometry; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides | 2003 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Negative Reactions; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Piperidines; Predictive Value of Tests; Quinolones; Urea | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome | 2003 |
Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Tablets | 2003 |
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroesophageal Reflux; Gastroscopy; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Predictive Value of Tests; Prospective Studies | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2003 |
Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Esophagitis; Female; Gastrins; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Safety | 2002 |
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Endoscopy, Gastrointestinal; Esophagitis; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Infant; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2002 |
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Infant; Lansoprazole; Male; Omeprazole | 2002 |
Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Safety; Stomach; Treatment Outcome | 2002 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cross-Over Studies; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Rabeprazole; Urea | 2003 |
The prophylactic use of a proton pump inhibitor before food and alcohol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alcohol Drinking; Anti-Ulcer Agents; Double-Blind Method; Female; Food; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2003 |
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymorphism, Genetic; Treatment Outcome | 2003 |
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Piperidines; Prospective Studies; Pyridines | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Nizatidine; Omeprazole; Proton Pump Inhibitors | 2003 |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2003 |
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Antacids; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2003 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Wound Healing | 2003 |
Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrectomy; Gastric Stump; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Omeprazole; Pepsinogen A; Pepsinogen C; Proton Pump Inhibitors; Proton Pumps; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome | 2003 |
Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Digoxin; Drug Interactions; Formularies, Hospital as Topic; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Age Factors; Aged; Anti-Ulcer Agents; Child, Preschool; Cross-Over Studies; Double-Blind Method; Gastric Acid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regression Analysis | 1993 |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2003 |
Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Patient Satisfaction; Probability; Prospective Studies; Proton Pump Inhibitors; Proton Pumps; Quality of Life; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2003 |
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Probability; Reference Values; Severity of Illness Index; Treatment Outcome | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Peptic Ulcer; Secondary Prevention; Treatment Outcome | 2003 |
Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotopes; Dose-Response Relationship, Drug; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Male; Middle Aged; Nizatidine; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Time Factors; Treatment Outcome; Urea | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Omeprazole; Polymorphism, Genetic; Probability; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2003 |
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Chest Pain; Cross-Over Studies; Double-Blind Method; Esophageal Motility Disorders; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Manometry; Middle Aged; Omeprazole; Peristalsis; Prospective Studies | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Proton Pump Inhibitors; Sensitivity and Specificity | 2003 |
Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; China; Cross-Over Studies; Double-Blind Method; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2004 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antibody Specificity; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Gastritis; Genetic Predisposition to Disease; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Patient Compliance; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Treatment Outcome | 2004 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 2004 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Lansoprazole; Male; Middle Aged; Omeprazole; Pilot Projects; Prospective Studies; Time Factors; Tinidazole; Urea | 2004 |
Helicobacter pylori eradication: efficacy of conventional therapy in India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Agents; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Tinidazole; Treatment Outcome | 2004 |
Schatzki's ring: to cut or break an unresolved problem.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Dilatation; Electrosurgery; Enzyme Inhibitors; Esophageal Stenosis; Humans; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2004 |
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Chlorates; Cross-Over Studies; Drug Carriers; Ethylene Glycol; Female; Gastric Acid; Humans; Infusions, Intravenous; Lansoprazole; Male; Omeprazole | 2004 |
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pain; Cross-Over Studies; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Sensitivity and Specificity | 2004 |
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Female; Follow-Up Studies; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Severity of Illness Index; Time Factors | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Peptic Ulcer; Prospective Studies; Tinidazole; Treatment Outcome; Wound Healing | 2004 |
A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Cross-Over Studies; Female; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Tablets | 2004 |
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2004 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2003 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Recurrence; Tinidazole; Urea | 2004 |
Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Azithromycin; Breath Tests; Child; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2004 |
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Tacrolimus | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Neutrophils; Omeprazole; Peptic Ulcer; Retrospective Studies | 2004 |
A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Tablets | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
On-demand PPI requirements in patients with endoscopy-negative GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Capsules; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endoscopes, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Treatment Outcome; Urease | 2004 |
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Care Management; Treatment Outcome | 2004 |
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dexlansoprazole; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism; Time Factors | 2004 |
Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 2004 |
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Female; Gastric Acid; Humans; Infusions, Intravenous; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2004 |
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimidazoles; Dose-Response Relationship, Drug; Endoscopes, Gastrointestinal; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Sulfoxides | 2004 |
Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Chemistry, Pharmaceutical; Cross-Over Studies; Drinking; Humans; Lansoprazole; Male; Omeprazole; Phenotype; Polymorphism, Genetic; Solubility; Tablets; Therapeutic Equivalency | 2004 |
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Peptic Ulcer Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Risk Factors; Secondary Prevention; Stomach Ulcer; Treatment Outcome | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Female; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Risk Factors; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Zollinger-Ellison Syndrome | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Stomach Ulcer; Treatment Outcome | 2005 |
Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aminopyrine; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Sex Characteristics | 2005 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Prospective Studies; Proton Pump Inhibitors; Sulfoxides | 2005 |
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Dose-Response Relationship, Drug; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Safety; Treatment Outcome | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Recurrence; Wound Healing | 2005 |
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Protein Synthesis Inhibitors; Proton Pump Inhibitors | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Ranitidine; Risk Factors | 2005 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lansoprazole; Male; Metaplasia; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2005 |
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Capsules; Cross-Over Studies; Dosage Forms; Female; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Solutions; Therapeutic Equivalency | 2004 |
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Esophagitis, Peptic; Follow-Up Studies; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Risk Assessment; Single-Blind Method | 2005 |
Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrectomy; Gastric Stump; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Posture; Tranexamic Acid; Treatment Outcome | 2005 |
Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Barrett Esophagus; Benzimidazoles; Esophageal pH Monitoring; Esophagus; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Proton-Translocating ATPases; Quality of Life; Rabeprazole; Treatment Outcome | 2005 |
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome | 2005 |
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endosonography; Female; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Wound Healing | 2005 |
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Famotidine; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; Drug Tolerance; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Pain Measurement; Prospective Studies; Proton Pump Inhibitors | 2005 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Monitoring, Physiologic; Omeprazole; Rabeprazole | 2005 |
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Treatment Outcome | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibitors; Esophagitis, Peptic; Famotidine; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Recurrence; Treatment Outcome | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Severity of Illness Index; Stomach; Treatment Outcome | 2005 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Agents; Asthma; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Recurrence; Respiratory Function Tests | 2005 |
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Dizziness; Dose-Response Relationship, Drug; Female; Headache; Humans; Lansoprazole; Male; Metabolic Clearance Rate; Methotrexate; Middle Aged; Naproxen; Nausea; Omeprazole; Vomiting | 2005 |
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Treatment Outcome | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prevalence; Prospective Studies; Risk Factors; Treatment Failure | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Treatment Outcome | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrazoles; Recurrence; Risk Factors; Sulfonamides; Treatment Outcome | 2005 |
Effect of N-acetyl cysteine on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Expectorants; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Diseases | 2005 |
[H. pylori eradication package set (Lansap)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Packaging; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[Cetraxate hydrochloride (Neuer) induces the effectiveness of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Tranexamic Acid; Treatment Outcome | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Needs Assessment; Omeprazole; Peptic Ulcer; Probability; Reference Values; Rheumatic Diseases; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2005 |
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2006 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Gastric Acidity Determination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Rabeprazole | 2006 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Brazil; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prevalence; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Cough; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2006 |
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Atazanavir Sulfate; Cross-Over Studies; Drug Antagonism; Female; Gastric Acid; HIV Protease Inhibitors; Humans; Intestinal Absorption; Lansoprazole; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2006 |
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Female; Humans; Intestines; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Stereoisomerism | 2006 |
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stomach | 2006 |
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Sulfoxides; Tablets | 2006 |
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds; Polyps; Proton Pump Inhibitors; Stomach Neoplasms; Tinidazole | 2006 |
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Clinical Protocols; Combined Modality Therapy; Endoscopy; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Middle Aged; Omeprazole; Proportional Hazards Models; Research Design; Sample Size; Stomach Neoplasms | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Family Practice; Female; Germany; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Recurrence | 2005 |
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation; Female; Forced Expiratory Volume; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peak Expiratory Flow Rate; Piperidines; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires | 2006 |
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2006 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pilot Projects; Prospective Studies; Rural Population | 2006 |
Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Benzazepines; Capsules; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Electrocardiography; Enzyme Inhibitors; Female; Half-Life; Heart Rate; Humans; Hypotension, Orthostatic; Ivabradine; Lansoprazole; Male; Metabolic Clearance Rate; Omeprazole; Tablets; Time Factors | 2006 |
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Melatonin; Mental Disorders; Mixed Function Oxygenases; Omeprazole; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2006 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Melena; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Ranitidine; Taste Disorders; Time Factors; Treatment Outcome | 2006 |
Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Humans; Lansoprazole; Laparoscopy; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires | 2006 |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2007 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Surveys and Questionnaires; Treatment Outcome | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retreatment; Stomach Diseases; Treatment Outcome | 2007 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2007 |
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Bacterial Infections; Enzyme Inhibitors; Female; Follow-Up Studies; Gastric Acid; Gastroenteritis; Gastroesophageal Reflux; Humans; Incidence; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; United Kingdom | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Gastric Acidity Determination; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Mutation; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2008 |
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome | 2008 |
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2009 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection | 2009 |
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Stomach Neoplasms; Young Adult | 2009 |
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Nonprescription Drugs; Omeprazole; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2010 |
Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Young Adult | 2010 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Levofloxacin; Male; Middle Aged; Nitro Compounds; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Thiazoles; Young Adult | 2011 |
Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Brazil; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stereoisomerism; Substrate Specificity; Young Adult | 2012 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
Conservative long-term treatment of children with eosinophilic esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Deglutition Disorders; Endoscopy; Eosinophilic Esophagitis; Female; Follow-Up Studies; Humans; Infant; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Treatment Outcome; Vomiting | 2012 |
Comparison of the effect of a single dose of omeprazole or lansoprazole on intragastric pH in Japanese participants: a two-way crossover study.
Topics: Adult; Cross-Over Studies; Gastric Acidity Determination; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2013 |
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2013 |
Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Healthy Volunteers; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Platelet Aggregation; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2014 |
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Topics: Adult; Asian People; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Dabigatran; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Thrombin; Young Adult | 2015 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Epithelial Cells; Esophagoscopy; Esophagus; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2015 |
Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cohort Studies; Female; Humans; Incidence; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Tuberculosis; United Kingdom | 2017 |
683 other study(ies) available for lansoprazole and omeprazole
| Article | Year |
|---|---|
(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Benzimidazoles; Dogs; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Omeprazole; Pantoprazole; Pyridines; Rabbits; Structure-Activity Relationship; Sulfoxides | 1992 |
Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors.
Topics: Ammonia; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzamides; Binding Sites; Cysteine; Drug Design; Enzyme Inhibitors; Helicobacter pylori; Hydrogen-Ion Concentration; Mercaptoethanol; Mice; Mice, Inbred Strains; Omeprazole; Structure-Activity Relationship; Urease | 1995 |
Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
Topics: Aminopyrine; Animals; Bucladesine; Enzyme Inhibitors; Gastric Acid; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Structure; Niacinamide; Parietal Cells, Gastric; Proton Pump Inhibitors; Pyridines; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship | 1997 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Transport; Caco-2 Cells; Digoxin; Drug Interactions; Enzyme Inhibitors; Epithelial Cells; Humans; Lansoprazole; LLC-PK1 Cells; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Sulfoxides; Swine | 2001 |
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Repositioning; Fatty Acid Synthases; Humans; Hydrogen-Ion Concentration; Lansoprazole; Palmitic Acid; Palmitoyl-CoA Hydrolase; Protein Structure, Tertiary; Proton Pump Inhibitors | 2015 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship | 2019 |
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone-Lysine N-Methyltransferase; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Molecular Structure; Myeloid-Lymphoid Leukemia Protein; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship | 2020 |
[Discovery and development of the proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Depression, Chemical; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Microsomes; Omeprazole; Rabeprazole | 1992 |
[Clinical effect of proton pump inhibitors on reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis, Peptic; Esophagoscopy; Esophagus; H(+)-K(+)-Exchanging ATPase; Humans; Hydrogen-Ion Concentration; Lansoprazole; Monitoring, Physiologic; Omeprazole; Time Factors | 1992 |
[Proton pump inhibitor for maintenance therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Endoscopy, Gastrointestinal; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Recurrence; Time Factors | 1992 |
[Changes in the rat stomach after long-term administration of proton pump inhibitors (AG-1749 and E-3810)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastric Acid; Gastrins; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Rabeprazole; Rats; Rats, Inbred Strains; Stomach; Vacuoles | 1992 |
[Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Binding Sites; Binding, Competitive; Biotransformation; Disulfides; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Imidazoles; Lansoprazole; Omeprazole; Potassium | 1992 |
[Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Depression, Chemical; Drug Resistance; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1992 |
[H2-receptor antagonist-refractory ulcer--its pathophysiology and role of proton-pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Depression, Chemical; Drug Resistance; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Prostaglandins; Stomach Ulcer | 1992 |
[Evaluation of the effect of proton pump inhibitors on stomal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Drug Evaluation; Endoscopy, Gastrointestinal; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1992 |
[Proton pump inhibitors: their merits and demerits, and perspectives for future investigation].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Depression, Chemical; Drug Interactions; Drug Resistance, Microbial; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole | 1992 |
Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Enterochromaffin Cells; Female; Gastric Acid; Gastrins; Histamine; Histidine Decarboxylase; Lansoprazole; Omeprazole; Parietal Cells, Gastric; Rats; Rats, Inbred Strains; Somatostatin; Stomach | 1992 |
Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Aged; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Omeprazole; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1992 |
The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 7-Alkoxycoumarin O-Dealkylase; Adenosine Triphosphatases; Animals; Benzimidazoles; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Ethylmorphine-N-Demethylase; Female; H(+)-K(+)-Exchanging ATPase; Kinetics; Lansoprazole; Liver; Omeprazole; Pantoprazole; Pyrazoles; Rats; Rats, Inbred Strains; Sulfoxides | 1991 |
Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Bucladesine; Dogs; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Microsomes; Omeprazole; Parietal Cells, Gastric; Stereoisomerism | 1991 |
Activity of lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Helicobacter pylori; In Vitro Techniques; Lansoprazole; Microbial Sensitivity Tests; Omeprazole | 1991 |
High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Male; Omeprazole | 1991 |
[Proton-pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Anti-Ulcer Agents; Energy Metabolism; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton-Translocating ATPases | 1991 |
Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Acetic Acid; Animals; Anti-Ulcer Agents; Cimetidine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hydrocortisone; Lansoprazole; Male; Omeprazole; Rats; Rats, Inbred Strains; Stomach Ulcer; Sucralfate; Wound Healing | 1991 |
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bethanechol Compounds; Dogs; Famotidine; Female; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Pentagastrin; Peptones; Pylorus; Rats; Rats, Inbred Strains | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esophagitis, Peptic; Famotidine; Gastric Mucosa; Immersion; Lansoprazole; Omeprazole; Peptic Ulcer; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Psychological | 1991 |
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Omeprazole; Pyridines; Structure-Activity Relationship | 1991 |
Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Survival; Gastric Mucosa; Immersion; Lansoprazole; Male; Omeprazole; Rats; Rats, Inbred Strains; Stomach Ulcer | 1990 |
Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Bucladesine; Carbachol; Cycloheximide; Dogs; Female; Gastric Acid; Histamine Antagonists; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Puromycin; Ranitidine | 1990 |
Human gastric acid secretion following repeated doses of AG-1749.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Pentagastrin | 1989 |
Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Dithiothreitol; Dogs; Ethylmaleimide; Female; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Microsomes; Omeprazole; Protons; Pyridines; Sulfhydryl Compounds | 1989 |
Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Dogs; Gastric Acid; Gastric Mucosa; Gastrins; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Pepsin A; Peptic Ulcer; Protons; Rats; Rats, Inbred Strains | 1989 |
[AG1749: a study of its inhibition of gastric pH after morning or evening dosage].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Depression, Chemical; Drug Administration Schedule; Duodenal Ulcer; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach | 1988 |
Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Chemical Analysis; Combined Modality Therapy; Duodenal Neoplasms; Female; Gastric Acid; Gastric Mucosa; Gastrinoma; Gastrins; Hepatic Artery; Humans; Interferons; Lansoprazole; Male; Middle Aged; Multiple Endocrine Neoplasia; Omeprazole; Pancreatic Neoplasms; Peptic Ulcer; Splenic Artery; Zollinger-Ellison Syndrome | 1994 |
Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1995 |
Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Adhesion; Drug Synergism; Enzyme Inhibitors; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Microscopy, Electron; Omeprazole; Proton Pump Inhibitors; Urease; Virulence | 1995 |
Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastric Mucosa; Indomethacin; Lansoprazole; Male; Omeprazole; Proton Pumps; Rats; Saline Solution, Hypertonic; Sodium-Potassium-Exchanging ATPase; Stomach Ulcer | 1995 |
Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anesthesia; Animals; Anti-Ulcer Agents; Cats; Female; Gastric Acid; Gastric Fundus; Gastric Mucosa; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Perfusion; Rats; Sodium-Potassium-Exchanging ATPase; Stomach Ulcer | 1995 |
Lansoprazole--a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1995 |
Second proton-pump inhibitor marketed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lansoprazole; Omeprazole; Zollinger-Ellison Syndrome | 1995 |
Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastric Acid; Gastric Juice; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Proton Pumps; Rats; Rats, Sprague-Dawley | 1995 |
Mechanism for species-specific induction of Leydig cell tumors in rats by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Carcinogens; Chorionic Gonadotropin; Dose-Response Relationship, Drug; Haplorhini; Ketoconazole; Lansoprazole; Leydig Cell Tumor; Male; Mice; Omeprazole; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Species Specificity; Testicular Neoplasms; Testosterone | 1995 |
Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa.
Topics: 16,16-Dimethylprostaglandin E2; 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Ethanol; Gastric Mucosa; Indomethacin; Lansoprazole; Male; Omeprazole; Prostaglandins; Proton Pump Inhibitors; Rats; Rats, Wistar; Stomach Ulcer | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pepsinogens; Peptic Ulcer; Proton Pump Inhibitors; Sex Factors; Smoking; Stomach Ulcer | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric Acid; Gastric Emptying; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Autoradiography; Colon; Gastric Acid; Gastric Fundus; Gastric Mucosa; Intestinal Mucosa; Lansoprazole; Omeprazole; Pyloric Antrum; Rats | 1995 |
Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cell Death; Cell Division; Cells, Cultured; Epithelial Cells; Epithelium; Gastric Mucosa; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1995 |
Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cells, Cultured; Free Radicals; Gastric Mucosa; Helicobacter pylori; Humans; Lansoprazole; Neutrophil Activation; Omeprazole; Proton Pump Inhibitors; Reactive Oxygen Species; Respiratory Burst | 1995 |
Lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Time Factors | 1995 |
[Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Gastritis; Helicobacter; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Stomach Ulcer; Tinidazole | 1995 |
Proceedings of the 2nd International Colloquium on Proton Pump Inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1995 |
Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Electronics, Medical; Famotidine; Female; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regeneration; Stomach Ulcer | 1995 |
Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Adhesion; Cells, Cultured; Drug Therapy, Combination; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Urease | 1995 |
Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Famotidine; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole | 1995 |
[Drug of the month. Lansoprazole (DakaR)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Glutathione; Helicobacter pylori; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Urease | 1995 |
Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Drug Administration Schedule; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1995 |
Uptake site of lansoprazole, a proton pump inhibitor, in human fundic mucosa: possible relevance with fibroblast and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Autoradiography; Fibroblasts; Gastric Fundus; Gastric Mucosa; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Image Processing, Computer-Assisted; Lansoprazole; Nerve Fibers; Omeprazole; Parietal Cells, Gastric; Proton Pump Inhibitors | 1995 |
[Lansoprazole--a new acid pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole | 1995 |
Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cation Transport Proteins; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Microsomes; Omeprazole; Potassium; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Wistar; Time Factors | 1994 |
Oxidative metabolism of lansoprazole by human liver cytochromes P450.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biotransformation; Cells, Cultured; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; DNA, Complementary; Female; Humans; Lansoprazole; Male; Microsomes, Liver; Middle Aged; Omeprazole; Oxidation-Reduction; Proton Pump Inhibitors; Substrate Specificity | 1995 |
Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with proton pump inhibitors versus H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Nizatidine; Omeprazole; Piperidines; Proton Pump Inhibitors; Stomach Ulcer; Ultrasonography, Interventional; Wound Healing | 1994 |
Safety of omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dog Diseases; Dogs; Lansoprazole; Omeprazole; Polyarteritis Nodosa | 1994 |
Safety of omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Ischemia; Lansoprazole; Male; Middle Aged; Omeprazole; Optic Nerve; Optic Nerve Diseases | 1994 |
[Proton pump inhibitors in the treatment of reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Time Factors | 1994 |
Treatment of acid peptic disease: focus on proton pump inhibitors. Proceedings of the 1st International Symposium on Lansoprazole. Athens, Greece, 24 September 1992.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pumps | 1993 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoid Tumor; Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Rats; Stomach Neoplasms; Zollinger-Ellison Syndrome | 1994 |
Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Blotting, Northern; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Humans; Lansoprazole; Liver; Male; Middle Aged; Omeprazole; Oxidoreductases; Oxidoreductases, N-Demethylating; Oxygenases; Receptors, Aryl Hydrocarbon; RNA, Messenger | 1994 |
[Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Depression, Chemical; Dose-Response Relationship, Drug; Gastric Acid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Zollinger-Ellison Syndrome | 1994 |
Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Aged; Female; Half-Life; Hepatitis; Hospitalization; Humans; Lansoprazole; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Omeprazole; Renal Insufficiency; Time Factors | 1993 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer | 1993 |
Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Ethylmaleimide; Helicobacter pylori; Hydroxamic Acids; Hydroxyurea; Indicators and Reagents; Iodoacetamide; Lansoprazole; Omeprazole; Oxidoreductases; Stomach; Sulfhydryl Reagents; Thiourea; Urease | 1993 |
Pharmacokinetics of lansoprazole in hemodialysis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Dialysis Solutions; Drug Administration Schedule; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Protein Binding; Proton Pump Inhibitors; Renal Dialysis | 1995 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Fundus; Gastrins; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Time Factors | 1995 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pilot Projects; Treatment Outcome | 1995 |
Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Anti-Bacterial Agents; Benzimidazoles; Enzyme Inhibitors; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyridines; Urea; Ureaplasma urealyticum; Urease | 1995 |
Identification of the human P450 enzymes involved in lansoprazole metabolism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Lansoprazole; Microsomes, Liver; Omeprazole; Rats; Recombinant Proteins | 1996 |
Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Bronchodilator Agents; Drug Interactions; Enzyme Inhibitors; Humans; Individuality; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Theophylline | 1995 |
Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Base Sequence; Benzimidazoles; Benzoflavones; beta-Naphthoflavone; Binding Sites; Caco-2 Cells; Cell Differentiation; Cimetidine; Cytochrome P-450 Enzyme System; Gene Expression Regulation; Humans; Kinetics; Lansoprazole; Molecular Sequence Data; Oligonucleotide Probes; Omeprazole; Receptors, Aryl Hydrocarbon; RNA, Messenger | 1996 |
Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bicarbonates; Capsaicin; Duodenum; Famotidine; Histamine H2 Antagonists; Intestinal Mucosa; Lansoprazole; Male; Neurons, Afferent; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Stimulation, Chemical; Vasoactive Intestinal Peptide | 1996 |
Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Bacteriological Techniques; Breath Tests; Clarithromycin; Clinical Enzyme Tests; Clinical Laboratory Techniques; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity; Urea; Urease | 1996 |
Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Air; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Helicobacter pylori; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Oxygen; Proton Pump Inhibitors | 1996 |
New therapeutic agents marketed in 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration | 1996 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1996 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole | 1996 |
Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach; Urease | 1996 |
Indomethacin-induced morphological changes in the rat gastric mucosa, with or without prior treatment with two proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Interactions; Gastric Mucosa; Indomethacin; Lansoprazole; Male; Microcirculation; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Stomach | 1995 |
Re: short-term treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Time Factors | 1996 |
The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Down-Regulation; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter pylori; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Omeprazole; Pyloric Antrum; Urease | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Electromyography; Female; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Myoelectric Complex, Migrating; Omeprazole | 1996 |
Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Chloramphenicol O-Acetyltransferase; Cytochrome P-450 CYP1A1; DNA Primers; DNA, Complementary; Enzyme Induction; Humans; Lansoprazole; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Omeprazole; Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Species Specificity; Thiabendazole; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Role of capsaicin-sensitive sensory neurons and nitric oxide in the protective effect of lansoprazole, a proton pump inhibitor, on the gastric mucosa in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Capsaicin; Enzyme Inhibitors; Ethanol; Gastric Mucosa; Lansoprazole; Male; Nitric Oxide; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Stomach Diseases; Taurocholic Acid | 1996 |
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Structure-Activity Relationship; Sulfoxides | 1996 |
Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin; Gene Rearrangement; Genes, Immunoglobulin; Helicobacter pylori; Humans; Immunoglobulin Heavy Chains; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Omeprazole | 1996 |
Only one proton-pump inhibitor for formulary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Formularies as Topic; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Therapeutic Equivalency | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer; Tinidazole | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blotting, Southern; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Peptic Ulcer; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Recurrence | 1996 |
Atopic dermatitis successfully treated by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Blotting, Western; Clarithromycin; Dermatitis, Atopic; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1996 |
[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Structure-Activity Relationship; Sulfoxides | 1996 |
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Structure-Activity Relationship; Sulfoxides; Treatment Outcome | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies | 1996 |
Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsinogens; Stomach Ulcer | 1997 |
[A case of hemolysis induced by lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia, Hemolytic; Anti-Ulcer Agents; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer | 1996 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Combined Modality Therapy; Diterpenes; Drug Evaluation; Drug Therapy, Combination; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Renal Dialysis; Time Factors | 1997 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Roxithromycin; Treatment Outcome | 1996 |
Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Blood Glucose; Gastrins; Insulin; Lansoprazole; Male; Omeprazole; Organ Size; Pancreas; Pancreatectomy; Proteins; Proton Pump Inhibitors; Rats; Rats, Wistar; Regeneration | 1996 |
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Indomethacin; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley | 1996 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley; Stress, Physiological | 1996 |
[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Stomach Neoplasms | 1997 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Time Factors | 1997 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Pyloric Antrum; Risk Factors | 1997 |
Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; beta-Naphthoflavone; Cell Line; Cytochrome P-450 CYP1A1; Enzyme Activation; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; RNA, Messenger; Sulfoxides | 1997 |
Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Stereoisomerism; Sulfoxides | 1997 |
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; False Negative Reactions; Female; Forecasting; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Ranitidine; Stomach; Urea | 1997 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child, Preschool; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Hypertrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillins; Protein-Losing Enteropathies | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole | 1997 |
Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Enzyme Inhibitors; Erythromycin; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1997 |
Barrett's esophagus: acid suppression, but no regression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Gastric Acid; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1997 |
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Dose-Response Relationship, Drug; Esophagoscopy; Esophagus; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Remission Induction | 1997 |
Lansoprazole pharmacokinetics in subjects with various degrees of kidney function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Area Under Curve; Case-Control Studies; Half-Life; Humans; Kidney; Kidney Diseases; Lansoprazole; Middle Aged; Omeprazole; Protein Binding; Proton Pump Inhibitors; Severity of Illness Index | 1997 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Penicillins; Stomach; Treatment Outcome | 1997 |
Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Blotting, Western; Cytochrome P-450 Enzyme System; Cytochromes b5; Enzyme Induction; Enzyme Inhibitors; Female; Lansoprazole; Microsomes, Liver; NADPH-Ferrihemoprotein Reductase; Omeprazole; Organ Size; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers; Biopsy; Chronic Disease; Clarithromycin; Duodenal Ulcer; Female; Follow-Up Studies; Gastric Juice; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-8; Lactoferrin; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pyloric Antrum | 1997 |
In-vitro activity of lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors; Vacuoles | 1997 |
Proton-pump inhibitors: three of a kind?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1997 |
Acute generalized exanthematous pustulosis induced by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Exanthema; Female; Humans; Lansoprazole; Omeprazole | 1997 |
High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chromatography, Thin Layer; Enzyme Inhibitors; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Tablets, Enteric-Coated | 1997 |
Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Quality of Life; Recurrence; Sensitivity and Specificity; Severity of Illness Index | 1997 |
[Lansoprazol: acid blocking in peptic disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Peptic Ulcer | 1994 |
Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine | 1997 |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1997 |
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Enzyme Inhibitors; Humans; In Vitro Techniques; Isoenzymes; Lansoprazole; Mephenytoin; Microsomes, Liver; Omeprazole; Phenacetin; Tolbutamide | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Vaccination | 1997 |
Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Polymorphism, Genetic | 1997 |
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amino Acid Sequence; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Indicators and Reagents; Lansoprazole; Molecular Sequence Data; Omeprazole; Oxidoreductases; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sequence Homology, Amino Acid; Sphingosine; Stomach; Sulfhydryl Compounds; Sulfoxides; Swine | 1997 |
[Lansoprazole-induced hepatitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chemical and Drug Induced Liver Injury; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1997 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 1997 |
Lanzoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; False Negative Reactions; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Radiopharmaceuticals; Ranitidine; Urea | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Diarrhea; Duodenal Ulcer; Enzyme Inhibitors; Female; Follow-Up Studies; Gastritis; Gastroesophageal Reflux; Headache; Humans; Lansoprazole; Male; Middle Aged; Nausea; Omeprazole; Product Surveillance, Postmarketing; Prospective Studies; Proton Pump Inhibitors | 1997 |
H. pylori eradication by LAC.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Food-Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1997 |
Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Peptic Ulcer | 1997 |
Lansoprazole, H. pylori, and atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pilot Projects; Tetracycline; Treatment Outcome | 1996 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analysis; Decision Support Techniques; Delphi Technique; Drug Costs; Enzyme Inhibitors; Esophagitis, Peptic; Follow-Up Studies; Gastroenterology; Histamine H2 Antagonists; Humans; Lansoprazole; Medicare; Omeprazole; Probability; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Recurrence; Relative Value Scales; Sensitivity and Specificity; United States; Value of Life | 1997 |
Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Circadian Rhythm; Drug Administration Schedule; Enzyme Inhibitors; Follow-Up Studies; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1997 |
An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Enzyme Induction; Enzyme Inhibitors; Female; Lansoprazole; Liver; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides | 1997 |
Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Binding Sites; Enzyme Inhibitors; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Kinetics; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Sulfoxides; Valinomycin | 1997 |
Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Glossitis; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomatitis | 1997 |
Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Bile; Enzyme Inhibitors; Female; Glucuronosyltransferase; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides; Thyroid Hormones | 1997 |
[Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Diterpenes; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Neoplasms; Tegafur; Uracil | 1997 |
Effects of enprostil on gastric endocrine secretion during chronic administration of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Drug Interactions; Enprostil; Enterochromaffin Cells; Gastric Mucosa; Gastrin-Secreting Cells; Gastrins; Immunohistochemistry; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Somatostatin; Somatostatin-Secreting Cells; Stomach | 1997 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Lansoprazole; Middle Aged; Omeprazole; Stomach; Time Factors | 1997 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Penicillins | 1997 |
Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alcohol Dehydrogenase; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Ethanol; Glutathione; Humans; In Vitro Techniques; Lansoprazole; Liver; Male; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Stomach | 1997 |
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Epithelial Cells; Esophagitis, Peptic; Gastric Mucosa; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Time Factors | 1997 |
[Gastric lymphoma--a case report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Penicillins; Stomach; Stomach Neoplasms | 1998 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-8; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Stomach Ulcer | 1997 |
Possible lansoprazole-induced eosinophilic syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Eosinophilia-Myalgia Syndrome; Female; Humans; Lansoprazole; Middle Aged; Omeprazole | 1998 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Neoplasms; Time Factors | 1998 |
PPIs vs H2RAs for erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lansoprazole; Markov Chains; Omeprazole; Ranitidine; Recurrence; Reproducibility of Results | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Lansoprazole; Male; Metronidazole; Omeprazole; Peptic Ulcer; Time Factors | 1998 |
Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Growth Inhibitors; Helicobacter pylori; Humans; Lansoprazole; Microscopy, Electron, Scanning; Omeprazole; Pantoprazole; Sulfoxides; Urease | 1998 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Synergism; Erythromycin; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Roxithromycin | 1998 |
[Problems in the diagnosis and treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1996 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studies; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acid; Gastric Juice; Gastric Mucosa; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer | 1998 |
Severe eosinophilia related with lansoprazole in a hemodialysis patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Blood Chemical Analysis; Cell Count; Eosinophilia; Humans; Lansoprazole; Male; Omeprazole; Renal Dialysis | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillin Resistance; Penicillins; Peptic Ulcer | 1998 |
Appearance of myofibroblasts in the gastric mucosa after ingestion of ethanol and lansoprazole with reevaluation of the mucoid cap.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme-Linked Immunosorbent Assay; Ethanol; Fibroblast Growth Factor 2; Fibroblasts; Gastric Mucosa; Lansoprazole; Male; Microscopy, Fluorescence; Mucus; Omeprazole; Rats; Rats, Wistar; Wound Healing | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Spiramycin | 1998 |
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagus; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Prospective Studies | 1998 |
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Proton Pump Inhibitors | 1998 |
Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemokine CXCL1; Chemokines, CXC; Chemotactic Factors; Gastric Mucosa; Gastritis; Growth Substances; Helicobacter Infections; Helicobacter pylori; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lansoprazole; Middle Aged; Omeprazole; Stomach Diseases; Stomach Ulcer | 1998 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Child, Preschool; Cystic Fibrosis; Growth; Humans; Lansoprazole; Nutritional Status; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Tetracycline | 1997 |
Sample size calculation in economic evaluations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Esophagitis, Peptic; Fibrinolytic Agents; Health Services Research; Humans; Lansoprazole; Models, Statistical; Myocardial Infarction; Omeprazole; Probability; Sample Size; Streptokinase | 1998 |
Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Helicobacter pylori; Hydrogen-Ion Concentration; Kinetics; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1998 |
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Prescriptions; Family Practice; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; United Kingdom | 1998 |
In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzenesulfonates; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Organometallic Compounds; Ranitidine; Thiazoles | 1998 |
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Proton Pump Inhibitors; Sensitivity and Specificity; Spectrum Analysis; Urea | 1998 |
An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Humans; Lansoprazole; Liver; Male; Methylcholanthrene; Middle Aged; Omeprazole; Pantoprazole; Rifampin; Steroid Hydroxylases; Structure-Activity Relationship; Sulfoxides | 1998 |
[Drug interactions. Proton pump inhibitors. 1].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Diagnostic Errors; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Urea | 1998 |
Effect of pirenzepine on gastric endocrine cell kinetics during lansoprazole administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enterochromaffin Cells; Gastric Mucosa; Gastrin-Secreting Cells; Gastrins; Kinetics; Lansoprazole; Male; Muscarinic Antagonists; Omeprazole; Pirenzepine; Proton Pump Inhibitors; Rats; Rats, Wistar; Somatostatin; Somatostatin-Secreting Cells | 1998 |
[Drug interactions. Proton pump inhibitors II].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
Lansoprazole: a cause of secretory diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Diarrhea; Female; Gastrins; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine | 1998 |
Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cell Division; Cells, Cultured; Enterochromaffin-like Cells; Gastric Mucosa; Gastrins; Gene Expression Regulation; Indoles; Lansoprazole; Male; Omeprazole; Rats; Rats, Sprague-Dawley; Regeneration | 1998 |
[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Esophagitis, Peptic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 1998 |
The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Gastric Acid; Gastric Acidity Determination; Gastrostomy; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach | 1998 |
Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Cimetidine; Clarithromycin; Diterpenes; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Hypoproteinemia; Lansoprazole; Omeprazole; Time Factors | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Stomach Ulcer; Treatment Outcome; Wound Healing | 1998 |
Effect of combined administration of lansoprazole and sofalcone on microvascular and connective tissue regeneration after ethanol-induced gastric mucosal damage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; CD36 Antigens; Chalcone; Chalcones; Connective Tissue; Drug Therapy, Combination; Endothelium, Vascular; Ethanol; Fibroblast Growth Factor 2; Fibroblasts; Gastric Mucosa; Immunohistochemistry; Irritants; Lansoprazole; Male; Microcirculation; Omeprazole; Rats; Rats, Wistar; Regeneration; Stomach Ulcer | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Chalcone; Chalcones; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome; Urea; Urease | 1998 |
Pharmacokinetic differences between lansoprazole enantiomers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anesthesia; Animals; Anti-Ulcer Agents; Area Under Curve; Chromatography, High Pressure Liquid; Fasting; In Vitro Techniques; Lansoprazole; Male; Molecular Structure; Omeprazole; Protein Binding; Rats; Rats, Wistar; Stereoisomerism | 1998 |
Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Biopsy; Clarithromycin; Drug Synergism; Helicobacter pylori; Humans; Kinetics; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Roxithromycin; Time Factors | 1998 |
[A case of Behcet's syndrome associated with esophageal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Anti-Ulcer Agents; Behcet Syndrome; Esophageal Diseases; Female; Humans; Lansoprazole; Omeprazole; Prednisolone; Ulcer | 1998 |
Stress ulcer prevention and histamine-2-receptor antagonists: leaps of faith or back to the drawing board?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Intensive Care Units; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine; Stress, Physiological | 1999 |
Effect of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of mononuclear cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Critical Care; DNA; Histamine H2 Antagonists; Humans; Immunity, Cellular; Lansoprazole; Leukocytes, Mononuclear; Male; Omeprazole; Proton Pump Inhibitors; Radionuclide Imaging; Radiopharmaceuticals; Ranitidine; Stomach Ulcer; Thymidine; Tritium | 1999 |
Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Aspirin; Drug Interactions; Gastric Acid; Lansoprazole; Male; Nizatidine; Omeprazole; Proton Pump Inhibitors; Ranitidine; Rats; Rats, Wistar; Sucralfate | 1998 |
Omeprazole and lansoprazole suspensions for nasogastric administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Drug Compounding; Humans; Intubation, Gastrointestinal; Lansoprazole; Omeprazole; Sodium Bicarbonate; Suspensions | 1999 |
Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Bicarbonates; Dose-Response Relationship, Drug; Duodenal Ulcer; Enzyme Inhibitors; Epirizole; Gastric Acid; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides; Wound Healing | 1999 |
Symptomatic heterotopic gastric mucosa in the upper oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Choristoma; Cimetidine; Esophageal Diseases; Esophagoscopy; Female; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1998 |
Effect of lansoprazole on human leukocyte function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chemotaxis, Leukocyte; Cytotoxicity, Immunologic; Enzyme Inhibitors; Female; Humans; Killer Cells, Natural; Lansoprazole; Leukocytes; Male; Middle Aged; Neutrophils; Omeprazole; Proton Pump Inhibitors; Superoxides | 1999 |
Prostacyclin analog prevents stress-induced expression of immediate early genes and gastric mucosal lesions in the rat stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epoprostenol; Famotidine; Gastric Mucosa; Genes, Immediate-Early; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Regional Blood Flow; Stress, Physiological | 1999 |
Alternative method for administering proton-pump inhibitors through nasogastric tubes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Intubation, Gastrointestinal; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1999 |
Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dogs; Drug Interactions; Hydroxylation; In Vitro Techniques; Lansoprazole; Male; Microsomes, Liver; Omeprazole | 1999 |
Combined activity of azithromycin and lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Drug Synergism; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1999 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies | 1999 |
The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Carbachol; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gastric Acid; Gastric Fistula; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine; Hydrogen-Ion Concentration; Imidazoles; Lansoprazole; Male; Microsomes; Omeprazole; Proton Pump Inhibitors; Pyridines; Stomach; Tetragastrin; Time Factors | 1999 |
The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Endoscopes; Endoscopy; Esophagoscopy; Esophagus; Humans; Lansoprazole; Light Coagulation; Male; Middle Aged; Omeprazole; Preoperative Care; Safety | 1999 |
Lansoprazole and glottis edema.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Hypersensitivity; Humans; Lansoprazole; Laryngeal Edema; Male; Omeprazole | 1999 |
Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Drug Eruptions; Enzyme Inhibitors; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1999 |
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Carrier Proteins; Cell Differentiation; Cell Division; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Immunoblotting; Immunohistochemistry; Lansoprazole; Male; Microfilament Proteins; Middle Aged; Omeprazole; Proliferating Cell Nuclear Antigen | 1999 |
Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Administration Schedule; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Linear Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values | 1999 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tests; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Sensitivity and Specificity; Urea | 1999 |
Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Psychometrics; Quality of Life; Reproducibility of Results; Sick Role; Sickness Impact Profile | 1999 |
Mechanical manipulation of polymorphonuclear leukocyte plasma membranes with optical tweezers causes influx of extracellular calcium through membrane channels.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biological Transport, Active; Calcium; Calcium Channels; Cell Membrane; Enzyme Inhibitors; Humans; Lansoprazole; Lasers; Micromanipulation; Neutrophils; Omeprazole; Proton Pump Inhibitors; Stress, Mechanical | 1999 |
Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Enzyme Inhibitors; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Reproducibility of Results; Salts; Sulfoxides; Time Factors | 1999 |
[Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Combined Modality Therapy; Esophagoscopy; Esophagus; Female; Gastric Acidity Determination; Humans; Lansoprazole; Laser Coagulation; Long-Term Care; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; California; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Formularies, Hospital as Topic; Gastroesophageal Reflux; Health Care Surveys; Hospitals, Veterans; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Surveys and Questionnaires; Therapeutic Equivalency; Treatment Outcome | 1999 |
Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Ethanol; Gastric Acid; Gastric Mucosa; Hydrochloric Acid; Lansoprazole; Male; Mucus; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Shock, Hemorrhagic | 1999 |
Establishment of surgically induced chronic acid reflux esophagitis in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Disease Models, Animal; Enzyme Inhibitors; Esophagitis, Peptic; Gastric Outlet Obstruction; Lansoprazole; Ligation; Male; Omeprazole; Rats; Rats, Wistar; Stomach | 1999 |
Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diazepam; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pharmacies; Prevalence; Proton Pump Inhibitors; Retrospective Studies; Theophylline; Warfarin | 1999 |
Fecal clearance of alpha1-antitrypsin with lansoprazole can detect protein-losing gastropathy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; alpha 1-Antitrypsin; Enzyme Inhibitors; Feces; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Protein-Losing Enteropathies; Proton Pump Inhibitors | 1999 |
Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Intubation, Gastrointestinal; Lansoprazole; Omeprazole | 1999 |
Importance of adequate acid suppression in the management of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Carrier Proteins; Cell Differentiation; Cell Division; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Microfilament Proteins; Omeprazole; Proliferating Cell Nuclear Antigen | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Recurrence; Stomach Ulcer | 1999 |
Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Precancerous Conditions; Stomach Neoplasms | 1999 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 2000 |
Lichenoid drug eruption with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Drug Eruptions; Enzyme Inhibitors; Humans; Lansoprazole; Lichenoid Eruptions; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2000 |
Continued use of the proton-pump inhibitor lansoprazole following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Time Factors | 2000 |
Determination of Lansoprazole in pharmaceutical dosage forms by two different spectroscopic methods.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Calibration; Capsules; Evaluation Studies as Topic; Excipients; Lansoprazole; Omeprazole; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 1999 |
The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 3T3 Cells; Animals; Benzimidazoles; Cell Size; Chloride Channels; Dithiothreitol; Electrophysiology; Enzyme Inhibitors; Fibroblasts; Lansoprazole; Mice; Omeprazole; Proton Pump Inhibitors; Pyridines; Stomach; Sulfhydryl Reagents; Thymine Nucleotides | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States | 2000 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prognosis; Prospective Studies; Remission Induction; Spain | 2000 |
Spectrophotometric methods for the determination of lansoprazole and pantoprazole sodium sesquihydrate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Calibration; Capsules; Hydrogen-Ion Concentration; Indicators and Reagents; Lansoprazole; Omeprazole; Pantoprazole; Pharmaceutical Solutions; Spectrophotometry, Ultraviolet; Sulfoxides; Tablets | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Omeprazole; Reverse Transcriptase Polymerase Chain Reaction; Stomach; Stomach Neoplasms | 2000 |
The acid test for formulary policy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Costs and Cost Analysis; Formularies as Topic; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 1999 |
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Costs and Cost Analysis; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2000 |
[Lansoprazole-induced gynecomastia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Gynecomastia; Humans; Lansoprazole; Male; Omeprazole | 2000 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Cell Culture Techniques; Endothelium; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Creatinine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Ranitidine | 2000 |
Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Drug Storage; Humans; Lansoprazole; Omeprazole; Suspensions; Syringes; Temperature | 2000 |
Preformulation investigation of the novel proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chemistry, Pharmaceutical; Drug Stability; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Solubility | 2000 |
Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antibiosis; Bacterial Adhesion; Butyric Acid; Clostridium; Female; Germ-Free Life; Helicobacter Infections; Helicobacter pylori; Lactic Acid; Lansoprazole; Mice; Omeprazole; Spores, Bacterial; Stomach | 2000 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Endoscopy, Gastrointestinal; Feces; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Iron; Lansoprazole; Male; Metronidazole; Omeprazole; Stomach; Urea | 2000 |
How do we offer clinical relief to patients with gastro-oesophageal reflux disease?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Quality of Life; Treatment Outcome | 2000 |
Controlling acid reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 1999 |
[In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Child, Preschool; Enzyme Inhibitors; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pumps; Rabeprazole; Sulfides | 2000 |
Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Carnivora; Clarithromycin; DNA, Bacterial; Drug Therapy, Combination; Endoscopy; Female; Helicobacter; Helicobacter Infections; Lansoprazole; Male; Omeprazole; Penicillins; Polymerase Chain Reaction; Stomach; Stomach Ulcer | 2000 |
Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Drug Costs; Humans; Lansoprazole; Medical Audit; Middle Aged; Omeprazole; Outcome Assessment, Health Care; Peptic Ulcer; Proton Pump Inhibitors; Retrospective Studies | 2000 |
Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Managed Care Programs; Omeprazole; Patient Satisfaction; Therapeutic Equivalency; Treatment Failure; Wisconsin | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2000 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Systems; Age Distribution; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Cohort Studies; Diarrhea; Drug Prescriptions; England; Family Practice; Female; Headache; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2000 |
Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pilot Projects; Rifabutin; Treatment Failure | 2000 |
Suppressive effect of antiulcer agents on granulocytes--a role for granulocytes in gastric ulcer formation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Animals; Anti-Ulcer Agents; Depression, Chemical; Granulocytes; Histamine H2 Antagonists; Humans; Lansoprazole; Leukocyte Count; Luminescent Measurements; Mice; Middle Aged; Omeprazole; Piperidines; Proton Pump Inhibitors; Stomach Ulcer; Stress, Physiological; Superoxides | 2000 |
[lymphocytic colitis associated with lansoprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mucosa; Lansoprazole; Lymphocytes; Male; Middle Aged; Omeprazole | 2000 |
Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Deglutition Disorders; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Hypopharynx; Lansoprazole; Laryngeal Edema; Laryngoscopy; Male; Middle Aged; Omeprazole; Pharyngeal Diseases; Prospective Studies; Proton Pump Inhibitors; Sensation Disorders; Severity of Illness Index | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B-Lymphocytes; Base Sequence; Biopsy; Clone Cells; Data Interpretation, Statistical; DNA, Complementary; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Metronidazole; Middle Aged; Molecular Sequence Data; Omeprazole; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Time Factors | 2000 |
Helicobacter pylori infection in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Omeprazole; Postoperative Complications; Proton Pump Inhibitors; Time Factors | 2000 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Female; Gastric Acid; Gastrins; Gastritis; Helicobacter pylori; Humans; Hyperplasia; Intestinal Mucosa; Lansoprazole; Male; Metaplasia; Middle Aged; Omeprazole; Zollinger-Ellison Syndrome | 2001 |
Coprescribing proton pump inhibitors with other medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Interactions; Drug Prescriptions; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Managed Care Programs; Medication Errors; Middle Aged; Omeprazole; Pharmaceutical Services; Proton Pump Inhibitors; Retrospective Studies | 2000 |
Evaluation of the gastroprotective activity of cordatin, a diterpene isolated from Aparisthmium cordatum (Euphorbiaceae).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Euphorbiaceae; Female; Gastric Acid; Gastric Juice; Gastric Mucosa; Lansoprazole; Male; Mice; Mucus; Omeprazole; Plant Extracts; Rats; Rats, Wistar; Stomach Ulcer; Trees | 2000 |
Asymptomatic giardiasis--an association with proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastroesophageal Reflux; Giardiasis; Humans; Intestine, Small; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2000 |
Allergic contact dermatitis due to lansoprazole, a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross Reactions; Dermatitis, Allergic Contact; Dermatitis, Occupational; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Occupational Exposure; Omeprazole; Patch Tests; Proton Pump Inhibitors | 2001 |
Analysis of gastrin receptor gene expression in proliferating cells in the neck zone of gastric fundic glands using laser capture microdissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cell Division; Dissection; Gastric Fundus; Gastric Mucosa; Gastrins; Gene Expression Regulation; Immunohistochemistry; Lansoprazole; Lasers; Male; Omeprazole; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Receptors, Cholecystokinin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach | 2001 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Misoprostol; Omeprazole; Peptic Ulcer; Ranitidine | 2001 |
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Omeprazole; Penicillins; Prospective Studies; Remission Induction; Stomach Neoplasms | 2001 |
[Observations regarding internet-based applications in gastroenterology specialty practices--aspects of quality control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Computer Literacy; Data Collection; Education, Medical, Graduate; Esophagitis, Peptic; Feasibility Studies; Gastroenterology; Germany; Humans; Internet; Lansoprazole; Omeprazole; Quality Assurance, Health Care | 2000 |
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Omeprazole; Proton Pump Inhibitors; Remission Induction; Stomach Neoplasms | 2001 |
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Endosonography; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Plasmacytoma; Stomach Neoplasms; Treatment Outcome | 2001 |
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastritis, Atrophic; Helicobacter Infections; Humans; Intestines; Lansoprazole; Male; Metaplasia; Middle Aged; Omeprazole; Precancerous Conditions; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method | 2001 |
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Area Under Curve; Biotransformation; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; Enzyme Inhibitors; Half-Life; In Vitro Techniques; Isoenzymes; Lansoprazole; Male; Microsomes, Liver; Omeprazole; Protein Binding; Proton Pump Inhibitors; Stereoisomerism | 2001 |
[Suppressive effect of lansoprazole on anti-Candida activity of murine macrophages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Candida albicans; Cells, Cultured; Female; Lansoprazole; Macrophages, Peritoneal; Mice; Omeprazole; Proton Pump Inhibitors | 2001 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transport; Clarithromycin; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Duodenum; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Penicillins; Peptic Ulcer; Rats; Rats, Wistar | 2001 |
Electrochemical studies and differential pulse polarographic analysis of lansoprazole in pharmaceuticals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Calibration; Capsules; Lansoprazole; Omeprazole; Polarography; Sensitivity and Specificity; Spectrophotometry | 2001 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromocriptine; Cimetidine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indomethacin; Lansoprazole; Male; Mice; Mice, Inbred Strains; Misoprostol; Omeprazole; Pantoprazole; Peptide Fragments; Proteins; Ranitidine; Stomach Diseases; Sulfoxides | 2001 |
Inhibitory activities of lansoprazole against respiration in Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Oxygen | 2001 |
Gastroprotective effect of aparisthman, a diterpene isolated from Aparisthmium cordatum, on experimental gastric ulcer models in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Brazil; Cimetidine; Disease Models, Animal; Diterpenes; Euphorbiaceae; Female; Gastric Acid; Gastric Acidity Determination; Gastric Juice; Gastric Mucosa; Indomethacin; Lansoprazole; Male; Mice; Omeprazole; Peptic Ulcer; Plant Extracts; Rats; Rats, Wistar; Trees | 2001 |
Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; False Negative Reactions; Female; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Sensitivity and Specificity; Urea | 2001 |
[Gynecomastia associated with the simultaneous use of cisapride and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cisapride; Drug Combinations; Gastrointestinal Agents; Gynecomastia; Humans; Lansoprazole; Male; Omeprazole | 2001 |
Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Humans; Hydrogen Peroxide; Lansoprazole; Neutrophils; Omeprazole; Phagocytosis; Pirenzepine; Rabeprazole; Superoxides | 2001 |
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Edema; Female; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 2001 |
Proton pump inhibitors: a study of GPs' prescribing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Costs; Drug Prescriptions; Drug Utilization; England; Family Practice; Female; Health Services Research; Hospitals, Teaching; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Sulfoxides | 2001 |
Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Crohn Disease; Data Interpretation, Statistical; Disaccharides; Duodenal Diseases; Esophageal Diseases; Famotidine; Female; Humans; Lansoprazole; Male; Mannitol; Mesalamine; Middle Aged; Omeprazole; Permeability; Proton Pumps; Retrospective Studies; Stomach Diseases; Treatment Outcome | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Omeprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2001 |
High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Calibration; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stereoisomerism | 2001 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2001 |
Discoloured tongue: a new cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Humans; Lansoprazole; Male; Omeprazole; Pigmentation Disorders; Proton Pump Inhibitors; Tongue Diseases | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Ampulla of Vater; Biopsy; Clarithromycin; Common Bile Duct Neoplasms; Drug Therapy, Combination; Duodenal Neoplasms; Endosonography; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Lymphoma, Follicular; Male; Middle Aged; Omeprazole | 2001 |
Lansoprazole triple therapy for Turkish children with Helicobacter pylori infections.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Female; Helicobacter Infections; Humans; Lansoprazole; Male; Omeprazole; Time Factors; Treatment Outcome | 2001 |
Inhibition of hyphal growth of Candida albicans by activated lansoprazole, a novel benzimidazole proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Benzimidazoles; Candida albicans; Culture Media; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2001 |
Factors associated with non-response in proton pump inhibitor users: a study of lansoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Case-Control Studies; Child; Child, Preschool; Drug Resistance; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Prospective Studies; Proton Pump Inhibitors | 2001 |
Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Health Care Costs; Heartburn; Hospitals, Veterans; Humans; Lansoprazole; Male; Medical Records; Middle Aged; Omeprazole; Outcome Assessment, Health Care; Patient Satisfaction; Proton Pump Inhibitors; United States | 2001 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Enterocolitis, Pseudomembranous; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Occult Blood; Omeprazole; Penicillins | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease; Female; Gastritis; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Time Factors; Treatment Outcome | 2001 |
[Administration of proton pump inhibitor caused esophageal stenosis in two patients with severe reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Esophageal Stenosis; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2001 |
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2001 |
Advantage of expressing the variations in some digestive parameters as a function of gastric emptying instead of time.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Emptying; Gastric Juice; Humans; Hydrogen-Ion Concentration; Lansoprazole; Lipase; Male; Middle Aged; Omeprazole; Time Factors | 2001 |
The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; California; Clinical Trials as Topic; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Managed Care Programs; Omeprazole; Organizational Case Studies; Patient Satisfaction; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; United States; United States Department of Veterans Affairs | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Breath Tests; Clarithromycin; Cohort Studies; Costs and Cost Analysis; Decision Support Techniques; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Predictive Value of Tests; Recurrence; Unnecessary Procedures | 2001 |
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Pathways; Esophagitis, Peptic; Ethics, Medical; Heartburn; Humans; Lansoprazole; Managed Care Programs; Omeprazole; Patient Advocacy; Therapeutic Equivalency; Treatment Outcome | 2001 |
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Inflammation; Intestinal Mucosa; Intestines; Lactulose; Lansoprazole; Longitudinal Studies; Male; Mannitol; Nitric Oxide; Omeprazole; Permeability; Rhamnose | 2001 |
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Enzyme Inhibitors; Female; Homocysteine; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Risk Factors; Vitamin B 12; Vitamin B 12 Deficiency | 2001 |
Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Lansoprazole; Laryngeal Diseases; Male; Middle Aged; Omeprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Retrospective Studies; Treatment Failure | 2001 |
What is the best pharmacologic approach to managing moderate to severe heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Multicenter Studies as Topic; Omeprazole; Proton Pump Inhibitors; Ranitidine; Reproducibility of Results; Treatment Outcome | 2001 |
Endogenous gastrin stimulates regeneration of remnant pancreas after partial pancreatectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Enzyme Inhibitors; Gastrins; Lansoprazole; Male; Omeprazole; Pancreatectomy; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Regeneration | 2001 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Health Care Costs; Helicobacter Infections; Humans; Lansoprazole; Markov Chains; Omeprazole; Penicillins; Stomach Ulcer; Treatment Outcome | 2001 |
Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Gastric Acid; Gastric Acidity Determination; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pepsin A; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Zollinger-Ellison Syndrome | 2001 |
Key topics in Helicobacter pylori eradication in the management of the dyspeptic patient: a panel discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2001 |
Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Neoplasm Regression, Spontaneous; Omeprazole; Stomach Neoplasms | 2001 |
A systematic gene expression screen of Caenorhabditis elegans cytochrome P450 genes reveals CYP35 as strongly xenobiotic inducible.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Animals, Genetically Modified; beta-Naphthoflavone; Caenorhabditis elegans; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; DNA; Enzyme Inhibitors; Gene Expression; Green Fluorescent Proteins; Intestinal Mucosa; Lansoprazole; Luminescent Proteins; Oligonucleotide Array Sequence Analysis; Omeprazole; Promoter Regions, Genetic; Protein Isoforms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Xenobiotics | 2001 |
Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Interactions; Duodenum; Gastric Mucosa; Gastrointestinal Contents; In Vitro Techniques; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Penicillins; Rats; Rats, Wistar; Stomach; Tissue Distribution | 2001 |
[Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Laryngeal Diseases; Male; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2001 |
Localization of [14C]amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbon Radioisotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Lansoprazole; Male; Omeprazole; Penicillins; Rats; Rats, Wistar | 2001 |
Fine-needle aspiration biopsy of an intra-abdominal inflammatory mass secondary to a penetrating duodenal ulcer mimicking neoplasm.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Diagnosis, Differential; Duodenal Ulcer; Duodenitis; Duodenum; Endoscopy, Digestive System; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2001 |
Pill-induced esophagitis caused by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagitis; Female; Humans; Lansoprazole; Omeprazole; Radiography | 2001 |
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Collagenous colitis associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Collagen; Female; Humans; Lansoprazole; Middle Aged; Omeprazole | 2002 |
Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkalosis; Anorexia Nervosa; Bicarbonates; Bulimia; Chlorides; Female; Humans; Hypokalemia; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2002 |
Laryngospasm: an atypical manifestation of severe gastroesophageal reflux disease (GERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngismus; Male; Metoclopramide; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Syncope | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Exons; Female; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
[Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Purpura, Thrombocytopenic, Idiopathic | 2001 |
Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Lansoprazole; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Protein Isoforms; Proton Pump Inhibitors; Stereoisomerism | 2001 |
[Lansoprazole-associated collagenous colitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole | 2001 |
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pepsin A; Prospective Studies; Zollinger-Ellison Syndrome | 2002 |
In support of "step-up therapy" for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2002 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Serologic Tests | 2002 |
A comparative study on the activity of lansoprazole, omeprazole and PD-136450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System Depressants; Enzyme Inhibitors; Ethanol; Female; Indoles; Indomethacin; Lansoprazole; Male; Omeprazole; Phenethylamines; Rats; Rats, Wistar; Stomach Ulcer | 2002 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Data Interpretation, Statistical; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillin Resistance; Penicillins; Retrospective Studies | 2002 |
Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Antigens; Clarithromycin; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2002 |
Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Enzyme Inhibitors; Female; Fundoplication; Gastric Fundus; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Lansoprazole; Omeprazole; Polyps; Remission, Spontaneous; Stomach Diseases | 2002 |
Conformational analysis: a new approach by means of chemometrics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Lansoprazole; Models, Molecular; Molecular Conformation; Omeprazole; Pantoprazole; Pharmaceutical Preparations; Sulfoxides; Thermodynamics | 2002 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibitors; Esophagitis; Fundoplication; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Laparoscopy; Omeprazole; Proton Pump Inhibitors; Quality of Life; Treatment Outcome | 2002 |
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundoplication; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Ion Concentration; Lansoprazole; Laparoscopy; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Treatment Outcome | 2002 |
Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Heterozygote; Homozygote; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors | 2002 |
Does reduction in gastric acid secretion in bariatric surgery increase diet-induced thermogenesis?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Calorimetry; Diet; Digestion; Female; Gastrectomy; Gastric Acid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Thermogenesis; Weight Loss | 2002 |
Effect of hypergastrinemia on pancreatic carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Animals; Anti-Ulcer Agents; Azaserine; Carcinoma in Situ; Carcinoma, Acinar Cell; Disease Models, Animal; Gastrins; Lansoprazole; Male; Omeprazole; Organ Size; Pancreas; Pancreatic Neoplasms; Precancerous Conditions; Rats; Rats, Inbred Lew | 2002 |
Lansoprazole-induced thrombocytopenia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Omeprazole; Stomach Ulcer; Thrombocytopenia | 2002 |
Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Evidence-Based Medicine; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2002 |
[Treatment of NSAIDs induced ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Famotidine; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2002 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Informed Consent; Japan; Lansoprazole; Male; Omeprazole; Peptic Ulcer; Practice Guidelines as Topic; Treatment Failure | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Peptic Ulcer; Treatment Failure | 2002 |
Gastroprotective activity of oleanolic acid derivatives on experimentally induced gastric lesions in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Drug; Ethanol; Hydrochloric Acid; Lansoprazole; Ligation; Male; Mice; Molecular Structure; Oleanolic Acid; Omeprazole; Phytotherapy; Pylorus; Ranitidine; Rats; Rats, Sprague-Dawley; Solanaceae; Stomach Ulcer; Toxicity Tests, Acute | 2002 |
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Gastric Acidity Determination; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Statistics, Nonparametric | 2002 |
Symptomatic ulceration of an acid-producing oesophageal inlet patch colonized by helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Endoscopes; Esophagus; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Ulcer | 2002 |
Protection against aspiration with the Proseal laryngeal mask airway.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anesthesia, General; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngeal Masks; Omeprazole; Pneumonia, Aspiration; Preoperative Care; Treatment Outcome; Vaginal Diseases | 2002 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Antinuclear; Autoimmune Diseases; Azathioprine; Calcium; Connective Tissue Diseases; Fractures, Bone; Gastritis; Hernia, Hiatal; Humans; Hypogonadism; Immunosuppressive Agents; Klinefelter Syndrome; Lansoprazole; Lupus Erythematosus, Discoid; Male; Muscle Weakness; Omeprazole; Osteoporosis; Pain; Photosensitivity Disorders; Prednisolone; Testosterone | 2002 |
[Eradication of helicobacter pylori: symptomatic treatment of reflux disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Randomized Controlled Trials as Topic | 2002 |
[Effect of various antisecretory drugs on morphological changes in rat gastric mucosa in experimental stomach ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epithelium; Famotidine; Gastric Mucosa; Lansoprazole; Male; Microcirculation; Octreotide; Omeprazole; Rats; Rats, Wistar; Stomach Ulcer; Treatment Outcome | 2002 |
Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Hematologic Tests; Humans; Lansoprazole; Omeprazole; Penicillins; Treatment Outcome | 2002 |
Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Blood Platelets; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunosuppressive Agents; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2002 |
An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Circadian Rhythm; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
Tetany secondary to the use of a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Humans; Hypocalcemia; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Risk Factors; Tetany; Thyroidectomy | 2002 |
Localization of [14C]clarithromycin in rat gastric tissue when administered with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Animals; Carbon Radioisotopes; Clarithromycin; Drug Interactions; Gastric Mucosa; Injections, Intravenous; Intestinal Mucosa; Intubation, Gastrointestinal; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Stomach | 2002 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Phospholipids; Stomach Ulcer; Treatment Outcome | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Preschool; Drug Costs; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2002 |
Effects of clarithromycin and amoxicillin on gastric emptying in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Carbon Radioisotopes; Clarithromycin; Drug Therapy, Combination; Duodenum; Gastric Emptying; Gastric Mucosa; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2002 |
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; CD5 Antigens; Clarithromycin; Colonoscopy; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Omeprazole; Penicillins; Rectal Neoplasms | 2002 |
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Proton Pump Inhibitors; Sulfoxides | 2002 |
Asymmetries in H+/K+-ATPase and cell membrane potentials comprise a very early step in left-right patterning.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Barium Compounds; Body Patterning; Cell Membrane; Chick Embryo; Chlorides; Electrophysiology; Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; In Situ Hybridization; Lansoprazole; Membrane Potentials; Molecular Sequence Data; Omeprazole; Potassium Channels, Inwardly Rectifying; Proton Pump Inhibitors; RNA, Messenger; Time Factors; Xenopus | 2002 |
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Odds Ratio; Omeprazole | 2002 |
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Humans; Lansoprazole; Misoprostol; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 2002 |
Medication errors. Liquid lansoprazole: gumming up the works.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enteral Nutrition; Humans; Lansoprazole; Medication Errors; Omeprazole | 2002 |
Restoration of acid secretion following treatment with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Dithiothreitol; Enzyme Activation; Enzyme Inhibitors; Gastric Acid; Glutathione; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley; Stomach | 2002 |
Spectrophotometric determination of omeprazole, lansoprazole and pantoprazole in pharmaceutical formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chemistry, Pharmaceutical; Lansoprazole; Omeprazole; Pantoprazole; Spectrophotometry, Ultraviolet; Sulfoxides | 2002 |
[Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Humans; Lansoprazole; Omeprazole; Peptic Ulcer Hemorrhage; Peptic Ulcer Perforation; Postoperative Care; Proton Pump Inhibitors; Ranitidine; Time Factors | 2002 |
Lansoprazole-associated microscopic colitis: a case series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Enzyme Inhibitors; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2002 |
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Secondary Prevention | 2002 |
Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Ethanol; Gastric Mucosa; Isoenzymes; Lansoprazole; Male; Omeprazole; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Stomach Ulcer; Up-Regulation | 2002 |
[In small steps to far ahead. Diminished risk of interactions as definite advantage].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2002 |
Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, Liquid; Humans; Lansoprazole; Omeprazole; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Therapeutic Equivalency | 2003 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole | 2002 |
Facial swelling and eosinophilia in a 44-year-old woman.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Angioedema; Cefuroxime; Cetirizine; Diagnosis, Differential; Drug Hypersensitivity; Edema; Eosinophilia; Face; Fatigue; Female; Humans; Hypereosinophilic Syndrome; Indoles; Lansoprazole; Methylprednisolone; Methylprednisolone Acetate; Omeprazole; Penicillins; Phenylcarbamates; Prednisone; Ranitidine; Recurrence; Sulfonamides; Syndrome; Terfenadine; Tosyl Compounds | 2002 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Secondary Prevention; Ulcer | 2002 |
Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Polypharmacy; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2002 |
A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antioxidants; Apoptosis; DNA Damage; Free Radical Scavengers; Hydroxyl Radical; Lansoprazole; Omeprazole; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Stomach Ulcer | 2003 |
Hydrogen-potassium ATPase inhibitors induce relaxation on rabbit prostatic strips in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Disease Models, Animal; Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Muscle Relaxation; Muscle Tonus; Omeprazole; Prostate; Prostatic Hyperplasia; Proton Pump Inhibitors; Rabbits; Stromal Cells | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Diseases; Heart Diseases; Humans; Lansoprazole; Omeprazole; Secondary Prevention; Ulcer | 2003 |
Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Antibodies; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2003 |
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chronic Disease; Cisapride; Cough; Diagnostic Techniques, Digestive System; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Metoclopramide; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2003 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Gastric Acid; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Mucus; Omeprazole; Severity of Illness Index | 2003 |
Utility and limitations of a method for detecting Helicobacter pylori-specific antigens in the stool.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antigens, Bacterial; Breath Tests; Drug Therapy, Combination; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Sensitivity and Specificity | 2003 |
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gene Expression Regulation; Humans; Hypericum; Lansoprazole; Omeprazole; Pantoprazole; Plant Preparations; Rabeprazole; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfoxides | 2003 |
Anodic voltammetric assay of lansoprazole and omeprazole on a carbon paste electrode.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Capsules; Lansoprazole; Omeprazole; Polarography; Proton Pump Inhibitors; Sensitivity and Specificity | 2003 |
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Anticoagulants; Benzimidazoles; Drug Interactions; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; United States; United States Food and Drug Administration | 2003 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastrointestinal Agents; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Sulfasalazine; Treatment Outcome | 2003 |
Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Fucosyltransferases; Genotype; Helicobacter pylori; Humans; Lansoprazole; Lewis Blood Group Antigens; Male; Middle Aged; Omeprazole; Polymorphism, Genetic; Prospective Studies; Smoking | 2003 |
Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Blotting, Northern; Electroshock; Gastric Acid; Gastric Mucosa; Gastrins; Gene Targeting; Hydrogen-Ion Concentration; Hyperplasia; Immunohistochemistry; Lansoprazole; Mice; Omeprazole; Pain Threshold; Proton Pump Inhibitors; Receptors, Histamine H2; Seizures | 2003 |
Isolated granulomatous gastritis successfully treated by Helicobacter pylori eradication: a possible association between granulomatous gastritis and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Granuloma; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole | 2003 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Omeprazole; Peptic Ulcer Hemorrhage; Peptic Ulcer Perforation; Practice Guidelines as Topic; Recurrence; Stomach Ulcer; Vagotomy | 1997 |
Lansoprazole overutilization: methods for step-down therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enzyme Inhibitors; Formularies, Hospital as Topic; Gastric Acid; Gastroenteritis; Gastroesophageal Reflux; Gastrointestinal Diseases; Health Services Misuse; Health Services Research; Hospitals, Veterans; Humans; Lansoprazole; Medical Audit; Omeprazole; Pennsylvania; Prospective Studies; Proton Pump Inhibitors | 2003 |
The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe Ph monitoring in laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Larynx; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Proton Pump Inhibitors; Reproducibility of Results; Time Factors | 2003 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Myoelectric Complex, Migrating; Omeprazole; Proton Pump Inhibitors; Stomach; Stomach Ulcer; Wound Healing | 2003 |
Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Chemistry, Pharmaceutical; Compressive Strength; Dogs; Intestinal Absorption; Lansoprazole; Male; Omeprazole; Solubility; Tablets, Enteric-Coated | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome | 2003 |
Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Buffers; Chemistry, Pharmaceutical; Citrates; Drug Incompatibility; Drug Stability; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Lansoprazole; Microspheres; Omeprazole; Polyethylene Glycols; Saliva; Tablets; Tablets, Enteric-Coated; Taste | 2003 |
Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Aging; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Omeprazole; Sulfides; Sulfones | 1993 |
Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cytochrome P-450 Enzyme System; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism | 2003 |
Relaxant effect of omeprazole and lansoprazole in guinea pig gallbladder muscle strips in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Enzyme Inhibitors; Gallbladder; Guinea Pigs; In Vitro Techniques; Lansoprazole; Male; Muscle Relaxation; Omeprazole; Proton Pump Inhibitors | 2003 |
Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chemistry, Pharmaceutical; Humans; Lansoprazole; Omeprazole; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical; Tensile Strength; Viscosity | 2003 |
Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for Leydig cell carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Enzyme-Linked Immunosorbent Assay; Gene Expression; Lansoprazole; Leydig Cell Tumor; Liver; Male; Omeprazole; Polymerase Chain Reaction; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Testicular Neoplasms; Testis; Testosterone | 2003 |
Immunoelectron microscopic study for histamine in the gastric enterochromaffin-like cells of rats treated with the proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antibodies, Monoclonal; Cytoplasm; Enterochromaffin-like Cells; Enzyme Inhibitors; Exocytosis; Histamine; Lansoprazole; Male; Microscopy, Immunoelectron; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Secretory Vesicles; Vacuoles | 2003 |
A 100 kDa vanadate and lanzoprazole-sensitive ATPase from Streptococcus mutans membrane.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bacterial Outer Membrane Proteins; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Lansoprazole; Molecular Weight; Omeprazole; Proton-Translocating ATPases; Streptococcus mutans; Vanadates | 2003 |
Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Blood Platelets; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure | 2003 |
Lansoprazole-induced hepatic dysfunction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chemical and Drug Induced Liver Injury; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2003 |
["Mirror, mirror on the wall which is the best proton pump inhibitor of all?"].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Benzimidazoles; Drug Interactions; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Vitamin K | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2003 |
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cell Transformation, Neoplastic; Clarithromycin; Female; Gastrectomy; Gastric Mucosa; Gastroenterostomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Neoplasm Recurrence, Local; Omeprazole; Stomach Neoplasms; Treatment Outcome | 2004 |
The acidity index: a simple approach to the measurement of gastric acidity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2004 |
Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Ethanol; Gastric Juice; Gastric Mucosa; Hydrochloric Acid; Isoenzymes; Lansoprazole; Male; Malondialdehyde; Membrane Proteins; Necrosis; Omeprazole; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Stomach Ulcer; Sulfhydryl Compounds | 2004 |
Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Child; Cimetidine; Diagnosis, Differential; Enzyme Inhibitors; Eosinophilia; Esophagitis; Esophagoscopy; Esophagus; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Omeprazole; Prednisone | 2004 |
Gastric antiulcer activity of Syngonanthus arthrotrichus SILVEIRA.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bethanechol; Cimetidine; Disease Models, Animal; Eriocaulaceae; Ethanol; Gastric Juice; Gastrointestinal Contents; Hydrogen-Ion Concentration; Indomethacin; Lansoprazole; Male; Mice; Mucus; Omeprazole; Phytotherapy; Plant Extracts; Prostaglandins; Rats; Rats, Wistar; Stomach Ulcer; Stress, Psychological | 2004 |
Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Creatinine; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Middle Aged; Nephritis, Interstitial; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; United Kingdom | 2004 |
Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Synergism; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Tacrolimus | 2004 |
Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5-11 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Child; Child, Preschool; Consumer Behavior; Delayed-Action Preparations; Female; Flavoring Agents; Forecasting; Fragaria; Humans; Lansoprazole; Male; Mentha piperita; Omeprazole; Prospective Studies; Ranitidine; Suspensions; Taste | 2004 |
[Myoclonic encephalopathy associated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Brain Diseases; Humans; Lansoprazole; Myoclonus; Omeprazole; Proton Pump Inhibitors | 2004 |
Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Administration, Oral; Animals; Duodenogastric Reflux; Enzyme Inhibitors; Gastrins; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Stomach Neoplasms | 2004 |
Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Humans; Kidney Transplantation; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2004 |
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Female; Fibroblast Growth Factors; Gastric Acid; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Time Factors; Wound Healing | 2004 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; Esophagoscopy; Esophagus; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Manometry; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2004 |
[Successful treatment of long-standing iron-deficiency anemia in adults by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole | 2004 |
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Platelet Count; Remission Induction; Thrombocytopenia | 2004 |
Wyeth found guilty of paying to boost use of a specific medicine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Industry; Family Practice; Humans; Lansoprazole; Marketing; Omeprazole; Practice Patterns, Physicians'; United Kingdom | 2004 |
Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzimidazoles; Carrageenan; Helicobacter pylori; Inflammation; Lansoprazole; Male; Neutrophils; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Sulfoxides | 2004 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal Ulcer; Eosinophilia; Female; Gastritis; Gastroenteritis; Gastroscopy; Glucocorticoids; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Omeprazole; Prednisone; Proton Pump Inhibitors; Stomach Ulcer; Treatment Failure | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Determination of pantoprazole in human plasma by LC-MS-MS using lansoprazole as internal standard.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; Humans; Indicators and Reagents; Lansoprazole; Mass Spectrometry; Omeprazole; Pantoprazole; Quality Control; Reference Standards; Reproducibility of Results; Sulfoxides; Therapeutic Equivalency | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Microbial; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Point Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Stomach Ulcer; Treatment Outcome | 2004 |
Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length | 2004 |
Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Gastrointestinal Agents; Inflammation; Intestinal Mucosa; Ischemia; Lansoprazole; Lipid Peroxidation; Male; Omeprazole; Rats; Rats, Sprague-Dawley; Reperfusion | 2004 |
Determination of lansoprazole in pharmaceutical capsules by flow injection analysis using UV-detection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Capsules; Flow Injection Analysis; Lansoprazole; Omeprazole; Pharmaceutical Preparations; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2004 |
Chiral separation of omeprazole and several related benzimidazoles using supercritical fluid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohols; Amylose; Benzimidazoles; Chromatography; Lansoprazole; Models, Chemical; Omeprazole; Pantoprazole; Pressure; Rabeprazole; Stereoisomerism; Sulfoxides; Temperature; Time Factors | 2004 |
Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antibodies; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glyburide; Humans; In Vitro Techniques; Ketoconazole; Kinetics; Lansoprazole; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Recombinant Proteins | 2004 |
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cyclooxygenase 2; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Membrane Proteins; Middle Aged; Neutrophil Activation; Omeprazole; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Statistics, Nonparametric; Time Factors | 2004 |
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Treatment Failure; White People | 2004 |
Neuropathy associated with lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Heartburn; Humans; Lansoprazole; Omeprazole; Peripheral Nervous System Diseases | 2005 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hypertrophy; Lansoprazole; Laryngeal Diseases; Laryngeal Mucosa; Laryngoscopy; Long-Term Care; Male; Middle Aged; Omeprazole; Pantoprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Retrospective Studies; Sulfoxides; Treatment Outcome; Voice Disorders | 2004 |
Effect of lansoprazole for an idiopathic thrombocytopenic purpura patient with Helicobacter pylori infection who did not respond to prednisolone treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2004 |
[Galactorrhea induced by lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Galactorrhea; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors | 2004 |
Serum cholinesterase inhibition by omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cholinesterase Inhibitors; Enzyme Inhibitors; Humans; In Vitro Techniques; Indicators and Reagents; Lansoprazole; Omeprazole; Rats; Rats, Sprague-Dawley | 2004 |
Evaluation of fast disintegrating lansoprazole tablet in human subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Drug Evaluation; Humans; Lansoprazole; Mouth Mucosa; Omeprazole; Saliva; Tablets | 2004 |
[Choice of proton pump inhibitors--does it play any role?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drugs, Generic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2004 |
Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism; Substrate Specificity | 2005 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, Bacterial; Enzyme-Linked Immunosorbent Assay; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Sensitivity and Specificity | 2004 |
Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; Cell Proliferation; Choristoma; Clarithromycin; Gastric Mucosa; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Intestines; Lansoprazole; Omeprazole; Stomach | 2004 |
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Benzamides; Drug Eruptions; Edema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lansoprazole; Middle Aged; Omeprazole; Piperazines; Proton Pump Inhibitors; Pyrimidines; Stevens-Johnson Syndrome | 2005 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2004 |
Fatal toxic epidermal necrolysis due to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Eruptions; Erythema Multiforme; Fatal Outcome; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Stevens-Johnson Syndrome | 2004 |
Patent expiration for lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Industry; Lansoprazole; Omeprazole; Patents as Topic | 2004 |
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Chemistry, Pharmaceutical; Clarithromycin; Drug Combinations; Female; Gastritis; Half-Life; Helicobacter Infections; Helicobacter pylori; Hydrogen-Ion Concentration; Immunoglobulin G; Lansoprazole; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Omeprazole; Penicillins; Sucralfate; Viscosity | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retreatment; Time Factors | 2004 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic Disease; Cough; Cross-Sectional Studies; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Lansoprazole; Lung Diseases; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Morpholines; Omeprazole; Pneumonectomy; Postoperative Complications; Posture; Proton Pump Inhibitors; Surveys and Questionnaires; Weight Lifting | 2005 |
Effect of adsorbents on the absorption of lansoprazole with surfactant.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adsorption; Animals; Area Under Curve; Biological Availability; Dogs; Drug Evaluation, Preclinical; Duodenum; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Powders; Rats; Rats, Wistar; Silicon Dioxide; Solutions; Surface-Active Agents | 2005 |
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chromatography, High Pressure Liquid; Female; Humans; Lansoprazole; Male; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Sulfones | 2005 |
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Enterochromaffin-like Cells; Esophagitis; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Immunohistochemistry; Lansoprazole; Long-Term Care; Male; Middle Aged; Omeprazole; Pentagastrin; Proton Pump Inhibitors | 2005 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Tokyo | 2005 |
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Breath Tests; Carbon Isotopes; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Sensitivity and Specificity; Urea | 2005 |
Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Clarithromycin; Enterobacteriaceae; Enterococcus; Feces; Helicobacter Infections; Helicobacter pylori; Intestines; Lansoprazole; Macaca; Omeprazole; Proton Pump Inhibitors | 2005 |
Antimicrobial actions of benzimidazoles against oral streptococci.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Enzyme Inhibitors; Glycolysis; Hydrogen-Ion Concentration; Lansoprazole; Mouth; Omeprazole; Phosphoenolpyruvate Sugar Phosphotransferase System; Proton Pump Inhibitors; Proton-Translocating ATPases; Streptococcus | 2005 |
Gastroprotective activity of a new semi-synthetic solidagenone derivative in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Anti-Ulcer Agents; Cell Line; Cell Proliferation; Chile; Dinoprostone; Disease Models, Animal; Diterpenes; Drug Evaluation, Preclinical; Epithelium; Ethanol; Fibroblasts; Furans; Gastric Mucosa; Humans; Hydrochloric Acid; Inhibitory Concentration 50; Lansoprazole; Lung; Mice; Naphthalenes; Neutral Red; Omeprazole; Stomach Ulcer; Tetrazolium Salts | 2005 |
The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Endosomes; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Female; Gene Expression; Humans; Hydrogen-Ion Concentration; Intercellular Adhesion Molecule-1; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Rhinovirus; RNA, Messenger; RNA, Viral; Trachea | 2005 |
Simultaneous herpetic and candidal esophagitis in an immunocompetent teenager.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acyclovir; Adolescent; Antifungal Agents; Antiviral Agents; Candidiasis; Esophagitis; Fluconazole; Herpes Simplex; Humans; Immunocompetence; Lansoprazole; Male; Omeprazole; Treatment Outcome | 2005 |
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gene Rearrangement; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin Heavy Chains; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Prognosis; Remission Induction; Stomach Neoplasms | 2005 |
Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Male; Omeprazole; Specific Pathogen-Free Organisms | 2005 |
Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cysteamine; Duodenal Ulcer; Gastric Mucosa; Gene Expression; Ghrelin; Lansoprazole; Male; Omeprazole; Peptide Hormones; Rats; Rats, Wistar; Severity of Illness Index; Somatostatin | 2005 |
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexlansoprazole; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Stereoisomerism | 2005 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pain; Patient Satisfaction; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2005 |
Lack of interaction between atazanavir and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Atazanavir Sulfate; Contraindications; Drug Interactions; Drug Therapy, Combination; Gastroesophageal Reflux; HIV Infections; Humans; Lansoprazole; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2005 |
Multifocal gastric carcinoid tumor in a patient with pernicious anemia receiving lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia, Pernicious; Biopsy, Needle; Carcinoid Tumor; Female; Follow-Up Studies; Gastroscopy; Humans; Immunohistochemistry; Lansoprazole; Middle Aged; Omeprazole; Risk Assessment; Stomach Neoplasms | 2005 |
Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rosacea | 2005 |
Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Community Pharmacy Services; Cost-Benefit Analysis; Drug Costs; Enzyme Inhibitors; Health Care Surveys; Humans; Ireland; Lansoprazole; National Health Programs; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Beverages; Chromatography, High Pressure Liquid; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Plant Extracts; Water | 2005 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Israel; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2005 |
CYP35: xenobiotically induced gene expression in the nematode Caenorhabditis elegans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Atrazine; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cytochrome P-450 Enzyme System; Fluorenes; Gene Expression Regulation, Enzymologic; Lansoprazole; Omeprazole; Polychlorinated Biphenyls; Reproduction; Xenobiotics | 2005 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Failure | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Biopsy; Clarithromycin; Colony Count, Microbial; Cytochrome P-450 CYP2C19; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Outcome | 2005 |
Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Immunoglobulin E; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2005 |
Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Endoscopy, Gastrointestinal; Female; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Japan; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Microscopy, Electron, Transmission; Middle Aged; Omeprazole; Stomach; Treatment Outcome | 2005 |
Gastroprotective effect of the Mapuche crude drug Araucaria araucana resin and its main constituents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cells, Cultured; Cycadopsida; Diterpenes; Dose-Response Relationship, Drug; Gastric Mucosa; Humans; Lansoprazole; Mice; Omeprazole; Resins, Plant | 2005 |
Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Beverages; Esomeprazole; Intubation, Gastrointestinal; Lansoprazole; Malus; Omeprazole; Particle Size; Polyurethanes; Proton Pump Inhibitors; Rheology; Silicones; Solvents; Water | 2005 |
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Fiber Optic Technology; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Hypopharynx; Lansoprazole; Laryngoscopy; Male; Manometry; Middle Aged; Omeprazole; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2005 |
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Disease Models, Animal; Gastric Mucosa; Lansoprazole; Male; Omeprazole; Oxidative Stress; Rats; Rats, Wistar; Stomach | 2005 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differential; Diarrhea; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2005 |
[Role of esophageal motility abnormalities in severe reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophageal Motility Disorders; Esophagitis, Peptic; Esophagus; Female; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Peristalsis | 2005 |
Mechanisms of action of leptin in preventing gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Lansoprazole; Leptin; Nitric Oxide; Omeprazole; Prostaglandin-Endoperoxide Synthases; Ranitidine; Rats; Rats, Wistar; Stomach Ulcer | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Remission Induction; Time Factors | 2005 |
Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastritis, Hypertrophic; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Minocycline; Omeprazole; Peptides; Remission Induction | 2005 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Child, Preschool; Chronic Disease; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Infant; Lansoprazole; Male; Omeprazole; Prospective Studies; Recurrence | 2006 |
Determinants of non-response in Helicobacter pylori eradication trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2005 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Cyclin-Dependent Kinase Inhibitor p27; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Interleukin-8; Lansoprazole; Male; Middle Aged; Omeprazole; Proteins; Proto-Oncogene Proteins c-myc; Proton Pump Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S-Phase Kinase-Associated Proteins | 2006 |
Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Heart Atria; Imidazoles; In Vitro Techniques; Lansoprazole; Male; Milrinone; Myocardial Contraction; Omeprazole; Ouabain; Phosphodiesterase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Theophylline; Verapamil | 2005 |
A decade-long sour-taste sensation successfully treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Taste Disorders; Treatment Outcome | 2005 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme-Linked Immunosorbent Assay; Eosinophilia; Eosinophils; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphocytes; Male; Middle Aged; Omeprazole; Peptic Ulcer | 2005 |
[The cause of failure of eradication treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2005 |
Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Diet; Gastroesophageal Reflux; Histamine H2 Antagonists; Hoarseness; Humans; Lansoprazole; Life Style; Male; Nasal Cavity; Omeprazole; Pain; Proton Pump Inhibitors; Ranitidine; Sleep Initiation and Maintenance Disorders; Snoring | 2005 |
Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Diagnosis, Differential; Female; Humans; Lansoprazole; Lupus Erythematosus, Cutaneous; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Female; Gastrointestinal Diseases; Gastrointestinal Motility; Gastrointestinal Tract; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Quality of Life; Stomach Ulcer; Surveys and Questionnaires | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2005 |
Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Infective Agents; Apoptosis; Autoradiography; Binding Sites; Binding, Competitive; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastric Fundus; Infusions, Intra-Arterial; Intestinal Mucosa; Lansoprazole; Macrophages; Male; Microscopy, Electron; Neutrophils; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Tritium | 2005 |
Degradation of lansoprazole and omeprazole in the aquatic environment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Hydrogen-Ion Concentration; Hydrolysis; Lansoprazole; Magnetic Resonance Spectroscopy; Molecular Structure; Omeprazole; Photochemistry; Ultraviolet Rays; Water Pollutants, Chemical | 2006 |
Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Advertising; Cohort Studies; Cost Sharing; Drug Utilization; Enzyme Inhibitors; Financing, Personal; Gastroesophageal Reflux; Health Benefit Plans, Employee; Humans; Insurance Coverage; Lansoprazole; Marketing; Omeprazole; Prescription Fees; Proton Pump Inhibitors; Retrospective Studies; United States | 2005 |
Fatal toxic epidermal necrolysis due to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diagnosis, Differential; Drug Eruptions; Humans; Lansoprazole; Omeprazole; Stevens-Johnson Syndrome | 2006 |
"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Support Techniques; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2005 |
Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CXCL1; Chemokines, CXC; Enteritis; Indomethacin; Intercellular Signaling Peptides and Proteins; Intestinal Mucosa; Intestine, Small; Lansoprazole; Male; Omeprazole; Peroxidase; Proton Pump Inhibitors; Proton Pumps; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances | 2006 |
Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Female; Humans; Lansoprazole; Methotrexate; Omeprazole; Pancytopenia | 2006 |
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Treatment Outcome | 2005 |
Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Expectorants; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2005 |
Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Calcium; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Histamine; Humans; In Vitro Techniques; Lansoprazole; Male; Mammary Arteries; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Omeprazole; Ouabain; Phenylephrine; Potassium; Proton Pump Inhibitors; Radial Artery; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2006 |
Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Androstadienes; Anti-Allergic Agents; Cough; Endoscopy, Gastrointestinal; Esophageal Diseases; Fluticasone; Gastric Mucosa; Humans; Lansoprazole; Laryngeal Diseases; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Respiratory Function Tests; Vocal Cords | 2006 |
Cholecystoduodenal fistula secondary to penetrating duodenal ulcer: a case of conservative management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Intestinal Fistula; Lansoprazole; Omeprazole | 2006 |
Hydroxylation of lansoprazole in poor metabolizers of CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Humans; Hydroxylation; Lansoprazole; Mixed Function Oxygenases; Omeprazole | 2006 |
Microscopic colitis associated with exposure to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Biopsy; Chronic Disease; Colitis, Collagenous; Colitis, Lymphocytic; Colitis, Microscopic; Colon; Diarrhea; Female; Follow-Up Studies; Humans; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Time Factors | 2006 |
Hydroxyl radical scavenging reactivity of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Copper Sulfate; Deoxyribose; Enzyme Inhibitors; Erythrocytes; Free Radical Scavengers; Heme; Hyaluronic Acid; Hydroxyl Radical; Iron Compounds; Lansoprazole; Omeprazole; Pantoprazole; Proton Pumps; Sulfides; Sulfoxides | 2006 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cohort Studies; Controlled Clinical Trials as Topic; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Meta-Analysis as Topic; Odds Ratio; Omeprazole; Peptic Ulcer Hemorrhage; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Risk Factors; Stomach; Stomach Ulcer; Tablets, Enteric-Coated; Time Factors | 2006 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2006 |
Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2006 |
Ion flow regulates left-right asymmetry in sea urchin development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Body Patterning; Calcimycin; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Embryonic Development; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Imidazoles; Ionophores; Ions; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Sea Urchins | 2006 |
Increased microvascular permeability in early stage of dextran sulfate sodium-induced colitis: its interaction with lansoprazole binding sites.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Binding Sites; Capillary Permeability; Colitis; Cytoplasm; Dextran Sulfate; Goblet Cells; Intestinal Mucosa; Lansoprazole; Macrophages; Neutrophils; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Wistar | 2006 |
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Drug Administration Schedule; Enzyme Inhibitors; Esophageal Diseases; Esophageal Neoplasms; Female; Humans; Lansoprazole; Long-Term Care; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Sex Factors; Treatment Outcome | 2006 |
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; British Columbia; Cost Savings; Databases, Factual; Drug Utilization Review; Female; Health Services for the Aged; Hospitalization; Humans; Insurance, Pharmaceutical Services; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Rabeprazole; Sulfoxides | 2006 |
Design and evaluation of jingzhiguanxin monolithic osmotic pump tablet.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzoates; Bridged-Ring Compounds; Delayed-Action Preparations; Drug Design; Drugs, Chinese Herbal; Glucosides; Lactates; Lansoprazole; Monoterpenes; Omeprazole; Osmosis; Polyethylene Glycols; Solubility; Spectrophotometry, Ultraviolet; Tablets; Technology, Pharmaceutical | 2006 |
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory Flow Rates; Forced Expiratory Volume; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peak Expiratory Flow Rate; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2006 |
Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2006 |
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cell Line, Tumor; Cyclooxygenase 1; Deuteroporphyrins; Endothelial Cells; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Heme Oxygenase-1; Humans; Lansoprazole; Omeprazole; Oxidative Stress; Rats | 2006 |
Gastroprotective and ulcer-healing activity of oleanolic acid derivatives: in vitro-in vivo relationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Line; Cell Proliferation; Cell Survival; Central Nervous System Depressants; Chemical Phenomena; Chemistry, Physical; Dinoprostone; Epithelial Cells; Ethanol; Fibroblasts; Free Radical Scavengers; Gastric Mucosa; Glutathione; Humans; Hydrochloric Acid; Lansoprazole; Male; Mice; Oleanolic Acid; Omeprazole; Stomach Ulcer; Superoxides; Taurocholic Acid | 2006 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Child; Child, Preschool; Cough; Cross-Sectional Studies; Endoscopy, Digestive System; Esophagitis; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Male; Omeprazole; Severity of Illness Index; Vomiting | 2006 |
Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pilot Projects; Proton Pump Inhibitors; Single-Blind Method | 2006 |
Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2006 |
Effect of proton pump inhibitors on hepatic regeneration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Female; Hepatectomy; Ki-67 Antigen; Lansoprazole; Liver; Liver Regeneration; Male; Omeprazole; Organ Size; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Sulfoxides | 2006 |
An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Catalysis; Dimerization; Drug Stability; Electrochemistry; Enzyme Inhibitors; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Polarography; Proton Pump Inhibitors | 2006 |
Endoplasmic reticulum stress response is involved in the pathogenesis of stress induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Apoptosis; Caspase 12; Caspases; Disease Models, Animal; Endoplasmic Reticulum; Gastric Mucosa; Heat-Shock Proteins; Immunohistochemistry; Lansoprazole; Male; Molecular Chaperones; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Stress, Psychological | 2006 |
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Respiratory Hypersensitivity; Surveys and Questionnaires | 2006 |
The Efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura--the first study in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Purpura, Thrombocytopenic, Idiopathic; Turkey | 2006 |
Specific H+/K(+)-ATPase inhibitors decreased contractile responses of isolated rat vas deferens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adrenergic alpha-Agonists; Animals; Calcium; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Imidazoles; In Vitro Techniques; Lansoprazole; Male; Muscle Contraction; Muscle, Smooth; Omeprazole; Ouabain; Phenylephrine; Potassium; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Vas Deferens | 2006 |
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2006 |
Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents; Calcium; Cell Line, Tumor; Cell Movement; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Epithelium; Humans; Interleukin-8; Lansoprazole; Ligases; Neutrophils; NF-kappa B; Omeprazole; Proton Pump Inhibitors; Stomach Neoplasms | 2006 |
The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Advertising; Anti-Ulcer Agents; Cost Control; Cost Sharing; Drug Prescriptions; Drug Utilization; Female; Health Benefit Plans, Employee; Humans; Insurance, Pharmaceutical Services; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2005 |
Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Translocation; Dose-Response Relationship, Drug; Humans; Indomethacin; Intestinal Mucosa; Intestine, Small; Intubation, Gastrointestinal; Jejunum; Lansoprazole; Male; Malondialdehyde; Neutrophil Infiltration; Omeprazole; Oxidative Stress; Peroxidase; Proton Pump Inhibitors; Rats; Rats, Wistar; Severity of Illness Index | 2007 |
An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esomeprazole; Female; Humans; Infusions, Parenteral; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Proton Pumps | 2006 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastroesophageal Reflux; Gastroscopy; Humans; Incidence; Infant; Lansoprazole; Long-Term Care; Male; Nausea; Omeprazole; Probability; Prognosis; Proton Pump Inhibitors; Proton Pumps; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Time Factors; Vomiting | 2007 |
Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Ferritins; Gastric Acid; Hemochromatosis; Humans; Intestinal Absorption; Iron, Dietary; Lansoprazole; Middle Aged; Omeprazole; Phlebotomy; Postprandial Period; Proton Pump Inhibitors | 2007 |
Preparative chiral chromatography and chiroptical characterization of enantiomers of omeprazole and related benzimidazoles.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography; Chromatography, Supercritical Fluid; Circular Dichroism; Enzyme Inhibitors; Lansoprazole; Models, Chemical; Molecular Conformation; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2007 |
Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Animals; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Poison Control Centers; Poisoning; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Texas | 2007 |
[A case of gastroesophageal reflux disease with marked eosinophilia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Eosinophilia; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Acidity Determination; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Muscarinic Antagonists; Omeprazole; Parietal Cells, Gastric; Pirenzepine; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Receptors, Histamine H2; Receptors, Muscarinic | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2007 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Liver Function Tests; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Vitamin B 12 | 2008 |
Proton pump inhibitor utilization patterns in infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Drug Administration Schedule; Drug Utilization Review; Female; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Insurance, Pharmaceutical Services; Lansoprazole; Male; Medical Audit; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Retrospective Studies; United States | 2007 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans; Lansoprazole; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Skin | 2008 |
[Drug treatment and surgical indications in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Fundoplication; Gastroesophageal Reflux; Histamine Antagonists; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Time Factors | 2007 |
[Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Costs and Cost Analysis; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Japan; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 2008 |
The alternating current polarographic behavior and determination of lansoprazole and omeprazole in dosage forms and biological fluids.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Body Fluids; Calibration; Dosage Forms; Electrochemistry; Hydrogen-Ion Concentration; Lansoprazole; Molecular Structure; Omeprazole | 2008 |
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Fluorouracil; Gastric Mucosa; Gastrointestinal Diseases; Intestinal Mucosa; Lansoprazole; Male; Mucins; Mucositis; Omeprazole; Piperidines; Pyridines; Rats; Rats, Wistar | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Activation and stabilization of drugs by supramolecular pKa shifts: drug-delivery applications tailored for cucurbiturils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Delivery Systems; Drug Stability; Hydrogen-Ion Concentration; Lansoprazole; Macrocyclic Compounds; Omeprazole; Prodrugs; Proton Pump Inhibitors | 2008 |
Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anesthesia; Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Electrocardiography; Female; Heart Atria; Heart Rate; Humans; In Vitro Techniques; Injections, Intravenous; Lansoprazole; Male; Myocardial Contraction; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar | 2008 |
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Utilization Review; Esomeprazole; European Union; Gastroesophageal Reflux; Government Agencies; Humans; Isomerism; Lansoprazole; Multicenter Studies as Topic; Omeprazole; Pediatrics; Proton Pump Inhibitors; United States; United States Food and Drug Administration | 2009 |
Transmucosal gastric leak induced by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Epithelium; Esomeprazole; Gastric Mucosa; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Permeability; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley | 2009 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Liver Transplantation; Living Donors; Male; Middle Aged; Omeprazole; Tacrolimus | 2009 |
Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Humans; Inflammation; Interferon-gamma; Interleukin-6; Lansoprazole; Microglia; Monocytes; Neuroblastoma; Omeprazole; Polysaccharides; Proton Pump Inhibitors; Tumor Necrosis Factor-alpha | 2009 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoxazoles; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Zonisamide | 2009 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Myocardial Infarction; Odds Ratio; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine | 2009 |
[Eosinophilic esophagitis: report of three cases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Adolescent; Child; Cyclopropanes; Eosinophilia; Esophagitis; Esophagoscopy; Humans; Lansoprazole; Male; Omeprazole; Quinolines; Sulfides | 2009 |
Inappropriate use of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cross-Sectional Studies; Dyspepsia; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Ireland; Lansoprazole; Male; Omeprazole; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Stomach Ulcer | 2010 |
Long-term treatment with proton pump inhibitor is associated with undesired weight gain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Weight Gain | 2009 |
Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line; Gene Expression Regulation; Humans; Lansoprazole; Liver X Receptors; Mice; Mice, Knockout; Molecular Structure; Neuroglia; Omeprazole; Orphan Nuclear Receptors; Proton Pump Inhibitors | 2010 |
A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, Liquid; Humans; Lansoprazole; Limit of Detection; Omeprazole; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2010 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Immunoproliferative Small Intestinal Disease; Lansoprazole; Male; Omeprazole; Organometallic Compounds; Tinidazole; Young Adult | 2010 |
Generics offer pharmacy plans specific benefits.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Commerce; Cost Control; Drug Industry; Drugs, Generic; Humans; Lansoprazole; Omeprazole; Pharmacies; Practice Guidelines as Topic; Proton Pump Inhibitors; United States; United States Food and Drug Administration | 2010 |
Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Chi-Square Distribution; Female; Gastrointestinal Hemorrhage; Guideline Adherence; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Retrospective Studies; Risk Factors; Wounds and Injuries | 2010 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine Antagonists; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ranitidine | 2010 |
Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Astrocytes; Blotting, Western; Cell Line; Cell Survival; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Humans; Intercellular Adhesion Molecule-1; Interferon-gamma; Lansoprazole; Omeprazole; Phosphorylation; Proton Pump Inhibitors; Recombinant Proteins; STAT3 Transcription Factor | 2011 |
Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Specimen Collection; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Monitoring; Fluvoxamine; Genotype; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2011 |
Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Breath Tests; Carbon Isotopes; Cytochrome P-450 CYP2C19; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2012 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Esophagitis, Peptic; Faith Healing; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Logistic Models; Los Angeles; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Racial Groups; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Celecoxib; Colon; Denaturing Gradient Gel Electrophoresis; Disease Models, Animal; Drug Interactions; Gastrointestinal Hemorrhage; Hematocrit; Jejunum; Lansoprazole; Male; Naproxen; Omeprazole; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors | 2011 |
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biological Transport; Cell Line; Humans; Imidazoles; Immunoblotting; Inhibitory Concentration 50; Lansoprazole; Metformin; Omeprazole; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Protein Binding; Proton Pump Inhibitors; Rabeprazole | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian; Asian People; Blood Platelets; China; Clopidogrel; Drug Resistance; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; New York City; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors | 2011 |
Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angiotensins; Animals; Carbachol; Electric Stimulation; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Lansoprazole; Muscle Relaxation; Muscle, Smooth; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar | 2011 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Cohort Studies; Databases, Factual; Female; Fetal Diseases; Gastroesophageal Reflux; Humans; Israel; Lansoprazole; Omeprazole; Pregnancy; Pregnancy Trimester, First; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Young Adult | 2012 |
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Biotransformation; Child; Child, Preschool; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genetic Association Studies; Hospitals, Pediatric; Humans; Lansoprazole; Male; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Turkey | 2012 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
[Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome | 2012 |
Transport through liquid membranes containing omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bicarbonates; Biochemistry; Cations; Chemistry, Pharmaceutical; Chlorides; Cholesterol; Drug Design; Enzyme Inhibitors; Hydrogen-Ion Concentration; Ions; Lansoprazole; Lecithins; Membranes, Artificial; Models, Biological; Models, Chemical; Molecular Conformation; Omeprazole; Permeability | 2002 |
In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Survival; Cells, Cultured; Epithelial Cells; Gastrointestinal Hemorrhage; Indomethacin; Intestinal Mucosa; Intestine, Small; Lansoprazole; Male; Omeprazole; Phosphatidylcholines; Proton Pump Inhibitors; Pyrimidinones; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 2012 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2C19; Drug Resistance; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophagectomy; Genotype; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Pharmacogenetics; Phenotype; Plastic Surgery Procedures; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer; Treatment Outcome; Wound Healing | 2013 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Ambystoma; Animals; Calcium; Electrophysiology; Feedback; Female; Fluorescein Angiography; Hallucinations; Humans; Lansoprazole; Male; Membrane Potentials; Omeprazole; Ophthalmodynamometry; Patch-Clamp Techniques; Proton Pump Inhibitors; Retinal Cone Photoreceptor Cells; Retinal Horizontal Cells; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration | 2013 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Inhibition of lysosomal enzyme activities by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzymes; Humans; Hydrogen-Ion Concentration; Immune System; Immunotherapy; Lansoprazole; Lysosomes; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Omeprazole; Pantoprazole; Prodrugs; Proton Pump Inhibitors; Spleen | 2013 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2014 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Retrospective Studies; Tokyo; Young Adult | 2013 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Reaction of proton pump inhibitors with model peptides results in novel products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Catalytic Domain; Cysteine; Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; Lansoprazole; Mass Spectrometry; Molecular Structure; Omeprazole; Pantoprazole; Peptides; Proton Pump Inhibitors; Pyridones; Sulfamerazine | 2013 |
Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antioxidants; Benzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Indicators and Reagents; Lansoprazole; Magnetic Resonance Spectroscopy; Omeprazole; Pantoprazole; Spectrometry, Mass, Electrospray Ionization; Tablets; Temperature; Thiones | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Binding Sites; Cytochrome P-450 CYP2C19; Lansoprazole; Molecular Conformation; Molecular Dynamics Simulation; Omeprazole; Pantoprazole; Protein Binding; Protein Structure, Tertiary; Proton Pump Inhibitors; Stereoisomerism; Thermodynamics | 2014 |
Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines.
Topics: Cell Line; Hepatocytes; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Receptors, Aryl Hydrocarbon; Stereoisomerism | 2014 |
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis.
Topics: Anti-Ulcer Agents; Cells, Cultured; Cytochrome P-450 CYP3A; Hep G2 Cells; Hepatocytes; Humans; Lansoprazole; Omeprazole; Pregnane X Receptor; Receptors, Glucocorticoid; Receptors, Steroid | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Tokyo | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Topics: Age Factors; Bicarbonates; Buffers; Chemistry, Pharmaceutical; Esomeprazole; Geriatrics; Humans; Hydrogen-Ion Concentration; Kinetics; Lansoprazole; Omeprazole; Particle Size; Pediatrics; Phosphates; Proton Pump Inhibitors; Sodium Chloride; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical | 2015 |
Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drugs, Generic; Female; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Practice Patterns, Physicians'; Private Sector; Proton Pump Inhibitors; Retrospective Studies; South Africa; Young Adult | 2015 |
Membrane anchor of cytochrome P450 reductase suppresses the uncoupling of cytochrome P450.
Topics: Amitriptyline; Biocatalysis; Cytochrome P-450 CYP2C19; Humans; Hydrogen Peroxide; Imipramine; Lansoprazole; Mutation; NADPH-Ferrihemoprotein Reductase; Omeprazole; Oxidation-Reduction | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antitubercular Agents; Cell Line; Drug Discovery; Drug Resistance, Bacterial; Electron Transport Complex III; Fibroblasts; High-Throughput Screening Assays; Humans; Lansoprazole; Macrophages; Mice; Mycobacterium tuberculosis; Omeprazole; Pantoprazole; Prodrugs; Proton Pump Inhibitors; Sulfides; Tuberculosis, Multidrug-Resistant | 2015 |
Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal--An In vitro Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Urease; Young Adult | 2016 |
Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Lansoprazole; Multiple Myeloma; Omeprazole; Proton Pump Inhibitors; Signal Transduction; Time Factors | 2016 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by Omeprazole and Lansoprazole treatment.
Topics: Cells, Cultured; Cellular Senescence; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Developmental; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Transcriptional Activation; Transcriptome | 2017 |
[Current findings on drug-induced skin reactions].
Topics: Cephalosporins; Drug Eruptions; France; Glucocorticoids; Humans; Hypersensitivity, Delayed; Lansoprazole; Omeprazole; Penicillins; Taxoids; Xenobiotics | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats.
Topics: Animals; Electrocardiography; Lansoprazole; Male; Malondialdehyde; Myocardial Infarction; Myocardium; Necrosis; Nitric Oxide; Omeprazole; Oxidative Stress; Rats; Rats, Wistar | 2019 |
Proton pump inhibitors: New mechanisms of action.
Topics: Cardiovascular Diseases; Cathepsin B; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Endothelium, Vascular; Humans; Lansoprazole; Omeprazole; Oxidative Stress; Proton Pump Inhibitors; Xanthine Dehydrogenase | 2019 |
Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin.
Topics: Adolescent; Adult; Amoxicillin; Child; Cholestasis; Drug Therapy, Combination; Female; Humans; Lansoprazole; Male; Middle Aged; Odds Ratio; Omeprazole; Pregnancy; Retrospective Studies; Risk Factors; Young Adult | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Proton Pump Inhibitors Prevent Gastric Antral Ulcers Induced by NSAIDs via Activation of Capsaicin-Sensitive Afferent Nerves in Mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Disease Models, Animal; Gastric Emptying; Gastric Juice; Gastric Mucosa; Histamine H2 Antagonists; Indomethacin; Lansoprazole; Male; Mice; Neurons, Afferent; Omeprazole; Proton Pump Inhibitors; Pyloric Antrum; Stomach Ulcer | 2020 |
Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Lansoprazole; Male; Molecular Docking Simulation; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Retrospective Studies; Voriconazole | 2020 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism; Tandem Mass Spectrometry | 2020 |
Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Fertilization; Humans; Lansoprazole; Male; Membrane Potentials; Middle Aged; Omeprazole; Pantoprazole; Phosphorylation; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Semen Analysis; Sperm Capacitation; Sperm Maturation; Sperm Motility; Spermatozoa; Young Adult | 2020 |
An electrochemical sensor based on an Eriochrome Black T polymer and deep eutectic solvent for the simultaneous determination of omeprazole and lansoprazole.
Topics: Azo Compounds; Electrochemical Techniques; Lansoprazole; Omeprazole; Polymers; Solvents | 2020 |
Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water.
Topics: Coordination Complexes; Ferric Compounds; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Spectrophotometry; Transition Elements; Water | 2021 |
Acute upper gastrointestinal bleed in the puerperium following weight reduction surgery.
Topics: Acute Disease; Adult; Bariatric Surgery; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Infusions, Intravenous; Lansoprazole; Omeprazole; Postoperative Hemorrhage; Postpartum Period; Pregnancy; Proton Pump Inhibitors | 2020 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Naproxen; Omeprazole; Research Design; Tinidazole | 2022 |
Proton pump inhibitors associated with rapid eye movement sleep behaviour disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; REM Sleep Behavior Disorder | 2021 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Risk Assessment; Risk Factors | 2022 |
Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
Topics: Animals; Cytochrome P-450 CYP2E1; Indican; Lansoprazole; Mice; Omeprazole; Pantoprazole; Proteolysis; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Uremic Toxins | 2022 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Retrospective Studies | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Interleukin-1; Interleukin-8; Lansoprazole; Omeprazole; Prospective Studies; Stomach Ulcer; Tumor Necrosis Factor-alpha; Ulcer | 2023 |
Trends in prescribing volumes and costs of proton pump inhibitors in three outpatient specialties: a three-year retrospective study in a tertiary hospital in Thailand.
Topics: Humans; Lansoprazole; Omeprazole; Outpatients; Proton Pump Inhibitors; Retrospective Studies; Tertiary Care Centers; Thailand | 2023 |
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2023 |
In vivo analysis of acute eletropharmacological effects of proton pump inhibitors using halothane-anesthetized dogs: a translational study of cardiovascular adverse events.
Topics: Animals; Dogs; Halothane; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2023 |